[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TW202448B - - Google Patents

Download PDF

Info

Publication number
TW202448B
TW202448B TW081104270A TW81104270A TW202448B TW 202448 B TW202448 B TW 202448B TW 081104270 A TW081104270 A TW 081104270A TW 81104270 A TW81104270 A TW 81104270A TW 202448 B TW202448 B TW 202448B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
substituted
formula
alkoxy
Prior art date
Application number
TW081104270A
Other languages
Chinese (zh)
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Application granted granted Critical
Publication of TW202448B publication Critical patent/TW202448B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

These compounds correspond to the formula: <IMAGE> in which R1 represents H or an alkyl, phenylalkyl, aminoalkyl, optionally esterified carboxyalkyl, cyanoalkyl, carbamoylalkyl, hydroxyalkyl or alkoxyalkyl group; RIV represents an optionally substituted cycloalkyl group or an aromatic group such as an optionally substituted phenyl or heterocycle or RIV and RV together represent the group: <IMAGE> in which u has the value 1 to 3, optionally carrying (np) substituents Xp chosen from halogen, alkyl, alkoxy, nitro and trifluoromethyl, and np have a value from 0 to 3; RV represents a group (CH2)m-X in which m is 0 to 5 and X represents a halogen, a cycloalkyl, an optionally substituted phenyl, a group COOX1; -O-COX1; -SCOX1; (O)q-S-X1 with q = 0, 1 or 2; -O-COOX1; -N-X3-CO-X1 with X3 = H or alkyl; <IMAGE> with W = O or S and X1 being a C1 to C3 alkyl or an optionally substituted phenyl; a group -COX1X2; -O-CO-NX1X2; or -NX1X2; in which X1 represents an alkyl or phenyl which can be substituted, an alkoxy, or an optionally substituted cyclic or linear amine; a hydroxyl or carboxylic acid group; and Z represents a heterocycle containing one or more heteroatoms chosen from O, S and N, condensed with an aromatic ring which can also contain a heteroatom and which can be substituted, as well as their addition salts.

Description

£02448 Λ 6 ___Π_6_ 五、發明説明(1 ) 本發明係81於與臞囊收箱素(cholecystokinin)及胃泌 素(gastrin)受«相互作用之雜環衍生物。 臟囊收埔素(CCK)是一種多肽荷爾蒙·其在活《内以含 8-39僩胺基酸之幾種形式發生。其對膽管,宵腸道及在中 檷及末稍神經系统上持有許多生理活性,可參考由J. E. Morley在 Life Sciences, 1982, 3Q. p. 479- 493之論文 ,此篇代表其本身性霣之一詳佃回顧。藉特異性拮抗釀已 蛵偵Λ出CCK受β的二種不同群體;A型群《特別存在胰 臟•鼸囊及中樞神經系統的某些區帶•而B型則主要發生 在中檷神經系統。 霣泌素是一種多肽蒱爾蒙,其特別作用於霣之酸性分輅 :其5C-纗胺基酸與CCI(者相同。 甭泌素及/或CCK-拮抗化合物已經被描迷者,尤其是 progluBide,對-氣苯甲釀-L-色胺酸,或最近的纆取代 苯并二氮雜革•其為CCK A受《之特異性拮抗劑•諸如 3S(-)-N-2-n-甲基-2-氧基-5-苯基- 2,3-二氫 苯并二氰雜箪-3-基]-2-吲哚羧釀胺(J. Med. Che·.. 1988· 3丄,2235-46)或CCK B受《之特異性拮抗颺·諸如 3R(O-N-U -甲基-2-氧基-5-苯基- 2,3 -二 β-1Η-1,4 -笨并 二《轅革-3-基]-Η·-[3-甲苯基]_(£»1「.』· Pharmacology, 1989, L£L2_, 273-280) 0 嚷唑CCK-拮抗劑被描述在软洲專利-A-0432 040。 |,| II &quot; ...................................________. 而且,下式(A)之經取代噻唑: (請先閲诉背而^注意事項^蜞寫本頁) -3 - 本紙張尺度边用中8國¥:樣毕(CMS) 規格(210x297公及) 81. 6. 10,000張(H) 202448 Λ 6 η 6 五、發明説明(2) Η£ 02448 Λ 6 ___ Π_6_ V. Description of the invention (1) The present invention is a heterocyclic derivative subjected to interaction with cholecystokinin and gastrin. The visceral saccharin (CCK) is a peptide hormone which occurs in several forms containing 8-39 amino acids in the body. It holds many physiological activities on the bile duct, the intestinal tract, and on the mid-lime and the peripheral nervous system. Refer to the paper by JE Morley in Life Sciences, 1982, 3Q. P. 479-493, this article represents its own nature Jia Yi's detailed review. By specific antagonism, two different groups of CCK and β have been detected; the type A group "especially the pancreas • the sac and certain areas of the central nervous system • type B mainly occurs in the central nerve system. May secretin is a peptide called chlormonimum, which has a particular effect on the acidic compartment of may: its 5C-amino acid is the same as CCI (the same. The secretin and / or CCK-antagonist compounds have been described by fans, especially It is progluBide, p-gas benzol-L-tryptophan, or the most recent substituted benzodiazepine leather. It is a specific antagonist of CCK A by "Such as 3S (-)-N-2- n-methyl-2-oxy-5-phenyl-2,3-dihydrobenzocyano-3-yl] -2-indolecarboxamide (J. Med. Che · .. 1988 · 3 丄, 2235-46) or CCK B is antagonized by the specificity of Yang · such as 3R (ONU-methyl-2-oxy-5-phenyl-2,3-diβ-1Η-1,4- Benbendi "Yuange-3-yl] -Η ·-[3-tolyl] _ (£» 1 "." Pharmacology, 1989, L £ L2_, 273-280) 0 Cuzazole CCK-antagonist was Described in the soft state patent-A-0432 040. |, | II &quot; ....................................... ..________. Moreover, the substituted thiazole of the following formula (A): (Please read the complaint first and ^ Notes ^ Freak to write this page) -3-This paper is used for 8 countries in the standard size ¥: SAMPLE (CMS) Specifications (210x297 g) 81. 6. 10,000 sheets (H) 202448 Λ 6 η 6 V. Description of the invention (2) Η

AA

NHCO (A) 式中At代表2,4-二甲氧笨基;2,3,4-三甲氧笨基或蠊環基 ,諸如3,4-二氳-7-甲氧基-2,2,8-三甲基苯并吡嚙 -1-211-6-基或3,4-二氳-7-甲氧基-2,2-二甲基苯并吡哺 -1 -基 - 2 Η - 6 -基,被描述在 I n d i a n J . C h e . , S e c . B . 1988, 27(B) 7, 629-32,當作持有殺细菌或殺興菌性霣者NHCO (A) where At stands for 2,4-dimethoxybenzyl; 2,3,4-trimethoxybenzyl or cockroach ring groups, such as 3,4-dihydride-7-methoxy-2,2 , 8-trimethylbenzopyridin-1-211-6-yl or 3,4-dihydride-7-methoxy-2,2-dimethylbenzopyridin-1-yl-2 H -6-base, described in Indian J. C he., S ec. B. 1988, 27 (B) 7, 629-32, as a bactericidal or bactericidal fungi

NHCNHC

B (B) (請先閲讀背而之注意事項洱堝寫本頁) 裝- 線- 經濟部屮央榀毕·An工消作合作社印奴 式中队代表氲或澳原子者被描述在Che·. Pha「i 1977 , 25 (9), 2292-9 ·當作持有抗炎性霣者。 式Ο之其他經取代嗔唑: ·* * 1 -....... ho2ch2c^s^nhco-&lt;^〇)B (B) (Please read the notes on the back of Erguo to write this page first) 装-线-The Ministry of Economics 楮 楊 汀 戀 An An industrial and consumer cooperation cooperative Indian slave squadron representative 氲 or Australian atom person is described in Che. . Pha "i 1977, 25 (9), 2292-9 · As an anti-inflammatory eye-catcher. Other substituted oxazoles of formula Ο: ** 1 -....... ho2ch2c ^ s ^ nhco- &lt; ^ 〇)

•N C〇2H• N C〇2H

BullBull

ClCl

(Q 本紙張尺度边用中a B家榀準(CNS) TM規岱(210&gt;&lt;297公:«:) 81. 6, 10,000張(H) 202448 Λ 6 Π 6 五、發明説明(5) 持有免疫促進_及抗炎性霣並且被描述在Arch. Ieiunol. Ther. Exp., 1978, 26(1-6), 921-9〇 式〇之纆取代4-«啉羧鼸胺: Η(Q This paper is used for the standard side a B home standard (CNS) TM regulations Dai (210> &lt; 297 public: «:) 81. 6, 10,000 sheets (H) 202448 Λ 6 Π 6 V. Invention description (5 ) Possess immuno-enhancing and anti-inflammatory encyclopedia and is described in Arch. Ieiunol. Ther. Exp., 1978, 26 (1-6), 921-9〇, the formula 4-substituted 4-carbocarboxylamine: Η

NHCONHCO

(D) 在Che·. Abst. 112(13), 115589 x被提及,當作持有殺 綑菌及濟毒劑性質者。 根據本發明之化合物是式(I )之經嫌«取代2-胺基噻唑(D) It is mentioned in Che ·. Abst. 112 (13), 115589 x and is regarded as possessing bacillus-killing and poisoning properties. The compound according to the invention is a suspected «substituted 2-aminothiazole of formula (I)

R V、R V,

Rl I N-C-Z II 〇 (請先閲讀背而之注意事項再填寫本頁) 裝&lt; 訂_ 線_Rl I N-C-Z II 〇 (Please read the precautions before filling in this page) Install & Order _ Line_

RR

N (I)N (I)

IV 經濟部屮央標準劝Π工消&quot;合作社印製 式中 - Ri代表fi原子;(Ci-“)烷基或具(Ci-C*)烷基之苯 亞烴基;式- Zi-NI^IU之胺基亞烴基•其中h代表 (C2-C4)亞煙基且R*及Re分別代表Η或(“-Cd烷基或與 5- 本紙张尺度边用中S Η家標毕(CNS) Ή規格(210X29V公龙) 81. 6. 10,000張(Η) Λ 6 Π6 五、發明说明⑷ gjg接之《原子,形成鰌和_瓖諸如:嚅«基,%咯啶基 ,H-六«吡啶基,六氫吡畊基或(Ci-Cs) 4-烷基六氫吡畊 _ ; S-Z2COORe之視情況酯化羧亞煙基•其中Ζ2代表 (Cl-c*)亞嫌基且R«代表η或((Μβ)烷基;(c2-ce&gt; m g想3i ;式-Za-COHR^Re之胺基甲釀亞煙基•其中Z3代表 (Ci-Cd亞《基且h及R*分別代表Η或(Ci-“)烷基, 或具Η之雑瓖例如:NR*RS ; (Cz-Ce)羥亞《II ,或 ih-Cio)烷氧亞烴基; _ RIV代表未被取代或被一或多钃(Ci-D烷基取代之 (C3-C7)環烷基;芳基諸如苯基其為未被取代或钃薄 一或多僩選自鹵素*尤其氣或氟取代基者,(Ci-Ce) 烷基*及(Ci-Cs)烷氧基及硫代烷氧基,硝基及三氟 甲基或諸如螓瓖•其包含至少一雜原子選自〇, s及 Η,尤其呋_基,噻吩基,吡咯基,吡唑基·咪唑基 ,吡啶基•吡畊基,《1«基及噻唑基.其視情況被 (Ct-Cs)烷基或di索原子或(Ci-Ca)烷氧基取代者成 Riv 及 Rv起代..··表-------------------------- ,IV The Ministry of Economy ’s Standards Advise Π 工 消 &quot; Cooperatives to print the formula-Ri stands for fi atom; (Ci- ") alkyl or benzene alkylene group with (Ci-C *) alkyl; formula-Zi-NI ^ IU Aminoalkylene group • where h represents (C2-C4) nicotine group and R * and Re represent Η or (“-Cd alkyl or 5- and this paper scale is used in the S Η family standard ( CNS) Ή specification (210X29V male dragon) 81. 6. 10,000 sheets (Η) Λ 6 Π6 V. Description of the invention ⑷ gjg is connected to "atoms, forming 鰌 and _ 瓖 such as: 嚅« base,% pyrrolidyl, H- Hexa «pyridinyl, hexahydropyridinyl or (Ci-Cs) 4-alkylhexahydropyridinium ;; S-Z2COORe optionally esterifies the carboxynicotinoyl group • where Z2 represents (Cl-c *) And R «represents η or ((Μβ) alkyl; (c2-ce> mg think 3i; the formula -Za-COHR ^ Re amine methyl nicotinic group • where Z3 represents (Ci-Cd sub h and R * represent Η or (Ci- “) alkyl, or 盧 瓖 with Η for example: NR * RS; (Cz-Ce) hydroxyidene II, or ih-Cio) alkoxyalkylene; _ RIV Represents unsubstituted or substituted with one or more strontium (Ci-D alkyl (C3-C7) cycloalkyl; aryl such as phenyl which is unsubstituted or strontium one or Phenol selected from halogen * especially gas or fluorine substituents, (Ci-Ce) alkyl * and (Ci-Cs) alkoxy and thioalkoxy, nitro and trifluoromethyl or such as trioxa Contains at least one heteroatom selected from 〇, s and Η, especially fur_-yl, thienyl, pyrrolyl, pyrazolyl · imidazolyl, pyridyl • pyroctyl, "1« group and thiazolyl. It is subject to (Ct-Cs) alkyl or di-so atom or (Ci-Ca) alkoxy substituted for Riv and Rv ......................... ---------,

經濟郎屮央找半劝Α工消作合作杜印51 «嚐唯環之4位上的笨基碳结合且其中u等於1-3者· 視情況钃帶一或多届Up)取代基U,其為相阗或相舆,m 自鹵素原子,(G-Cd烷基及烷氧基,确‘基及三氟甲基· -6- 81. 6. 10,〇〇〇张(Η) (請先閱讀背而之注意事項#蜞寫本頁) 本紙5民尺度边用中明Η家標準(CNS) TM規怙(210X297公度) 202448 82.12.2 2 Λ 6 [? 6 五、發明説明(5) np 等於 0-3; ‘ - Rv代表-(CH2) _-X基,其中β是0-5且X代表 • '鹵素原子•較佳溴原子,羥基· (C3-C7)環烷基, 苯基其可被選自鹵素原子·(Ca-Cs)烷基或烷氧基 ',或硝基,胺基*羥基或三氟甲基其中一基取代者 遘自 -COOH; -COOXj -O-COX!; -SCOX!; (OJq-S-Xi with.q = 0.1 or 2; -O-COOXj; N-CO-Xi with X3 = H or (C^Cj) .alkyl; X3 -NH-C-O-X,; -O-C-NH-Xi; -NH-C-NHXi with W = O or S;II « I〇〇 w -NH~C-(CH2)b-C00H with s = 2,3,4II o (請先閲請πώ'之注意事項#艰¾本頁) 裝- 訂 經濟部屮夾從準而Π工消作合作社印5i 其中代表(Ci-Ce)烷基;苯基其可被一或多届選自鹵素 原子,(“-(:3)烷基或烷氧基或硝基,胺基•羥基或三氟 甲基取代者;金剛烷基;選自-CONXiXz; -NXiXa之一基; 其中Xi代表氫·(C/Ca)烷基或笨基其未被取代或被一或 多届埋自鹵索原子’·(Ci-U烧基或烷氧基或硝基,胺基 或三氟甲基取代者且5U代表氫原子,(Ca-Ca)烷基 &lt; 或變 更為¥1及5&lt;2與其連接之氮原子構成一雜環·此雜環^自吡 咯啶或六fi吡啶,其未被取代或被《基或被羥基取代者, 後者為未被取代或被豳基取代或被- cooXise-conXiXz基取 代者; -7- 本认法尺度边用中Η H 1MCNS) ΊΜ規仂(210x297公犮) 81. 6. 10,000¾ (Η) 線. 經濟部屮央ι-s準而Π工消仰合作杜印5i £02448 Λ 6 ___Π_6_ 五、發明説明(6 ) 或變更為Rvaa-C»*)烷氧基;羥基;具5或6元未被 取代或被氧基或羥基取代之環狀胺;未被取代或纆 -COOAlk N-取代之六氫吡畊基•其中Aik代表 (Ci-CB)烷基;羧酸基· -ΝΧ2Χ«基,X« = H或 X4 = -(CH2)t:-Xe ,t 等於 2, 3或 4 且 IU 代表-0H , -O-CO-Rz · -HHCORz · -HH-C-HHR2Economic Lang Langyang asked half to persuade A Gongxiao to cooperate Du Yin 51 «Taste only the 4th position of the stupid carbon combination and where u is equal to 1-3, depending on the situation with one or more sessions Up) substituent U, which For phases or phases, m is from a halogen atom, (G-Cd alkyl and alkoxy, and the base and trifluoromethyl · -6- 81. 6. 10, 〇〇〇 Zhang (Η) (please First read the back and the notes # 蜞 write this page) This paper is 5 people-scale side-by-side Zhongming Η family standard (CNS) TM regulations (210X297 degrees) 202448 82.12.2 2 Λ 6 [? 6 V. Description of invention ( 5) np is equal to 0-3; '-Rv represents-(CH2) _-X group, where β is 0-5 and X represents •' halogen atom • preferably bromine atom, hydroxyl · (C3-C7) cycloalkyl , Phenyl which may be selected from a halogen atom · (Ca-Cs) alkyl or alkoxy ', or nitro, amine * hydroxy or trifluoromethyl one of which is substituted by -COOH; -COOXj- O-COX !; -SCOX !; (OJq-S-Xi with.q = 0.1 or 2; -O-COOXj; N-CO-Xi with X3 = H or (C ^ Cj) .alkyl; X3 -NH- COX ,; -OC-NH-Xi; -NH-C-NHXi with W = O or S; II «I〇〇w -NH ~ C- (CH2) b-C00H with s = 2,3,4II o ( Please read the notes of πώ '# Difficulty Page) Binding-Ordered by the Ministry of Economic Affairs to be compliant and printed by the Cooperative Society 5i which represents (Ci-Ce) alkyl; phenyl which can be selected from halogen atoms for one or more sessions ("-(: 3) Alkyl or alkoxy or nitro, amino • hydroxy or trifluoromethyl substituted; adamantyl; selected from one of -CONXiXz; -NXiXa; wherein Xi represents hydrogen · (C / Ca) alkyl or The stupid group is unsubstituted or buried for one or more times from the halogen atom '· (Ci-U burning or alkoxy or nitro, amine or trifluoromethyl substituted and 5U represents a hydrogen atom, (Ca -Ca) alkyl &lt; or change to ¥ 1 and 5 &lt; 2 and the nitrogen atom to which it is connected constitutes a heterocyclic ring. This heterocyclic ring is derived from pyrrolidine or hexafi pyridine, which is unsubstituted or substituted by hydroxy or hydroxy In the latter case, the latter is unsubstituted or substituted by 豳 group or substituted by -cooXise-conXiXz group; -7- This standard method is used in the middle of the standard Η H 1MCNS) ΊΜ 簂 (210x297 公 犮) 81. 6. 10,000¾ (Η) line. The Ministry of Economy ’s quasi-square and Π Gong Xiao Yang cooperation Du Yin 5i £ 02448 Λ 6 ___ Π_6_ V. Description of the invention (6) or change to Rvaa-C »*) alkoxy; hydroxyl; 5 or 6 yuan is not substituted or oxygen Or hydroxy-substituted cyclic amine; unsubstituted or substituted -COOAlk N-substituted hexahydropyridyl • where Aik represents (Ci-CB) alkyl; carboxylate · -ΝΧ2Χ «group, X« = H or X4 =-(CH2) t: -Xe, t is equal to 2, 3 or 4 and IU stands for -0H, -O-CO-Rz · -HHCORz · -HH-C-HHR2

(I Ο 其中代表(Ci-Ce)烷基;或-HR2R3基•其中|^2或Rs分別 代表Η * (Ci-Ce)烷基,未被取代或被一或多e取代基取 代之苯基,此取代基選自鹵素原子或(Ci-Ca)烷基或 (Ci-Ca)烷氧基•或R2及R3與其連接之氮原子構成一具5 或6元姐份之雑環; -Z代表含一或多儡選自0, S及N雜原子之雜瑁,耦合 至一芳族環*其可含一選自0, S及N之辕原子並且可 被一或多個基取代,此取代基邇自鹵素原子. (h-Cs)烷基及烷氧基,或苄氣基•硝基,胺基及三 氟甲基·《I原子Η可能是芳香性或呈-NH形式,其為 未被取代或被(“-C*)烷基,羧亞烴基-24-(:00111〇取 代•其中Ζ4代表(Ci-“)亞烴基且是Η *苄基或 (Ci-Ce)烷基;胺基甲_亞烴基-Ze-CONRuR^ ,其 中Re代表(“-C*)亞烴基且Ru及1?12分別代表η , (C^-Ce)烷基•或與Ν形成飽和雜環諸如嗎啉基或六 氫吡啶基;Bf*C0R13 ,R13代表(C^U)烷基或笨 基;烷氧期基-C00R14 ,R14為第三-丁*或苄基; -8 _ 本紙張尺度逍用中曲Η家樣1HCNS)1M規格(210X297公龙) 81. 6, 10 000張(H) (請先閲#背而&lt;注意事項再蜞寫本頁) 裝_ 訂· 線. 203448 Λ 6 Π 6 五、發明説明(7 ) 以及這些化合物與嫵機或有機酸及鐮之附加鼸;本發明也 包括製備Β第上可接受之非毒性鹽的製備,但是其他豔類 可用於分離或純化式(I )之化合物的也包括在本發明之內 烷基·亞烴基•烷氧基及磙代烷氧基可為嫌狀或.分支者 &gt;,° 、/ Ζ特別代表苯并_吩基,笨并呋哺基•苯并嗶唑基•苯 并咪唑基,苯并噻唑基•吲哚基,異吲哚基•吲哚啉基· « 異吲哚啉基,嘈啉基,異_啉基,枝喏啉基,唼唑啉基, 啤啉基及[2,3-c]-噻吩并或[3,2-c]吡啶基。 當Z代表下式之吲哚基時: (請先閲#背而之_注意事項再填寫本頁) 裝 訂· / (Xi)ni(I Ο where represents (Ci-Ce) alkyl; or -HR2R3 group • where | ^ 2 or Rs respectively represents H * (Ci-Ce) alkyl, unsubstituted or substituted by one or more e substituents benzene The substituent is selected from a halogen atom or a (Ci-Ca) alkyl group or (Ci-Ca) alkoxy group • or R 2 and R 3 and the nitrogen atom to which they are connected constitute a 5 or 6-membered ring;- Z represents a heterogen containing one or more heteroatoms selected from 0, S and N heteroatoms, coupled to an aromatic ring * It may contain a copious atom selected from 0, S and N and may be substituted by one or more groups , This substituent is from a halogen atom. (H-Cs) Alkyl and alkoxy, or benzyl group • nitro, amine and trifluoromethyl · "I atom Η may be aromatic or in -NH form , Which is unsubstituted or substituted by ("-C *) alkyl, carboxyalkylene-24-(: 00111〇 • wherein Z4 represents (Ci-") alkylene and is H * benzyl or (Ci-Ce ) Alkyl; aminomethyl-alkylene-Ze-CONRuR ^, where Re represents (“-C *) alkylene and Ru and 1-12 represent η, (C ^ -Ce) alkyl • or with Ν Saturated heterocycle such as morpholinyl or hexahydropyridyl; Bf * COR13, R13 represents (C ^ U) alkyl or stupyl; alkoxy stage -C00R14, R14 is the third-butyl * or benzyl; -8 _ This paper size is easy to use Zhongqu Η home-like 1HCNS) 1M specifications (210X297 male dragon) 81. 6, 10 000 sheets (H) (please read first # 背 而 &lt; Precautions will be written on this page) _ _ binding · thread. 203448 Λ 6 Π 6 V. Description of the invention (7) and the additional reels of these compounds and organic acids or organic acids and sickles; the invention also includes Preparation of the B-th acceptable non-toxic salts, but other compounds that can be used to isolate or purify the compound of formula (I) are also included in the present invention alkyl, alkylene, alkoxy and alkoxy alkoxy The base may be suspected or branched, °, / Z especially represents benzo_phenyl, benzofuryl, benzopyrazolyl, benzimidazolyl, benzothiazolyl, indolyl, Isoindolyl • Indolinyl · «Isoindolinyl, nozinolyl, iso-pyridinyl, branched cinnolinyl, oxazolinyl, beerlinyl and [2,3-c] -thieno Or [3,2-c] pyridyl. When Z represents an indolyl group of the following formula: (Please read # 背 而 之 _Cautions before filling out this page) Binding · / (Xi) ni

R 9 線- 經濟部屮央標準&gt;(0卩工消价合作社印?4 式中(Xdu代表芳族環之視悄況取代基*Re可代表Η ; (U-C*)烷基;式-Z-C00Rlo之視悄況醮化羧亞烴基,其 中Z*代表(Ci-“)亞«基且R10代表Η ·苄基或(“-Ce) 烷基;式-Ze-CONR^Ru之胺甲醯亞烴基,其中Rn及 R12分別代表Η或(C^-Ce)烷基或與N形成鉋和雜環·此 雜環選自嘴啉基或六氲吡啶基且亞烴基:式 COR13之釀綦*其中R13代表(Ci-C*)烷基或苯基·•式 本紙5JL尺度逍用中S B家详半(CNS) &quot;ΡΊ規格(210x297公龙) 81. 6. 10,000張(H) 202448 Λ 6 Π 6 五、發明説明(8) C00R14之烷氧羰基•其中代表第三丁基或苄基。 I &gt; 式(I )之化合物中,IU代表氫者較佳且其中更特別地是 那些其中Z代表在氪原子上被取代或未被取代之«哚基者 ;RIV基中苯基較佳。 本發明之主題也是式(I)之化合物的製備,其藉由式( I )之胺基噻唑之耰合反懕製備之:.Line R 9-Ministry of Economic Affairs Standards (0 卩 工 消 价 合作社 印? 4 In the formula (Xdu stands for aromatic ring depending on the situation, the substituent * Re may represent H; (UC *) alkyl; formula- Z-C00Rlo is based on the fact that the carboxyalkylene group is substituted, where Z * represents a (Ci- ") subunit and R10 represents H · benzyl or (" -Ce) alkyl; an amine of the formula -Ze-CONR ^ Ru Carboxyalkylene, where Rn and R12 represent Η or (C ^ -Ce) alkyl or form a planicyclic and heterocyclic ring with N. This heterocyclic ring is selected from the group consisting of porphyrinyl or hexapyridyl and alkylene: the formula COR13 Brewing Qi * where R13 stands for (Ci-C *) alkyl or phenyl •• type paper 5JL scale for SB family details (CNS) &quot; ΡΊ specification (210x297 male dragon) 81. 6. 10,000 sheets (H ) 202448 Λ 6 Π 6 V. Description of the invention (8) C00R14 alkoxycarbonyl group • which represents the third butyl or benzyl group. I &gt; Of the compounds of formula (I), IU represents hydrogen is more preferred and more particular The ground is those where Z represents a «dolyl group which is substituted or unsubstituted on the krypton atom; a phenyl group is preferred in the RIV group. The subject of the present invention is also the preparation of compounds of formula (I), which is obtained by the formula (I ) Of:

(請先閲,·**,?背而·v/注意事項#碭寫本頁) 經濟部屮央伐準而Π工消设合作社印5i 式中iU· RIV及“具有(I )之既定意義者,於胺基釀化之 普通條件下*與式Z’COOH之酸•其中Z’代表Z或一纆取代 Z ,其中Z之反應基已鋟被保護,且fU,Rv,RIV及Z與 式(I )中之意義相同者·或輿酸Z'COOH之活化形式,諸如 醣基鹵•酸酐•較佳混合酐諸如碳酸酐,或活化酯反應· 獲得在肽合成上普通使用之試麵。 化合物(Π)可被保護;在此情況,代表輿^相同取 代碁,其中存在之胺基是經保護,RIVA及RVA代表與 RIV及Rv相同之取代基•其中羥基或胺基是經0-及N-保罐 0 —旦此基纆保護·若霱要•於埔合之後•可進行遽當去 保護反應。 式(I)之許多胺基噻唑是巳知化合物。, -10- 本紙5fc尺度边用中《Β家«毕(CNS)tM規怙(2丨0x297公放) 81. 6. 10,000張(H) 2,02448 Λ 6 Π 6 五、發明説明(9) 此新胺基嘻唑可根據特別在Bull. Soc. Chia(c&gt; 1963, 2498-2503中描述之其中一種方法製備之。 一般,碴臃偽根據下列反應流程輿α 化,較佳 溴化酮反應: m η丄 NHR,(Please read first, · ** ,? 背 而 · v / Notices #Dang write this page) The Ministry of Economic Affairs has approved the central government and set up a cooperative cooperative to print 5i in the iU · RIV and "have (I) 's established Meaning, under the general conditions of amine brewing * and acid of the formula Z'COOH • where Z 'represents Z or a substituted Z, where the reactive group of Z has been protected by sulfonium, and fU, Rv, RIV and Z The same meaning as in formula (I) · or the activated form of the acid Z'COOH, such as sugar halide • anhydride • preferably mixed anhydride such as carbonic anhydride, or activated ester reaction • to obtain a trial for common use in peptide synthesis Compound (Π) can be protected; in this case, it represents the same substituted amine, the existing amine group is protected, RIVA and RVA represent the same substituents as RIV and Rv • where the hydroxyl or amine group is 0- and N- 保 罐 0-Once this base is protected, if it is required • after the Puhe • can be subjected to an immediate deprotection reaction. Many aminothiazoles of formula (I) are known compounds., -10- The 5fc scale of this paper is used in the "B Family" (CNS) tM specification (2 丨 0x297 public) 81. 6. 10,000 sheets (H) 2,02448 Λ 6 Π 6 5. Description of the invention (9) This new amine Hipzole can be prepared according to one of the methods described in Bull. Soc. Chia (c &gt; 1963, 2498-2503. In general, the sham is pseudo-α-formed according to the following reaction scheme, preferably bromoketone reaction: m η丄 NHR,

Rvv/BrRvv / Br

RR

NH 十 2 ^ιν οNH 十 2 ^ ιν ο

丨、-臟: 一 N (請先閲^'背而之,注意事項#填寫本瓦)丨,-Dirty: One N (please read ^ 'on the contrary, note #fill in this tile)

RR

IV mIV m

IV πIV π

Ri,RIV及Rv與式U)者具相同意義。 各種不同化合物(J J中代表胺烷基者之製《被描述在 M濟部屮央ιΐ準而=5工消奸合作社印5i 歐洲專利-A-0,283,390 ◊ ____________________ ·-·------------- ------ , . .. ·χ.... ~ C(-鹵化酮及硫脲可藉由其原理描述在文獻上之方法製 備之;因此,ct -溴化酮(IV)可_由RvCHaCORzv與溴;在 _酸基霣中反應製衡之或與溴化嗣在有機溶劑諸如乙酸乙 酯•含《溶劑或其混合液中反應製《之。起始芳族_ 一般 是鞴Friede卜Crafts反應製備之,而胞族甲基_則可由重 氮甲烷與《當羧酸氣反應* _後將對應重氮酮水解製備之 Ο α -氛化芳族酮可藉Friedel-Crafts反應,用迪當α - 11 本紙尺度边用中明a家標準(CNS) Τ4規格(2U1X29丫公徒) 81. 6.】〇,000張(H) 202448 A 6 η 6 五、發明説d (10) 氯化醯基氯製備之。、 當Rv代表醣基((:112:)_-(:0(^1時,下面式(V)之對應取代 噻唑’其中RIV ,/1及如(I )所定義者是已知化合物或 根據已知方法•由α-溴乙釀酸或α-溴酮基酯與磓脲, 根據下列反應流程反應製備之: ., ' '淹 理 2Ri, RIV and Rv have the same meaning as those of formula U). A variety of different compounds (made by those who represent amine alkyl groups in JJ "Described in the Ministry of Economic Affairs, Ministry of Economic Affairs and the People's Republic of China = 5 Gong Xiaotong Cooperative Society Printed 5i European Patent-A-0,283,390 ◊ ____________________ ·-· ------ ------- ------,....... ~ C (-halogenated ketones and thioureas can be prepared by methods described in the literature on their principles; therefore, ct- Brominated ketone (IV) can be prepared by reacting with RvCHaCORzv and bromine; reacting in an acid base or with brominated bromide in an organic solvent such as ethyl acetate • containing "solvent or its mixed solution". Shi Aromatics _ are generally prepared by the Friede Bu Crafts reaction, while the Cell Methyl _ can be prepared by the hydrolysis of the corresponding diazo ketone by diazomethane and "when the carboxylic acid gas reacts * _ α-Aromatic Aromatic Aromatics Ketones can be borrowed from Friedel-Crafts reaction, using DiDang α-11 paper scales and using Zhongming a's standard (CNS) Τ4 specifications (2U1X29 Yageong) 81. 6.】 〇, 000 sheets (H) 202448 A 6 η 6 V. The invention d (10) Prepared by acetyl chloride. When Rv represents a sugar group ((: 112:) _- (: 0 (^ 1, the corresponding substituted thiazole of the following formula (V) RIV, / 1 and as defined by (I) • or known compounds, prepared according to known methods α- or α- bromoacetyl stuffed bromo keto acid ester with urea according to the following reaction scheme Dui reaction of:., '' Li 2 flooded

Br 2 RIV-C〇'-(CH2)m+ rCOOX!'~► Riy-CO-CH-(CH2)m-COOX!Br 2 RIV-C〇 '-(CH2) m + rCOOX!' ~ ► Riy-CO-CH- (CH2) m-COOX!

Br (請先閲-ift背而之注·意事項再堝寫本頁)Br (please read -ift's note and notes before writing this page)

= S H〆= S H〆

X NHCOZ ♦ 醣化反懕X NHCOZ ♦ Saccharification and backwashing

X1〇C-(CH2)] o RX1〇C- (CH2)] o R

Ύ -NΎ -N

NH 2NH 2

IV (la) (V) 經濟部屮央榣準而Π工消价合作社印31 依取获:基Rv之值,使用下列製備方法: a) -當Rv代表-_(CH2)«-0H基時,下列式(VI)之對應取代 2-胺基_唑,其中如(I )所定義者,可由上面酯(V), 賴由用緻金鼷氫化物例如:氫化鋁鋰在對霣子梅性之$劑 諸如四氫呋庐中埋原成式(VI)之胺基酵: H〇-(CH2)m^S 丫 NH:IV (la) (V) The Ministry of Economic Affairs is approved by the central government, and the price is printed by the cooperative. According to the value obtained: base Rv, the following preparation method is used: a)-When Rv stands for -_ (CH2) «-0H base At the time, the corresponding substituted 2-amino-oxazoles of the following formula (VI), where as defined in (I), can be derived from the above ester (V), depending on the use of gold hydride for example: lithium aluminum hydride A medicinal agent such as tetrahydrofuran buried in the original formula (VI) amino enzyme: H〇- (CH2) m ^ S 丫 NH:

•N• N

RR

IV (VI) -12 本紙張疋度边用中《曲家1Ϊ苹(CNS)IM规t5(2K)x297公龙) 81. 6. 10,000¾ (H) 202448 Λ 6 Π 6 五、發明説明(11) (VI)用ZC00H鼸化*得下式之化合物(I b) HO-(CH2),IV (VI) -12 This paper is used in "Qu Qu 1 Ϊ Apple (CNS) IM regulation t5 (2K) x297 male dragon) 81. 6. 10,000¾ (H) 202448 Λ 6 Π 6 V. Description of invention ( 11) (VI) Using ZC00H to obtain the compound of formula (I b) HO- (CH2),

τ -Nτ -N

NHCOZNHCOZ

RR

IV (lb) 式中·,RIV及Z如(I)所定義者; b)_當Rv代表醮基-(CHaVM-O-CO-Xi或確_ 其中 iXiRq如(I)所定 義者,纆取代2 -胺基_唑(调)* (Vic)或(VId) 其中 Riv * ς ,《ϊ ,W及XiWU)所定義者,可依下列方法製 備之 _根據下列流程3: (請先閲-背而之注意事項再填W本頁) 經濟部屮央榀準工消&quot;合作社印14 -13 本尺度逍用中《81家榀準(€肊)〒&lt;1規岱(210父297公龙) 81. 6. 10,000張(H) 202448 ..,12. 五、發明説胡(12)IV (lb) where ·, RIV and Z are as defined in (I); b) when Rv stands for 鈮 基-(CHaVM-O-CO-Xi or indeed _ where iXiRq is as defined in (I), 纆Substitute 2-amino-oxazole (tune) * (Vic) or (VId) where Riv * ς, "ϊ, W and XiWU) can be prepared according to the following method_ according to the following procedure 3: (Please read first -For further considerations, please fill in this page.) The Ministry of Economic Affairs, Jiyang, quasi-work consumption &quot; Cooperative cooperative seal 14 -13, the standard is used in the "81 family quasi (€ 肊) 〒 &lt; 1 regulations Dai (210 father 297 male dragon) 81. 6. 10,000 sheets (H) 202448 .., 12. Fifth, the invention of Hu (12)

Nal RIV&quot;Jy'lCH2)m+ l'Cl Ο CH^COCH^Nal RIV &quot; Jy'lCH2) m + l'Cl Ο CH ^ COCH ^

Riw-C-iCHT)-1V li - m+1 O X^H R:IV-CO-CH-(CH2)m-W-CO-X1Riw-C-iCHT) -1V li-m + 1 O X ^ H R: IV-CO-CH- (CH2) m-W-CO-X1

0 4 Γ5ΧΙ 6 〇 Q i X,C〇WwκΓ or X^OW Cs , (請先閲^背而之注’意事項再碼寫本頁)0 4 Γ5ΧΙ 6 〇 Q i X, C〇WwκΓ or X ^ OW Cs, (please read ^ Backward Note ‘Notes before writing this page)

Br (W = O or S)Br (W = O or S)

H^NH ^ N

C ΗλΝ II 〇C ΗλΝ II 〇

Rt S、/NH2醢化反® N -► (Ic) 〇r (Id) X,-C-W.(CH2)m.Rt S, / NH2 醢 化 反 ® N -► (Ic) 〇r (Id) X, -C-W. (CH2) m.

(vnc)or(VHd) 經濟部屮央榀準A A工消·ί\··合作杜印31 R.(vnc) or (VHd) The Ministry of Economic Affairs of the People's Republic of China quasi-A Agong ·· \ ·· Cooperative Du Yin 31 R.

YY nh2 sYY nh2 s

II nh-,-c-nh2 N ^~:- R^-C-CH-CC^J^-SX,II nh-,-c-nh2 N ^ ~:-R ^ -C-CH-CC ^ J ^ -SX,

-14- 本紙張尺度通用中明a家烊半(CNS)IM規格(210x2974*) ία 6 • Br- 81. 6. 10,000張(Η) £02448 Λ 6η 6 五、發明说4 (13) -或由Ν -保護酵(VI )諸上面所定義者’與醣基氢諸如 乙鼸氛v在溶劑諸如ϋ中反應,_得下式之酯:-14- The size of this paper is generally applicable to the IM standard of the Ming Dynasty (CNS) (210x2974 *) ία 6 • Br- 81. 6. 10,000 sheets (Η) £ 02448 Λ 6η 6 V. Invention 4 (13)- Or by Ν-protected leaven (VI) as defined above 'reaction with glycosyl hydrogen such as ethyl monoxide v in a solvent such as ϋ, to obtain an ester of the formula:

Xi-C-〇-(CH2)i YSY •N ΜΗ·Xi-C-〇- (CH2) i YSY • N ΜΗ ·

RR

IV (Vllc)with W = 0 orIV (Vllc) with W = 0 or

-XrC-0-(CH2) ^ NHCOZ-XrC-0- (CH2) ^ NHCOZ

RR

N (請先閲-;'*?背而之注邊事項洱碭寫本頁) IV, (Ic) 式中Xi*· ,RIV或Z如上面(I)所定義者; c)-當Rv代表胺基甲酸酷- (CHzh-O-CO-HHXi,其中ϋ 及乂1如(I )所定義者,根據本發明之經取代噻唑是由對應 羥基化化合物(I b),由式Xi_N = C = 0之異氰酸酯,在對霣 子惰悸之溶劑例如:四氩呋喃或二氣甲烷,於2〇C-i〇〇t: 之湛度随反應,得下式之化合物(.1 f): 裝· 訂_ 經濟部屮央榀準而:^工消炸合作社印驭 Χι- ΗN (please read-; '*? Back to the side of the note to write this page) IV, (Ic) where Xi * ·, RIV or Z are as defined in (I) above; c) -When Rv Represents aminocarbamate-(CHzh-O-CO-HHXi, where ϋ and Q1 are as defined in (I), the substituted thiazole according to the present invention is composed of the corresponding hydroxylated compound (I b), represented by the formula Xi_N = The isocyanate with C = 0, in a solvent that is inert to the beaker, for example: tetrahydrofuran or methane gas, at 2〇Ci〇〇t: the degree of purity with the reaction, the compound of the following formula (.1 f): · Order _ The Ministry of Economic Affairs, the central government, is accurate: ^ 工 工 炸 炸 合作社 印 忆 Χι- Η

NH-COZ 及Ζ如(I )所定襄者; 15- 私紙張尺度边用中》W茱榀毕(CNS) 規格(210x297公放)NH-COZ and Z as defined by (I); 15-Private paper size in use "W Zhu Yubi (CNS) specifications (210x297 public)

Of) 81. 6. 10,000張(H) £02448 6: Λ6β 五、發明説明(h) &lt;1)二當{^代表_醮胺-((:1{2)*«-00.(^:112,其中,..,.-)^及 Xss$D(I)所定義者;’福據本發-明之嗅啤則令睽輿式 (乂&gt;或_(13)乏對應醮_.+在有或無溶劑諸如鐽酵存.在下, -. · - - 於2〇-12〇1之溫度間反靡製備之;此反應(依辑是否具揮 發性)·也可在密閉眘中進行,得下列化學式之也合物(相 ).或(I g): :、 .....·-、..、,. , . : .· . Λ * —·. · ). X :v-.,.:'.' XlX2-^t(CH2) ς ΝΗ, - 0 YV '· Ν m r 而 之 t- 事 項 m % 本 頁Of) 81. 6. 10,000 sheets (H) £ 02448 6: Λ6β V. Description of the invention (h) &lt; 1) Erdang {^ representative _ propanamine-((: 1 {2) * «-00. (^ : 112, where, .., .-) ^ and Xss $ D (I) are defined; 'Fu according to this issue-Mingzhi Beer makes the public opinion (乂> or _ (13) lack of corresponding _ . + Prepared in the presence or absence of solvents such as fermented yeast. Below,-. ·--It is prepared at a temperature between 2〇-12〇1; this reaction (depending on whether it is volatile) · can also be carefully sealed Carried out in the process, to get the following chemical formula (phase). Or (I g) ::, .....--, ..,....... Λ * — · ..). X : V-.,.: '.' XlX2- ^ t (CH2) ς ΝΗ,-0 YV '· Ν mr and t- matters m%

RR

IV (VIII) 或IV (VIII) or

XlX2-Nf(CH2)m ,NHCOZο \XlX2-Nf (CH2) m, NHCOZο \

ΝΝ

RR

IV (Ig) 經濟部屮央榀準而Η工消1V·合作社印31 式中Χα,χ2, ,RIV及,視情況Ζ如(I )所定義者; e&gt; -當Rv代表胺基-(CH2) «-ΝΧ^Χζ ,根據本發明之經取 代噻唑的製供例如,鞴由式(VI)之上述醢胺,用醮金饜氩 化物諸如氳化鋁鋰,在溶BI例如:四氫呋喃中*於201:及 溶銷之沸嫌溫度間《原,得式(I X)之化合物:IV (Ig) The Ministry of Economic Affairs has approved it and H Gongxiao 1V. Cooperative Society Seal 31 where Χα, χ2,, RIV and, as the case may be, as defined by (I); e &gt;-when Rv represents an amine group- ( CH2) «-ΝΧ ^ Χζ, the preparation of substituted thiazoles according to the present invention is provided, for example, from the above-mentioned compound amine of formula (VI), with a gold arsenide such as lithium aluminum hydroxide, dissolved in BI such as: tetrahydrofuran * Before 201: and the melting temperature of the dissolving agent "The original compound of formula (IX):

XlX2-N-(CH2)m+;XlX2-N- (CH2) m +;

Η- ΝΗ- Ν

RR

IV (DC) -16 本紙ft尺度边用中B國家樣準(CNS) 1M規仿(210x297公¢) 81. 6. 10,000¾ (H) 202448 Λ 6 Π 6 五、發明説兩(15) (I X }用ZC001T釀化•得式U l h)'之化合物: X2X2-N-(CH2)m+K ς .NH-CO-Z Υ —ΝIV (DC) -16 The ft scale of this paper is used in the National B National Standard (CNS) 1M standard (210x297 g) 81. 6. 10,000¾ (H) 202448 Λ 6 Π 6 V. Invention two (15) ( IX} Brewed with ZC001T • Compound of formula U lh) ': X2X2-N- (CH2) m + K ς .NH-CO-Z Υ —Ν

RR

IV (Ih) _ .-- · ~· ; · r - ' - - '·- · , ·, 及ζ '如(I )所定義者τ : 其中 Xi , χ2 , · R: f) - i Rv代表碳酸^酷 (CH2) /-Ο-ΟΟΟΧ:,;其:中:及 (.1 )所定義者,根據本發明之噻7唾是由酵(I b ) *3得· _ 藉由酵(ib)與氛甲酸酯(n-c-oxx,在鹺諸如三乙胺或吡 〇 啶存在下反應,得下式之化合物(I u : χΊο-|-ο-(αΗ2) 〇IV (Ih) _ .-- · ~ ·; · r-'--' ·-·, ·, and ζ 'as defined by (I) τ: where Xi, χ2, · R: f)-i Rv Represents carbonic acid ^ ku (CH2) / -Ο-ΟΟΟΧ: ;; ::: and (.1) as defined, according to the present invention, the thio 7 saliva is made by leaven (I b) * 3 get · _ by leaven (Ib) reacted with chloroformate (nc-oxx, in the presence of cyanide such as triethylamine or pyridine) to give a compound of the formula (I u: χΊο- | -ο- (αΗ2) 〇

ΥΥ

NH-CO-Z 先 閲 ff ιΓΓ; -¾ 意 事- 項 再 A%ΫΊ, 本. 頁 裝 玎 線NH-CO-Z first read ff ιΓΓ; -¾ Matters-Item then A% ΫΊ, this page. Thread

R Ν IV. (Ii) 式中Xi 及Z如(I )所定義者 經濟部屮央桴準:;Γβ工消坨合作社印¾. s)-當RIV及Rv在一起代表下基: (Xp)np. -17- 本《•張尺度边用中明®家標华(0Ν5)ΤΊ規格(210x297公没) 81. 6. )〇,_張⑻ £02448 五、發明説明(16) 式中(X»&gt;)nP及u如(I &gt;所定義者,經_唑環之4位上的苯 基碳原子结合時;例如:下式之中間Μ 4-澳-211-二氳-3,4-[1]-笨并維革-5-鬭:R Ν IV. (Ii) where Xi and Z are as defined by (I), the Ministry of Economic Affairs, Jiyang Zhenzhun :; Γβ 工 消 坨 cooperative cooperative seal ¾. S)-when RIV and Rv together represent the following base: (Xp ) np. -17- This "• Zhang Scale Edge Use Zhongming® Jiabiaohua (0Ν5) ΤΊ specification (210x297 public) 81. 6.) 〇, _ 张 ⑻ £ 02448 V. Description of the invention (16) where (X »&gt;) nP and u are as defined in (I &gt;, when they are bonded via the phenyl carbon atom at the 4-position of the _azole ring; for example: in the middle of the following formula Μ 4- 奥 -211- 二 氲- 3,4- [1] -Benweiweige-5-Liang:

係根據 G. Fontaine 等人,C. R. Acad. Sci., 1965 45 83中描述之方法製得;下式之2-肢基- 4,5--[5,4-d]-噻啤并[1] -苯并 xepine : NH2 氫 (請先閲請背而之注意事項#堝寫本頁) 裝·It was prepared according to the method described in G. Fontaine et al., CR Acad. Sci., 1965 45 83; 2-limb- 4,5-[5,4-d] -thiabo [1 ] -Benzo xepine: NH2 hydrogen (please read the notes on the back # Cao write this page)

(X) 係用硫腺根據上面描述之普通方法環化,然後醣化成下式 之化合物:(X) is cyclized with sulfur gland according to the general method described above, and then saccharified into a compound of the formula:

(【j) 訂 線- 式中z如(I )所定酱者; -18 本汍張尺度边用中09國家楳半(CNS)IM規格(210X297公¢) 81. 6· 10,000張(H) ^02448 Λ 6 Π 6 五、發明説明Ο7) h&gt; -當Rv代表胺基- ΗΧ2Χ4·其中Χ2及X*如(I &gt;所定義 者*根據本發明之經取代噻哇·可由式(X I &gt;之2-胺基 -5-溴痛唑製得:(【J) Threading-where z is as specified in (I); -18 This sheet is used in the mid-2009 National Suihan (CNS) IM specification (210X297 g) 81. 6 · 10,000 sheets (H) ^ 02448 Λ 6 Π 6 V. Description of invention Ο7) h &gt;-when Rv represents an amine group-ΗΧ2Χ4 · where Χ2 and X * are as defined by (I &gt; as defined * substituted thiwa according to the present invention · can be represented by the formula (XI &gt; The 2-amino-5-bromopazole prepared:

此化合物係根據J. Che·. Soc., 1947, 1 14製備之,然後 再: -鼸化•例如:用經取代ZC00H ,在Β0Ρ及_例如:三 乙胺之存在下釀化,然後將獲得之式(I k)之溴化衍生物This compound was prepared according to J. Che ·. Soc., 1947, 1 14, and then: -Synthesis • For example: with substituted ZC00H, brewed in the presence of Β0Ρ and _ for example: triethylamine, and then The brominated derivative of formula (I k) obtained

Br、 丨 1 ΥBr, 丨 1 Υ

NH-COZ (請先閲讀背而元注意事項再項寫本頁) 裝· 訂_NH-COZ (Please read the back-to-back precautions before writing this page) Binding · Order_

R •ΝR • Ν

IV (Ik) 式中RIV及Z如(I )所定義者•在鏈酵中•於20Ό -溶耀 沸騰溫度間之溫度,被胺HNX2X4取代•得式(I 1)之化合 物: 線- 經濟部屮央栉準而A工消·ι\··合作杜印¾. 式中X: ΧΛ-Ν、^γΝΗ-0:ΟΖ —Ν - R. (Π) 及Ζ如(I )所定義者 -19 本紙51·尺度逍用中as家標if(CNS)T4規岱(210x297公没) 81. 6. 10,000¾ (H) ^02448 Λ 6 Π 6 五 、發明説明(1¾ -或被胺HHX2X4取代,然41將嚙哇2位釀化,此2反應 是於與上面描述之栢同條件下進行; Π -當Rv代表- (CH2)e-X基,其中 = 0且X代表 烷氧基時,對應2-胺基噻唑是由2-澳-2-烷氧基 -卜笨基乙醑其視情況在苯基上被取代者製懺之•生成T 式之產物: ΧϊRivIV (Ik) where RIV and Z are as defined by (I) • in chain leaven • at a temperature between 20Ό-melting blaze boiling temperature, replaced by amine HNX2X4 • the compound of formula (I 1) is obtained: line-economy The Ministry of Finance and Industry and A Gongxiao · ι ··· Cooperative Duyin ¾. Where X: ΧΛ-Ν 、 ^ γΝΗ-0: ΟΧ—Ν-R. (Π) and ZO as defined by (I) -19 Original paper 51 · Standard as if standard (CNS) T4 gauge Dai (210x297 public) 81. 6. 10,000¾ (H) ^ 02448 Λ 6 Π 6 V. Description of the invention (1¾-or amine HHX2X4 Substitute, then 41 will brew the 2nd position of the bite, this 2 reaction is carried out under the same conditions as the above-mentioned cypress; Π-when Rv represents-(CH2) eX group, where = 0 and X represents alkoxy, Corresponding to 2-aminothiazole is produced by 2-O-2-alkoxy-bubenylacetin, which is optionally substituted on the phenyl group. • Produces the product of formula T: ΧϊRiv

NH 2 (.ΧΓ) (請先閲請背而之注意亊項#艰寫本頁) 其中RIV如上面所定義者且X代表(Ci-D烷氧基,其再 依上述方法醯化,得下式'之化合物(I : 裝-NH 2 (.ΧΓ) (please read it first, please note 亊 项 # Difficult to write this page) where RIV is as defined above and X stands for (Ci-D alkoxy, which is then compounded according to the above method, The compound of the following formula (I: Pack-

X- /S、/NH-COZX- / S, / NH-COZ

(Im) 訂_ 線. 經濟部屮央辟準幻0工消1\--合作社印31 式中Rjv及Z如(I)所定義者且X如(XI ·)所定義者· 或其明if其中之一者。 式(X I ’)之化合物是新中間體•此中間《也在本發明 之内。 一些酸ZC00H或Z’COOH為巳知,甚至商埸上可取得;.其 他是使用類似分子*用巳知方法製得。 因此,下式之吲哚羧酸•下文稱之為Z”C00H:(Im) 定 _ 线. The Ministry of Economic Affairs of the Ministry of Economics and the Ministry of Economics and Social Security 1 \-Cooperative seal 31 where Rjv and Z are as defined by (I) and X is as defined by (XI ·) · or its explicit if one of them. The compound of formula (X I ') is a new intermediate. This intermediate is also within the scope of the present invention. Some acids ZC00H or Z’COOH are well-known and even commercially available; others are made using well-known methods using similar molecules *. Therefore, the indole carboxylic acid of the following formula is hereinafter referred to as Z ”C00H:

COOHCOOH

N R( 本紙张尺度边用中a a x榀準(CNS) TM規怙(210X297公¢) 81. 6. 10,000». (Η) 20 - £02448 82. 12. 2 ? Λ 6 Η 6 五、發明説明(ι 9) 式中Re代表烷氧羰亞烴基者&gt;,可由吲哚羧酸,此為商場上 可取得或由習用方法獲得,使用下面反應流程4製備之。 流程NR (aax standard (CNS) TM standard (210X297) ¢) 81. 6. 10,000 ». (Η) 20-£ 02448 82. 12. 2? Λ 6 Η 6 V. Description of the invention (Ι 9) where Re represents alkoxycarbonylalkylene group>, which can be obtained from indole carboxylic acid, which is commercially available or obtained by conventional methods, and is prepared using the following reaction scheme 4.

COOQ COOQ ^ + R9Hal I .. ΗCOOQ COOQ ^ + R9Hal I .. Η

RiRi

H 2 (X;)H 2 (X;)

COOH (請先閲攻背而之注意事項再碭寫本頁) 裝. 訂_ 其中Hal代表鹵索原子且Q代表苄基。 流程⑷之苄_是由對應酸與苄酵,在肽合成上普通使用 之其中.一種酸基活化繭的存在下反應製備之,此酸基活化 劑例如 -1 , 1 ·-羰基二畔唑,可參考 Synthesis 1982, P. 833 · -Ν,Ν -二瑁己基碳化二亞胺,在4 -二甲胺基吡啶之存,在 下反《,此可參考 J. 〇rg. Chen. 1990, 5_5_(4), Ρ. 1390 , -六氟磷酸苯并三唑基參(二甲胺基)期,’此可參考 -21 線- 經濟部屮央榀毕而卩工消设合作社印製 本紙张尺度边用中a Η家搵準(CNS)T4mtM21〇x297公龙) 81. 6. 10,000ft (H) 202448 82, Λ 6 Β 6 五、發明説鈉(21) 式中Q,代表在胺基酸耰合反-應中,普通用於保®ΝΗ2基之 基,諸如’ COOitert -C4H9); C6Hy CH2-0-C- ; CH3-C-, Ο Ο 保護基Q可由下式之化合物去除:COOH (please read the precautions before writing to this page) Binding. Order _ where Hal represents halogen atom and Q represents benzyl. Process ⑷ benzyl is prepared from the corresponding acid and benzyl enzyme, which are commonly used in peptide synthesis. An acid group activates cocoons in the presence of the reaction, the acid group activator such as -1, 1 · -carbonyl dipanzole , Can refer to Synthesis 1982, P. 833 · -Ν, Ν-dioxanylcarbodiimide, in the presence of 4-dimethylaminopyridine, in the next ", this can refer to J. 〇rg. Chen. 1990, 5_5_ (4), Ρ. 1390,-benzotriazolyl hexafluorophosphate (dimethylamino) period, 'this can refer to the line -21 The scale is used in the middle of a Η family quasi (CNS) T4mtM21〇x297 male dragon) 81. 6. 10,000ft (H) 202448 82, Λ 6 Β 6 V. The invention says sodium (21) where Q represents the amine Basic acid complex reaction-stress, commonly used for protecting the NH2 group, such as' COOitert-C4H9); C6Hy CH2-0-C-; CH3-C-, Ο Ο The protective group Q can be removed by the compound of the following formula:

(請先閲1ίίι背而之汰意事項丹硯寫本頁) 經濟部屮央標準杓Α工消作合作社印31 此為耩合至衍生物(I)之後,糴習用去保護方法獲得者。 BOC可輻热解作用,在溶劑缺乏下,於1 80 - 2001之溫 度間去除之。 吲哚羧酸 Z”C00H ·其中 ReSC00C(CH3)3 或 C00CH2CeHe 者 *可由二碳酸第三丁 _或氯甲酸苄®與Z”C00H·其中 Re = H考 在鐮諸如三乙胺或4 -二甲胺基吡啶之存在下.在 溶劑例始* :乙騁或二氯甲烷中反應製僑之。 酸Z”C00H,其中Rb是醮基者·可由釀基氯或酸酐輿 Z&quot;C00H*其中Re = H者.在一當曇三乙胺及4-二甲胺基啦陡 存在下•例如:在二氯甲烷中反應製備之。 式zcoci之_基氯,尤其可由soc丨2或[»0(;13 &amp;Pa〇e之 混合物與對應酸* —般在缺乏溶爾下,於反應混合物之回 流a度下反應製.備之。 -23- 本紙张尺度返用中Η «家详準(CNS)IM規彷(2丨0x297公龙) 81. 6. ιό,〇〇〇張(H)(Please read 1 銆 關 關 關 見 話 類 丹 熚 writes this page) The Ministry of Economic Affairs's central standard 揓 Α 工 消 作 akusha cooperative seal 31 This is the winner of the method of deprotection after the conversion to the derivative (I). BOC can be radiated and pyrolyzed, and it can be removed at a temperature of 180-2001 in the absence of solvent. Indole carboxylic acid Z "C00H · Where ReSC00C (CH3) 3 or C00CH2CeHe * can be made from third butane dicarbonate_ or benzyl chloroformate® and Z" C00H · where Re = H is considered in a sickle such as triethylamine or 4-di In the presence of methylaminopyridine. In the beginning of the solvent example *: Ethylene or dichloromethane reacted to produce overseas Chinese. Acid Z ”C00H, where Rb is an alkyl group. It can be made of chlorinated chloride or acid anhydride and Z &quot; C00H * where Re = H. In the presence of triethylamine and 4-dimethylamino radicals, for example, for example: It is prepared by reaction in dichloromethane. The _-based chloride of the formula zcoci can be prepared from the mixture of soc 丨 2 or [»0 (; 13 &amp; Pa〇e and the corresponding acid *, in general, in the absence of solubles, in the reaction mixture The reaction system is prepared under the reflux a degree. Prepared. -23- This paper standard is reused in the H «Family Standard (CNS) IM specification (2 丨 0x297 male dragon) 81. 6. ιό , 〇〇〇 Zhang (H )

202448 Λ 6 ______Β 6 _ 五、發明説明(22) 式ZC00Y”, Z’COOY”或Z”C00Y”之活化_之中,那些其 中Y ”代表 Μ I202448 Λ 6 ______ Β 6 _ V. Description of the invention (22) The activation of the formula ZC00Y ”, Z’COOY” or Z ”C00Y” _, among which Y ”represents M I

經濟部屮央標準而Π工消作合作杜印5i 可由1-羥基苯并噻唑與酸,在二瓖己基碳化二亞胺之存在 下,根據 J. A·. Che·., Soc. 1971, 9 3 · 6318-6319 (1971 )所描述之方法反應製備之,或由六氣播 酸1-笨并噻唑氧基參(二甲胺基)級,根據Synthesis, 197 6, 751-7 52所描述之方法反應製備之。 胺基噻唑(H)與呈活化酯形式之酸的縝合反應,可在溶 劑中進行•溶酾之特性的選揮係根據化合物之溶解度及酸 基之活化類型•較佳在鐮例如三級胺諸如三乙胺之存在下 反應;此反應一般是於0*C-30t:之《度間進行。 當式(I)之化合物在Z含羧酸基時,它們是由較佳 在Μ基霣中水解製得•例如:由無機_t喆如鐮金鼷羥基, 在稀酵·Ιΐ質中反應製得或躭三級丁醏而言,韉酸水解製備 之。 式(I)之化合物與酸或Ml之附加η是Μ替通方式,由酸 或鐮導入式(I )之化合物的溶液製備之。依Μ之溶解度特 .性,於溶劃蒸發之後或無溶劑添加後,將鹽單鑪。 式(I )之化合物及其《I類抑制_囊收縮素结合至其受播 。它們或多或少對Α或Β類型受《具選擇性•且多少有嫌 -24- 本紙張尺度边用中國Η家樣準(CNS) T4規ίΜ210χ29Υ公货) 81. 10,_張(Η) (請先閲·1-ΓΙ背而之注意事項Λ-塥寫本頁) £02448 Λ 6 Π 6 五、發明説明(23) 分潛在霣泌素拮抗钃。 其CCK A受_之親和力已經使用下面描述之方法,姪活 β 外测定,其原理在 Life Sciences, 1 985, ϋ (26), 2 483-2490中提及;其包括在一》胰臓均漿中•«定得自 其受體之經碘化CCK 8S的置換:取適置胰臓膜懸浮液 (1〇〇微克蛋白霣/毫升)在1*1=7.4之了1{15-11(:1嫒衢液 (50·Μ),其中含MgCU (5 »0*枯草样菌索(0.1 «克/ 奄升)·氟化甲苯基甲磺酸(0.1 «克/ ¾升)·於25 t * 在_化(:(:![ 8S(2000居里/毫奠耳,相當於50·Μ终濃度)之 存在下並且增加試驗物質之统度下*堵蓍40分鐘;此反應 藉離心,於40分後停止。上淸液去除後•测量九之放射活 性。並且於1 wM濃度下,在CCK 8S存在下,瀰定非特興 性结合。 於埴些條件下,本發明之產物的50%抑制結合濃度 (ICeo)少於10 — M而且許多是約1〇_ι〇Μ。 經濟你屮央ιΐ苹::? :^工消作合作杜印¾ 其CCK B受《之親和力•鞴由研究存在天竺联皮層均漿 之特興性受體的碘化CCK 8S之置換测定之,使用與CCK A 受《相同之方法•但是_懸浮液含60 0微克蛋白質/ ¾升 用出6.5 之 HEPES «衢液(10·Μ),其含 Ν3(:1(130·Μ), MgCU (5·Μ) ,EDTA(1««M)及枯草桿Η索(250奄克/毫升 )並且培養2小時。 於1〇_βΜ濃度•所有產物置換大於25%得自Β受體之經 檷定 CCK 8S; —些 IC«〇 約 1〇-βΜ。 最具CCK Β受驩特異性化合物之霣泌索受《的親和力是 -25- 81. 6. 10,〇〇〇張_(幻 (請先閲&gt;,?背而t注意事項再碭寫本頁) 本紙张尺度逍用中B國家楳毕(CNS) T4规怙(210x297公使) £02448 Λ 6 Η 6 五、發明説明fe/t) 根據下面描述之方法研究*其原理在J. Receptor.The Ministry of Economic Affairs's standards and the cooperation between the work and the production of Duin 5i can consist of 1-hydroxybenzothiazole and acid, in the presence of dioxanylcarbodiimide, according to J. A ·. Che ·., Soc. 1971, 9 3 · 6318-6319 (1971) prepared by the reaction described in the method, or by hexafluoroacid 1-benzthiazolyloxy ginseng (dimethylamino) grade, according to Synthesis, 197 6, 751-7 52 The method described is prepared by reaction. The reaction of aminothiazole (H) with acid in the form of an activated ester can be carried out in a solvent. The selection of the characteristics of dissolution depends on the solubility of the compound and the type of activation of the acid group. The reaction takes place in the presence of amines such as triethylamine; this reaction is generally carried out between 0 * C-30t :. When the compound of formula (I) contains a carboxylic acid group in Z, they are prepared by preferably hydrolyzing in M-based 霣 • For example: from inorganic _t, such as the hydroxy group of sickle gold, reacted in dilute enzymes As far as the third-grade butyl ketone is obtained or prepared, it is prepared by the hydrolysis of mandelic acid. The additional η of the compound of formula (I) and the acid or Ml is prepared by introducing the acid or sickle into the solution of the compound of formula (I) in the M substitution mode. Depending on the solubility characteristics of M, after evaporation of the solution or after no solvent is added, the salt is placed in a single furnace. The compound of formula (I) and its "Class I inhibitory_cystokinin bind to its receptor. They are more or less subject to the type Α or Β is "selective • and somewhat suspected -24- this paper scale side use Chinese Η home sample standard (CNS) T4 regulation ίΜ210χ29Υ public goods) 81. 10, _ 张 (Η ) (Please read · 1-ΓΙ Contrary Precautions Λ- 塥 write this page) £ 02448 Λ 6 Π 6 V. Description of the invention (23) Divided potential may secretin antagonizes the metal. The affinity of CCK A has been determined using the method described below, and the beta is measured outside. Its principle is mentioned in Life Sciences, 1 985, ϋ (26), 2 483-2490; it includes In the slurry • The replacement of iodinated CCK 8S determined from its receptor: take a suitable pancreatic pancreatic membrane suspension (100 μg protein per minute / ml) at 1 * 1 = 7.4 out of 1 {15-11 (: 1 詒 衢 液 (50 · Μ), which contains MgCU (5 »0 * subtilisin fungus (0.1« g / liter) · Fluorinated toluene methanesulfonic acid (0.1 «g / ¾ liter) · Yu 25 t * In the presence of _ ((:! [8S (2000 Curie / milli-Ear, equivalent to 50 · Μ final concentration) and increase the degree of test substance * plug 40 minutes; this reaction borrowed Centrifuge and stop after 40 minutes. After removal of the lifting liquid • Measure the radioactivity of Nine. And at a concentration of 1 wM, in the presence of CCK 8S, quantify the non-specific combination. Under these conditions, the product of the present invention The 50% inhibitory binding concentration (ICeo) is less than 10 — M and many are about 10 μM. The economy is high: : : : 工 工作 作 工作 杜 印 ¾ Its CCK B is subject to "Affinity" • Nao exists by research The replacement of iodinated CCK 8S in the homogenous receptor of Zhulian cortical homogenate was determined using the same method as CCK A. However, the suspension contains 60 micrograms of protein / ¾ litre and uses 6.5 HEPES «衢Solution (10 · Μ), which contains N3 (: 1 (130 · Μ), MgCU (5 · Μ), EDTA (1 «« M) and subtilisin H cable (250 μg / ml) and is incubated for 2 hours. At 1〇_βΜ concentration • All products are replaced by more than 25% of the CCK 8S obtained from the B receptor; some IC «〇 about 10 〇-βΜ. The most CCK B-specific compounds of the Koji receptor "Affinity is -25- 81. 6. 10, 〇〇〇 Zhang _ (phantom (please read first,? Back to t notes and then write this page) This paper scale is easy to use in the country B's last ( CNS) T4 regulation (210x297 ambassador) £ 02448 Λ 6 Η 6 V. Description of the invention fe / t) Research according to the method described below * The principle is in J. Receptor.

Res., 1983, 3_ (5), 647-655提及;取龜量天竺»胥腺在 cH=7.4(24.5«M)HEPES緩衡液中,此嫒®液含 NaCl (98·Η) · KC1 (6·Η) , NaH2P0« (2.5bM)&gt; 丙醑酸鹽 (5·Μ)’,CaCU (0.5ιΜ) ,MgCU (IbM),葡萄糖 (11.5·Μ),麩釀胺(1·Μ) ·牛白蛋白(0.4克/100«升), 於37 t:,在水浴中,在碘化S泌素(2-17) ( 2000居里/毫 莫耳·;70ρΗ)存在下及增加試驗產物的濃度下•培養90分 鐘。藉離心使反應停止並澜量該丸之放射活性;於宵泌索 (2-17)存在1 下,测定非特異性结合。本發明之化合 物的ICeo值介於l〇-sM &amp;10_βΜ之間。 也已經證明本發明之化合物對於CCK具抑制活性。此巳 經活《外鏺明之,偽测ft試驗產物之抑制作用•根據類似 J. Biol. Che·., 1979, 254 (12), 5321 -5327 所描述之方 法,由大鼴腺泡细胞之濉粉酶的CCK 8S-剌激分泌作用證 明之•但是用天竺《胰臓姐織。此化合物之1C 8〇為 1〇-βΗ-1〇-βΜ 〇 最後,在小白》活《内試驗,化合物對CCK受髑具良好 親和性,拮抗 KLife Sciences, 1987, ϋ, 1631-1638 所描述之方法·鞴CCK 8S皮下投藥誘發筠空著之抑制作用 ;由此拥得之EDBO(有效劑量50),《霣上低於一巳知爾泌 素拮抗劑proglueide。 若造些化合物不楚很毒,則它們可使用作為由這些肽之分 泌*多或由包括它們之生物荷爾蒙系統調節異常產生之生 -2 6 _ 81. 6. 10,000張_(幻 背 而 之r ii 意 事 項 再 填 寫 本 頁 本紙诋尺度边用中Β)Β家楳準(CNS)&lt;fH規IM2〗0X297公放) 202448 Λ 6 It 6 經濟部中央柃準杓Αχ;νί价合作杜印虹 五、發明説明(2彡) 理病症的治療用蕖*在腸圏區域或在中樞神經糸统*依其 特異性而定。可參考1987年9月7-11日*J. P. Bali, J. Martinez篇著,Elsevier Science Pub. BV在 &quot;Proceedings of International Synposiun on Gastrin and Cholecystokinin” 發表之 CCK 及宵泌素之拮 抗劑的治療應用之回顧。 尤其,CCI(之拮抗劑在腿遲動困難諸如遇敏性结鼷症候 群之治療上有用,在急性或慢性胰炎之治療上或胰癌之治 療上,Μ及調節食慾上有用,或在疼痛治療上*與含鴉片 之止痛劑混合使用。 就更具選擇性宵泌索拮抗_而言,它們在霣潰瘍之治療 及預防上有用,在Zollinger-Ellison症候群之治療上有 用·在寶之G细胞的增生上有用或用於患有食道,霣或腰 癌性腫痛之病人有用。 在A受《程度上之臟囊收嫌素的拮抗之中•下列化合 物較佳: -2-[卜羧甲基-2-«!哚基)雄胺基]-4-苯基-5酸乙基 -2-[(2-«|哚基 &gt;鑛胺基]-4-苯基-5-期酸乙基噻唑。 根據本發明之B藥包含式&lt;1 )之至少其中一化合物或其 與B蕖上可接受酸或鐮之其中一鹽·視情況與普通K形劑 混合· Μ便構成一 B藥姐合物,其可Μ習用方式烴口,烴 黏液•非烴腸或直腸途徑投藥。投藥劑最依疾病之特性及 嚴重性•依投藥之化合物及依投藥之途徑而定。一般在成 -27- 本叭伥尺度逍用中Β Η家樣毕(CHS) 規仂(210X297公及) 81 6. 10,0〇〇张(H) (請先&quot;&gt;?背而之注意事項再碼寫本頁) £02448 Λ 6 η 6 五、發明説明(26) 天_悬介於20-100¾克之間*注射則介於 人纆口眼途徑毎 3 - 10 «克之間。 根據本發明之轚藥姐合物·以片_ 或粒劑或變更為呈溶液*懸浮液或凝 口眼投藥。供非經腸投藥,本發明之 浮液或乳劑形式提供•在注射用之油 況含此類型配方之習用佐麵的水合基 在皮虜上或黏膜上供局部投藥時* 將以乳霜,軟蕾或以經皮設計之形式 時,它們將以栓劑及直腸鏐囊之形式 在下文中描述本發明之完成實例以 成中間《的製法。熔黏,Κ·.Ρ.表示 核磁共振(NMR)光譜是對四甲基矽烷 製備A 在5位上基取代之2-胺 2-胺基- 4-(2,4-二甲氧苯基)-5-苄基 •丸fl! *硬 膠形式提供 姐合物將Μ 或任何溶_ 爾。 根據本發明 攆供*而供 提供。 及某些式I •係Κ毛畑 記錄之。 基_唑。 噻唑。 明謬膠囊 者,可供 溶液,想 中•視情 之姐合物 直腸投蕖 及IV之合 管测得。 (請先閲請背而之注意枣項洱堝寫本頁) 裝· 訂_ 線-Res., 1983, 3_ (5), 647-655 mentioned; take turtle volume Tianzhu »thymus gland in cH = 7.4 (24.5« M) HEPES slow-balance solution, this pi® solution contains NaCl (98 · Η) · KC1 (6 · Η), NaH2P0 «(2.5bM)> Propionate (5 · Μ) ', CaCU (0.5ιΜ), MgCU (IbM), glucose (11.5 · Μ), branamine (1 · Μ) Bovine albumin (0.4 g / 100 «L), at 37 t :, in a water bath, in the presence of iodinated secretin (2-17) (2000 curies / millimol; 70 ρΗ) and Increase the concentration of the test product • Incubate for 90 minutes. The reaction was stopped by centrifugation and the radioactivity of the pill was measured; in the presence of Xiao Mi Suo (2-17), non-specific binding was determined. The ICeo value of the compound of the present invention is between 10-sM & 10-βΜ. The compounds of the present invention have also been shown to have inhibitory activity against CCK. This method is based on the "Inhibition of the Outer Mengming, Pseudo-Test FT Test Product Inhibition Effect". According to a method similar to that described in J. Biol. Che ·., 1979, 254 (12), 5321-5327, the acinar cells The CCK 8S-stimulated secretion effect of serotonin is proved • but with Tianzhu's "Secret Pancreas". The 1C 8〇 of this compound is 1〇-βΗ-1〇-βΜ. Finally, in the small white "internal test, the compound has good affinity for CCK, and antagonizes KLife Sciences, 1987, ϋ, 1631-1638 The method of description · Subcutaneous administration of CCK 8S induces the inhibitory effect of emptying; the EDBO (effective dose 50) thus obtained is "less than proglueide, a well-known secretin antagonist. If these compounds are unclear and very toxic, they can be used as the most secreted by these peptides or produced by the abnormal regulation of the biological hormonal system including them-2 6 _ 81. 6. 10,000 sheets _ (illusion to the r ii Please fill in this page again if you want to use it. This paper is for standard use. B) 戳 楳 准 (CNS) &lt; fH regulation IM2〗 0X297 public release) 202448 Λ 6 It 6 Central Ministry of Economic Affairs 惃 准 杓 Αχ; νί price cooperation Du Yinhong five 2. Description of the invention (2 彡) The treatment of physical disorders * in the intestinal area or in the central nervous system * depends on its specificity. Reference can be made to September 7-11, 1987 * JP Bali, J. Martinez article, Elsevier Science Pub. BV in &quot; Proceedings of International Synposiun on Gastrin and Cholecystokinin ’CCK and the therapeutic application of agonist antagonists Review. In particular, CCI (antagonists are useful in the treatment of leg bradykinesia such as allergic nodular syndrome, in the treatment of acute or chronic pancreatitis or the treatment of pancreatic cancer, M and appetite regulation, Or in the treatment of pain * mixed with analgesics containing opium. For more selective antagonists, they are useful in the treatment and prevention of ulcers, and in the treatment of Zollinger-Ellison syndrome. It is useful for the proliferation of G-cells or for patients suffering from esophagus, diarrhea, or lumbar cancer pain. Among A's antagonism of the degree of visceral sacral hormones • The following compounds are preferred: -2 -[Bucarboxymethyl-2- «! Indolyl) androsamino] -4-phenyl-5 acid ethyl-2-[(2-« | indolyl> minylamino] -4-phenyl 5-Phase acid ethylthiazole. Drug B according to the present invention comprises at least one compound of formula &lt; 1) or Accept one of acid or sickle salt on B. Mix with ordinary K-form agent as appropriate. Μ will constitute a B-medicine compound, which can be used in the usual way. Hydrocarbon mouth, hydrocarbon mucus • Non-hydrocarbon enteric or rectal Dosing. Dosing depends on the characteristics and severity of the disease. • Depends on the compound to be administered and the route of administration. Generally, it is used in the Cheng-27-Benjiao standard (CHS) regulation (210X297 Public and) 81 6. 10,000 Zhang (H) (please write “this page first” and then write this page) £ 02448 Λ 6 η 6 V. Description of the invention (26) Day_hang Between 20-100 ¾ grams * Injection is between 3-10 gram of the human eye and eye route. According to the invention, the drug compound is taken as tablets or granules or as a solution * suspension or It is used for parenteral administration. It is provided in the form of floating liquid or emulsion of the present invention. • In the case of oil for injection, the hydration base of the conventional side containing this type of formula is for topical administration on the skin or mucosa * In the form of creams, soft buds or percutaneous designs, they will be described in the form of suppositories and rectal capsules in the following Completion of the example to the preparation method of Chengzhong. Melt bonding, K · .P. Indicates that the nuclear magnetic resonance (NMR) spectrum is prepared for tetramethylsilane by A 2-amino substituted at the 5-position 2-amino-4- ( 2,4-Dimethoxyphenyl) -5-benzyl • Pill fl! * The hard gel form provides the sister compound to dissolve Μ or any sol. Provided according to the present invention. And some formulas I are recorded by Κ 毛 畑. Base_azole. Thiazole. For the Ming Mu capsules, the solution is available. I think it can be measured by the combination of rectal injection and IV. (Please read first, please pay attention to the jujube item Erguo write this page) Binding · Order _ Line-

(II) : R, = Η ; R(II): R, = Η; R

OCH3 ; Ry = -CH2~\0/ 經濟部屮央標^i;JM工消合作杜印2ί A)根據 E. Thomas 等人,J. Med. Chem., 1985, 2_8_, 422-446 ,經 Friede 卜Crafts反應,製併ί 1-(2,4 -二甲氣 笨基)-3-苯基丙烷-;[-酮。 28- 本紙尺度边用中B) Η家榀準(CNS)TM規tM2〗〇x297公:¾) 81. 6. 10,000張(Η) £02448 Λ 6 Π 6 五、發明説明 B) 根據習用方法,由使用溴在溶繭諸如二氯甲烷或四氣 化碳中溴化,製備1-(2,4-二甲氧笨基)-2-溴-3-苯基丙烷 -1 -嗣0 C) 2-胺基-4-(2,4-二甲氧笨基)-5-苄基噻唑。 將4.35克确腺添加至10克溶於100奄升95°乙酵之上面 製得之溴化衍生钧•此反應混合物画流3小時。混合物於 真空濃縮後,殘餘物溶於二氱甲烷,然後用飽和碳酸納 (Ha2C〇3)溶液洗之。有拥相藉傾析分開,置碕酸鎂 (HgSOd乾嫌並且於真空濃缩。残餘物自50奄升二氯甲烷 结晶。 重量=7. 10克 熔點=202-203TC:。 依上述方法進行製備,製得下表1所描述之2-胺基噻唑 (請先閲水背而之注意亊項洱艰寫本頁) -29- 本紙尺度边用中明Η家樣準(CNS)IM規怙(210x297公龙) 81. 6. 10,000張(H) £02448 Λ 6 Π 6 五、發明説明(28) 表 X-(CHn) Vs.OCH3; Ry = -CH2 ~ \ 0 / Ministry of Economic Affairs, Central Standard ^ i; JM Industry and Consumer Cooperation Du Yin 2ί A) According to E. Thomas et al., J. Med. Chem., 1985, 2_8_, 422-446, by Friede Bu Crafts reaction, the preparation of ί 1- (2,4-dimethylaminobenzyl) -3-phenylpropane-; [-one. 28- This paper is used in the standard B) Η Family Standard (CNS) TM regulations tM2〗 〇x297 public: ¾) 81. 6. 10,000 sheets (Η) £ 02448 Λ 6 Π 6 5. Description of the invention B) According to the customary method , By using bromine in a cocoon such as dichloromethane or four-gasified carbon bromide to prepare 1- (2,4-dimethoxybenzyl) -2-bromo-3-phenylpropane-1-嗣 0 C ) 2-amino-4- (2,4-dimethoxybenzyl) -5-benzylthiazole. 4.35 grams of gland was added to 10 grams of brominated derivative prepared in 100 liters of 95 ° ethyl acetate. The reaction mixture was flowed for 3 hours. After the mixture was concentrated in vacuo, the residue was dissolved in methylene chloride, and then washed with saturated sodium carbonate (Ha2C〇3) solution. Separated by decantation, magnesium sulfate (HgSOd was dried and concentrated in vacuo. The residue was crystallized from 50 liters of dichloromethane. Weight = 7.10 g Melting point = 202-203TC: as above After preparation, the 2-aminothiazole described in the following Table 1 is prepared (please read the back of the water first and pay attention to the hardships to write this page) -29- Regulations (210x297 male dragon) 81. 6. 10,000 sheets (H) £ 02448 Λ 6 Π 6 V. Description of invention (28) Table X- (CHn) Vs.

NH- 經濟部屮央榀半劝Μ工消讣合作杜印¾ X-(CH2)m- Γ4 r’4 洛鲇;0C OcH2· -och3 -OCH3 119 Or -och3 -OCH3 163-164 ΛΛΗ3 -och3 -OCH3 162 A -och3 -OCH3 121 LvV/^X〇CH3 Λ -och3 -OCH3 176 och3 Br H H 107 -30- 本紙张尺度边用中S國家烊準(CNS)IM規IM210X297公货) 81. 6. 10,〇〇〇張(H) (請先閲.諸背而之注意事項#蜞寫本頁) 裝· 線- 經濟部屮央伐苹心卩工消&quot;合作社印31 203448 Λ 6 ___Ιί_6_ 五、發明説明@9 ) 製備Β 在 5 位上被-(CIUU-COzX:或-(CH2)«-CH2〇H 取代之 2-胺 基嶁哇 A) 2-胺基-4-苯基-5-甲氧磺甲基痛唑 (I)Ri=H; Riv=-CeHB; Rv=-CH2-C〇zCH3 根雒 E. Knott, J. Che·, Soc.,1945,455 製供之。 B )2-胺基-4-苯基-5-羥乙基噻唑。 將5克上面製得之胺基醮添加至冷卻至〇 t:之含2克氫 化鋁鋰及100毫升四氫呋喃中之懸浮液中,此反應混合物 回流2小時。於冰浴上冷卻之後,陸纘再添加2毫升水, 1毫升濃氫氧化納(NaOH)及6毫升水•然後令此反應混合 物攪拌《夜。無機物質濾分闋•母液於真空下濃縮。 殘餘物溶於二氯甲烷,用水洗後,陸鑛將有機相傾析•置 MgS〇4乾烽並且於輿空下濃縮。殘餘物在矽膠上色暦分析 *溶*朗:二氯甲烷/中酵100 + 3(«積比)。 鈍粹部份瀰箱後得4克預期酵。 熔點=1211: 依上述方法進行製備•製得下表2描述之2-胺 (請先閲讀背而之注意事項再填寫本頁) 裝· 訂_ 線- -31 - 本紙Λ尺度边用中明Η家楳毕(CNS)IM規IM210X297公放) 81. 6. 10,000張(H) £02448 bz. ic. Λ 6 Ιί 6 五、發明説θ (3〇) 男 ^ 2. T-(CH^)NH-Ministry of Economics, Yan Yang, persuaded M Gong to eliminate Duan ¾ X- (CH2) m- Γ4 r'4 Luoyu; 0C OcH2 · -och3 -OCH3 119 Or -och3 -OCH3 163-164 ΛΛΗ3 -och3 -OCH3 162 A -och3 -OCH3 121 LvV / ^ X〇CH3 Λ -och3 -OCH3 176 och3 Br HH 107 -30- This paper size is used in the national S standard (CNS) IM regulations IM210X297 (commercial goods) 81. 6 . 10, 〇〇〇 Zhang (H) (please read first. Zhubei's precautions # 蜞 write this page) 装 · 线-Ministry of Economic Affairs 屮 漢 樮 切 心心 卩 工 消 &quot; Cooperative Society Seal 31 203448 Λ 6 ___ Ιί_6_ V. Description of the invention @ 9) Preparation of 2-amino group 2-amino-4-phenyl substituted by-(CIUU-COzX: or-(CH2) «-CH2〇H at the 5-position) 2-amino-4-phenyl- 5-Methoxysulfurazole (I) Ri = H; Riv = -CeHB; Rv = -CH2-C〇zCH3 Root Lo E. Knott, J. Che., Soc., 1945, 455. B) 2-amino-4-phenyl-5-hydroxyethylthiazole. 5g of the above-prepared amine base was added to a suspension containing 2g of lithium aluminum hydride and 100ml of tetrahydrofuran cooled to 0t: and the reaction mixture was refluxed for 2 hours. After cooling on an ice bath, Lu Zuan added another 2 mL of water, 1 mL of concentrated sodium hydroxide (NaOH) and 6 mL of water. • The reaction mixture was then stirred overnight. Inorganic substances are filtered and the mother liquor is concentrated under vacuum. The residue was dissolved in dichloromethane and washed with water, the land mine decanted the organic phase • placed MgS〇4 dry fiber and concentrated in public space. The residue is colored and analyzed on silica gel. * Solution * Lang: dichloromethane / middle yeast 100 + 3 («product ratio). After the blunt part of the box, 4 grams of expected leaven were obtained. Melting point = 1211: Prepared according to the above method • Prepare the 2-amine described in Table 2 below (please read the precautions before filling in this page) Η 楳 楳 Bi (CNS) IM regulation IM210X297 public) 81. 6. 10,000 sheets (H) £ 02448 bz. Ic. Λ 6 Ιί 6 5. Invention θ (3〇) Male ^ 2. T- (CH ^ )

T r4 r’4 m m.p; 〇q -co2ch3 H H 1 231 -OH H H 2 121 -COO-CH2CH3 H H 〇 175 -coo-ch2ch3 H H 1 162 -coo-ch2ch3 2-OCH3 4-OCH3 1 117-118 製備C 在 5 位上被- (CH2)»-〇-C-)U 或- (CDo-S-Xi-取代之 2-胺II 0 基噻唑Γ-胺基-5-U-金剛烷基-卜羰氧乙基)-4-笨基唾唑 Μ 芍-\背 \而 1 η 本 頁 裝 玎 線 經浒部屮央準杓=5工消作合作社印31T r4 r'4 m mp; 〇q -co2ch3 HH 1 231 -OH HH 2 121 -COO-CH2CH3 HH 〇175 -coo-ch2ch3 HH 1 162 -coo-ch2ch3 2-OCH3 4-OCH3 1 117-118 Preparation C 2-amine II 0 substituted by-(CH2) »-〇-C-) U or-(CDo-S-Xi- in the 5-position II ylthiazole Γ-amino-5-U-adamantyl-bucarbonyl Oxyethyl) -4-benzyl thiazole Μ 芍-\ 背 \ 而 1 η This page is decorated with thread by the Hube Biyang quasi-dipper = 5 Gongxiaozuo cooperative cooperative seal 31

A.4-U-金晒烷《氧基)-1-苯基-1-丁烷 -32- 本紙法尺度边用中a Hiis準(CNS)IM規格(21(1:&lt;2听公没) 81. 6. 10,000¾ (H) Λ 6 Π 6 ^02448 五、發明説明(31) (請先閲讀背而之注意事項再堝寫本頁) 根據 J. Org. Che·, 1977, 42, 8_, 1286,由 12 克卜金 _ 烷基羧酸及10.96克破酸绝製備1-金刚烷基羧酸之绝鹽。 將獲得之K溶於70毫升二甲替甲釀胺(DHF),然後添加 18克4-碘基-卜苯基丁烷-卜酮•此反應混合物回流遇夜。 DMF於真空下蒸發,殘餘物再懸浮在5 %Na2C〇s溶液中並 且用二氯甲烷(CH2CU萃取。有機相用水洙後•再置 Na2S〇4乾嫌。於真空下濃縮後•殘餘物在矽膠上色暦分析 •溶玀刻:CH2CU。 纯粹部份濃嫌得10克預期化合物。 B.2-胺基- 5-U-金W烷基-1-费氧乙基)-4-$基_畦。 將10克上面製備之化合物溶於100毫升四氣化磺 (CCU)。添加4.9克溶於50毫升四氛化碳之溴水·讓此反 應混合物攪拌30分鐘。用水洗後,將有機相傾析*置 MgS(U乾爍*過濾後*於輿空下濃縮。殘餘物溶於50«升 95°乙酵》於此溶液添加3.9克碕脲並且讓此反應混合物 於室溫靜置«夜。混合物於輿空濃縮後,殘餘物溶於 CH2CU,用5炻碳酸氫納(NaHC〇3)溶液洗後•將有櫬相傾 析,置MgS0«乾烯,《濾後•於興空澴箱。殘餘物溶於乙 醚並且乾烯之》 經濟部屮央榀^&quot;JM工消1,1··合作杜印虹 重量=6.8克A.4-U-golden alkyl "oxyl" -1-phenyl-1-butane-32- The standard of the paper is used in the standard a Hiis standard (CNS) IM specifications (21 (1: &lt; 2 listening public No) 81. 6. 10,000¾ (H) Λ 6 Π 6 ^ 02448 5. Description of the invention (31) (Please read the notes before writing this page) According to J. Org. Che ·, 1977, 42 , 8_, 1286, the absolute salt of 1-adamantyl carboxylic acid was prepared from 12 g of Bujin_ alkyl carboxylic acid and 10.96 g of broken acid. Dissolve the obtained K in 70 ml of DMF And then add 18 g of 4-iodo-buphenylbutane-buone. The reaction mixture was refluxed overnight. DMF was evaporated under vacuum, and the residue was resuspended in 5% Na2C0s solution and dichloromethane ( CH2CU extraction. After the organic phase was soaked with water • Na2S〇4 was dried. After concentration under vacuum • The residue was colored and analyzed on silica gel • Dissolved etched: CH2CU. The pure part was concentrated with 10 g of the expected compound. B .2-Amino-5-U-gold W alkyl-1-feroxyethyl) -4- $ yl_ 畦. Dissolve 10 g of the compound prepared above in 100 ml of tetragasified sulfonate (CCU). Add 4.9 g of bromine water dissolved in 50 ml of carbon tetrachloride. Let this reaction mixture stir for 30 minutes After washing with water, the organic phase was decanted * MgS was placed (U dry flashing * after filtration * concentrated under public space. The residue was dissolved in 50 «l 95 ° ethyl acetate>. To this solution was added 3.9 g of carbamide and let The reaction mixture was allowed to stand at room temperature for «night. After the mixture was concentrated in public space, the residue was dissolved in CH2CU and washed with 5% sodium bicarbonate (NaHC〇3) solution. The decanted phase was decanted and left to dry with MgS0. Ene, "After filtration • Yuxing empty box. Residues are dissolved in ether and dry olefins" Bi Yang, Ministry of Economic Affairs ^ &quot; JM Gongxiao 1,1 ·· Cooperative Du Yinhong Weight = 6.8g

熔點=1671C 依上述方法進行製備•製得下表3描述之2 -胺基噻唑。 -33- 81. 6- 1〇,〇〇〇張(H) 本紙張尺度逍用中a S家楳毕(CNS) ΊΜ規格(210X297公没) ^02448 Λ 6 η 6 五、發明説明(32) 表Melting point = 1671C. Prepared according to the above method • Prepare 2-aminothiazole as described in Table 3 below. -33- 81. 6- 10, 000 sheets (H) This paper is used in a small format a S home furniture (CNS) TIM specifications (210X297 public) ^ 02448 Λ 6 η 6 V. Description of invention (32 ) Table

|-o-(ch2)2 丫 Νη2 ° er^N 經濟部屮央柃準AM工消tv合作杜印¾| -o- (ch2) 2 丫 Νη2 ° er ^ N Ministry of Economic Affairs, quasi-AM industrial consumer TV cooperation Du Yin ¾

製備I) 在5位上被- (CH2)_X基取代之2 -胺基嘍唑•其中X代表 -3 4 - 本紙尺度边用中®困家標毕(CNS)IM規格(2〗〇x297公坺) 81. 6. 10,000¾ (H) (請先閲讀背而之注意事項#堝寫本頁) 裝· 訂- 線· ^02448 Λ 6 Β6 經濟部屮央柃苹Λ7Ώ:工消1Ϊ·合作社印3i 五、發明説明(33) -HLXz基· Χι=Χζ = Η。 2-胺基-5-胺乙基-4-苯基噻唑之製備 (I ):Ri=H· Riv=-CeHe» Rv=-CH2CH2MH2 AH-酞釀亞胺基-1-苯基丁烷-卜嗣 將27.4克4-碘基_卜苯基丁烷-卜酮及27克酞醯亞胺鉀’ 在100毫升DMF中,於120 t:加热2小時。DMF於真空濃 鑲之•殘餘物陸鑛用水及用IN NaOH溶液洗之並且用乙酸 乙_#取。有機相傾析後•置MgS0«乾嫌·過濾後,於輿 空濃编。 璽量=11克 B) 2-胺基-5-酞醣亞胺乙基-4-苯基噻唑。 將9.6克上面製得之化合物溶於50«升四氯碳及80毫升 二氰甲烷。於此溶液满加5.6克溴在3 0«升四氧化磧中之 溶液。此反應混合物用水洗後*有機相置MgS0«乾烽.纆 «瀘後,於真空濺縮之。殘鎗物溶於7 0毫升乙酵·並且添 加4.5克确脲•此反應混合物於室灌靜置過夜。 混合物冷卻後•溴化氲藉《濾分闋,用乙醇洗後,再於 5 %碳酸纳/乙醚绲合液中激烈攪拌。將结晶逢濾。 璽曇=8克 熔貼=208t: C) 2-胺基-5-胺乙基-4-笨基噻唑。 將8克上面製得之產物.1.5克溶於100 «升絕對乙酵 之水合肼處理。此反應混合物回流過夜,再_績進行下列 操作:乙》液於真空濃《,殘餘物溶於水·鶊由添加灞驩 -35- 尺度边用中明規怙(210x297公;《:) ' R, , 1Λ ηη (請先閲#背而&lt;注意事項再蜞寫本頁) 裝- 訂 媒, 202448 Λ 6 Π6 五、發明説明β4) 酸酸化至出=1,呔畊二酮藉遢濾分開,水相在冰浴上冷卻 •藉添加濃氫氧化納Λ化至出=9,將沈澱物遇濾,用水洗 後,在烘箱內乾爍之。 重量=3.7克 熔點=136-137¾ 製衡E 在5位上被-(CH2) ·Χ基取代之2-胺基噻唑,其中X代表 -ΝΧιΧζ基,其中)U=H且 X2 = -C〇-CH3。 2-胺基-5-(2-乙釀孩基-1-乙基)-4-苯基噻哇。 (I):Ri^H; Riv = -CeHB; Rv = CH3C0MH (CH2)2-根據製供D獲得之1克2-胺基嘻唑,溶於60毫升THF , 在0.7毫升三乙胺存在下,用0.44毫升鼸酸酐溶於20«升 THF之溶液處理。此反應混合物於室溫靜置2小時並且於 輿空潇縮。残餘物用5炻破酸簋納溶液洗之,沈霣物藉遘 濾分闋•用水洗後乾烯。 重量=1. 12克 熔黏=208-209Ό 使用根據製嫌D獲得之2-胺基噻唑,糴由根據製儋Ε之 方法進行製備•製得下表4描述之中間化合物。 (請先閲济背而&lt;注意事項#墦寫本页) 裝· 線· 經濟部屮央ιΐ半AM工消奸合作社印製 -36- 本紙尺度逍用中a B家標孕(CNS)T4珙彷(2K1X29V公龙) 81. 6. 10,000張(H) c,〇244e Λ 6 η 6 五、發明説明(55)Preparation I) 2-Aminopyrazole substituted with-(CH2) _X group at the 5 position • where X represents -3 4-The standard size of the paper on the paper side (CNS) IM specifications (2〗 〇x297 Publicity) 81. 6. 10,000¾ (H) (please read the back-to-back precautions ## to write this page) Installation · Order-line · ^ 02448 Λ 6 Β6 Ministry of Economic Affairs, 屮 央 柃 Apple Λ7Ώ: 工 消 1Ϊ · Cooperative printing 3i V. Description of the invention (33)-HLXz base · Χι = Χζ = Η. Preparation of 2-amino-5-aminoethyl-4-phenylthiazole (I): Ri = H · Riv = -CeHe »Rv = -CH2CH2MH2 AH-phthalimide-1-phenylbutane- Bu Si 27.4 g of 4-iodo-p-phenylbutane-p-one and 27 g of potassium phthalimide in 100 ml of DMF at 120 t: heated for 2 hours. DMF is concentrated in vacuum • The residue land mine is washed with water and IN NaOH solution and taken with acetic acid ethyl ##. After decanting the organic phase • After placing MgS0 «Dry suspected and filtered, edited by Yu Yucong. The amount of seal = 11 grams B) 2-amino-5-phthalosimine ethyl-4-phenylthiazole. Dissolve 9.6 g of the compound prepared above in 50 μl of tetrachlorocarbon and 80 ml of dicyanomethane. To this solution, add a solution of 5.6 grams of bromine in 30 liters of molybdenum tetraoxide. After the reaction mixture was washed with water, the organic phase was placed in MgS0 «乾 丰. 纆« Lu, and then it was condensed in vacuum. The residual gunpowder was dissolved in 70 ml of ethyl yeast and 4.5 g of urea was added. The reaction mixture was allowed to stand overnight in the chamber. After the mixture cools, use bromide to separate the filter, wash it with ethanol, and stir vigorously in 5% sodium carbonate / ether ether mixture. Will crystallize every filter. Xi Tan = 8g Melting paste = 208t: C) 2-amino-5-aminoethyl-4-benzylthiazole. Treat 8 g of the product prepared above with 1.5 g of hydrazine hydrate dissolved in 100 ng of absolute ethyl yeast. The reaction mixture was refluxed overnight, and then performed the following operations: B> The solution was concentrated in vacuo, and the residue was dissolved in water · Yi You was added by Ba Huan-35- Scale Side, with a clear rule (210x297 g; ":) ' R,, 1Λ ηη (please read # 背 而 &lt; Precautions before writing this page) Binding-bookmaking, 202448 Λ 6 Π6 V. Description of the invention β4) acidify to out = 1, digging a dione Separate the filter and cool the water phase on the ice bath. • Add the concentrated sodium hydroxide to the solution = 9 to filter the precipitate. After washing with water, dry it in the oven. Weight = 3.7 g Melting point = 136-137¾ Balance E 2-aminothiazole substituted with-(CH2) · X group at the 5-position, where X represents -ΝΧιΧζ group, where) U = H and X2 = -C. -CH3. 2-amino-5- (2-ethylhexyl-1-ethyl) -4-phenylthiazole. (I): Ri ^ H; Riv = -CeHB; Rv = CH3C0MH (CH2) 2-1 g of 2-aminohexazole obtained according to D for the preparation, dissolved in 60 ml of THF, in the presence of 0.7 ml of triethylamine , Treated with a solution of 0.44 ml of acetic anhydride dissolved in 20 «THF. The reaction mixture was allowed to stand at room temperature for 2 hours and shrank in the air. The residue was washed with 5% sodium bicarbonate solution, and Shen Yiwu was filtered to separate the water. After washing with water, dry the alkenes. Weight = 1.12 g Melt viscosity = 208-209Ό Using 2-aminothiazole obtained according to Preparation D, the bismuth was prepared according to the method of preparation of E • An intermediate compound described in Table 4 below was prepared. (Please read Jibei &lt; Notices # 冦 write this page) Printed by · Line · Printed by the Ministry of Economic Affairs, semi-AM industrial anti-crime cooperatives-36 T4 Gong imitation (2K1X29V male dragon) 81. 6. 10,000 sheets (H) c, 〇244e Λ 6 η 6 V. Description of the invention (55)

Η Ν 丁 熔點V °C ch7-o-c-nh- 3 II 157-158 !1 0 ch3 1 CH^-C-O-C-NH- 3 1 II oil I π ch3〇 ch3-ch2-nh-c-nh- 171 o CH^-CHn-NH-C-NH- 3 z II 151 11 s (請先閲诒背而之注意事項#蜞寫本頁) 經濟部屮央桴平XJH工消圯合作杜印¾ 製2- M F 按基-4,5-二g - [5,4-d]-噻唑并- [1]-笨并雜箄 1 1 一... —- — — — /—\ .S. ,ΝΗ, (inΗ Ν 丁丁 Melting point V ° C ch7-oc-nh- 3 II 157-158! 1 0 ch3 1 CH ^ -COC-NH- 3 1 II oil I π ch3〇ch3-ch2-nh-c-nh- 171 o CH ^ -CHn-NH-C-NH- 3 z II 151 11 s (please read the notes first # 蜞 write this page) The Ministry of Economic Affairs, Pyongyang Huping, XJH, Gongxiao, Co-operation, Du-Industry 2- MF according to the group -4,5-di g-[5,4-d] -thiazolo- [1] -swiggling complex 1 1 one ... —- — — — / — \ .S., ΝΗ, (in

N / 本紙尺度边用中Hffl家捣毕(CNS)&gt;fM規格(210X29/公放) 81. 6. 10,000¾ (H) 202448 Λ 6 Π 6 五、發明説明(5δ) AM-澳-4-2Η-3.4-二氫-[1]-苯并蟾箪-5_爾係根據〇 Fontaine, P. Maitte, C. R. Acad. Sci., 1964, 258· 4583製衡之。 B)2-胺基_4,5-二氫-[5,4-{1]-噻唑并-[1]-苯并雜革。 將2.05克硫膘添加至0.027奠耳溶解在100毫升乙酵中 之溴化衍生物中。此混合物回流3小時。將乙酵蒸發*殘 餘物溶於磺酸納水溶液中。用乙酸乙醮萃取’有機相置疏 酸納(》^25〇4)乾嫌並且蒸乾。獲得2.4克白色结晶° 熔點=216t: 製供G 在5位上被-(CH2) »-X基取代之2-胺基痛唑*其中 = 〇且 X代表(Ct-CiJ烷氧基或鹵素。 (請先閲1?背而之法意事項再艰寫本頁) 裝- 訂· 線- 經濟部屮央ir:苹·,工消仲合作杜印製 本紙張尺度遑用中明ffl家ttiMCNS)TM規怙(210x297公龙) 10,000張(H) 2,02448 Λ 6 Π 6 五、發明説明(37) 反應流程 COCH2BrN / The size of the paper is used in the Hffl family (CNS) &gt; fM specification (210X29 / Public) 81. 6. 10,000¾ (H) 202448 Λ 6 Π 6 V. Description of the invention (5δ) AM-A-4 -2Η-3.4-dihydro- [1] -benzotoxin-5_ is based on 〇Fontaine, P. Maitte, CR Acad. Sci., 1964, 258. 4583 checks and balances. B) 2-amino-4,5-dihydro- [5,4- {1] -thiazolo- [1] -benzo hybrid leather. 2.05 g of thione was added to 0.027 moles of brominated derivatives dissolved in 100 ml of ethyl yeast. This mixture was refluxed for 3 hours. Evaporate the residue of ethyl yeast * into the aqueous solution of sodium sulfonate. The organic phase was extracted with ethyl acetate and the organic phase was dried and evaporated to dryness. Obtained 2.4 g of white crystals ° Melting point = 216t: prepared for 2-aminopyrazole substituted with-(CH2) »-X group at the 5 position of G * where = 〇 and X represents (Ct-CiJ alkoxy or halogen (Please read 1? Contrary to legal matters before writing this page hard) Binding-Order · Thread-Ministry of Economic Affairs: Yang, Ping, and Gongzhong Zhong cooperated with Du to print this paper, and use Zhongming ffl's home ttiMCNS) TM specification (210x297 male dragon) 10,000 sheets (H) 2,02448 Λ 6 Π 6 V. Description of the invention (37) Reaction process COCH2Br

COCHOCOCHO

r4 HO-N; ,c2h5 c2h5r4 HO-N;, c2h5 c2h5

r4 根據 J. Org. Chem., 1977, 42 (4), 754. (請先閲請背而之注意事項孙蜞寫本頁) 第 2步r4 According to J. Org. Chem., 1977, 42 (4), 754. (Please read the notes on the back of this page firstly, Sun Wei wrote this page) Step 2

OCH COCHOCl-Si-iCH;) CH3〇H r4 根據 Synthesis, 1983, 203.OCH3 !CO-CH !OCH,OCH COCHOCl-Si-iCH;) CH3〇H r4 According to Synthesis, 1983, 203. OCH3! CO-CH! OCH,

CO-CH〇CH; .4-.CO-CH〇CH; .4-.

BrBr

CO-CH 裝· 線·CO-CH equipment · line ·

CH-,COBrCH-, COBr

OCH r4 r4 根據:J· Chem. Soc. , Perkin I, 1981, 2435 . -39- 本紙尺度边用中困困家榀準(CNS)»H規格(210X297公没) 81. 6. 10,000¾ (H) Λ 6 Β6 202448 五、發明説明(58) 2-胺基-5-甲氧基-4-苯基噻唑。 (H )*Ra=H* Riv=~CeHs* Rv=~0CH3 將15.65克2-溴-2-甲氣基-1-苯基乙酮及5.52克硫 於7 0«升甲酵。此反應混合物回流《夜·然後於真空 之。殘餘物溶於10%碾酸納水溶液中*此混合液用二 垸萃取•有機相分開後,陸續置碗酸納乾嫌•過濾後 興空潇嫌之。殘餘物Μ異丙醚再结晶。 重麄=7.5克 熔點=96¾ 溶緬甲於 朦濃氛, (請先|«1.讀背而之注意事項#蜞寫本頁) 表OCH r4 r4 According to: J. Chem. Soc., Perkin I, 1981, 2435. -39- This paper is used in the edge of the home (CNS) »H specifications (210X297 public) 81. 6. 10,000¾ ( H) Λ 6 Β6 202448 V. Description of the invention (58) 2-amino-5-methoxy-4-phenylthiazole. (H) * Ra = H * Riv = ~ CeHs * Rv = ~ 0CH3 Mix 15.65 g of 2-bromo-2-methylamino-1-phenylethanone and 5.52 g of sulfur in 7 0 «L of formazan. The reaction mixture was refluxed "night" and then vacuumed. The residue is dissolved in a 10% aqueous solution of sodium triacetate. * This mixture is extracted with two embankments. After the organic phase is separated, successively put bowls of sodium bicarbonate to dry. After filtering, Xing Kongxiao is suspected. The residue M isopropyl ether was recrystallized. Heavy weight = 7.5g Melting point = 96¾ Dissolve the Burmese Armor in the dim thick atmosphere, (please first | «1. Read the back and pay attention to matters # 蜞 write this page) table

經濟部屮央lr:芈::工消f,'·合作杜印¾. 「4 熔黏7 3C 2-C1 72 2-OCH3 159-160 4-CH3 112-114 製備Η 吲哚羧酸之製備: 本紙张尺度逍用中S«家楳iMCNS)T4規怙(210x297公放) 81. 6. 10,000張(H) 2,03^48 Λ 6 Η 6 經濟部屮央桴;!t-r-^;M工消1V·合作杜印3i 五、發明説明(39) Α)卜第三丁氧羰甲基吲哚-2-羧酸。 a)吲哚-2-羧酸苄醱。 將5克Ν,Ν'-羰基二咪唑導入含5克吲哚-2-羧酸及50毫 升無水四氫呋喃之溶液;於室溫攪拌12小時之後》添加 3.7克苄酵*此反應琨合物於其回流溫度加热;後者於減 壓下蒸饑去除溶繭之後· _持回流8小時。殘餘钧溶於乙 酸乙酯•有機相用1Ν氳氧化納水溶液洗後,於溶繭蒸發之 前乾埭之。 黄色殘餘物Μ異丙酵再结晶。 熔點=136t: 產率=85% b)l-第三丁氧獷甲基«I哚-2-菝酸苄醮 將80%氫化納油懸浮液(0.075莫耳;2.25克)於氰氣下 ,在(^-51之溫度間,分數次添加至含吲哚-2 -羧酸苄 酯(0.072莫耳;18.18克)之200奄升二甲替甲黼胺溶液 中。令此混合物再平衡至室溫,混合物攪拌1小時。然後 於lOt:滴加溴_酸第三丁醱(0.072莫耳;14克)。此反應 混合物於室溫_置3小時。將二甲替甲醢胺蒸掉並將殘餘 物陸續溶於水•用二«(甲烷萃取,有機相置确酸納乾嫌並 且蒸乾。殘酴物以二異丙醚使结晶化•獲得23.8克白色结 晶。 熔黏=95*C c )卜第三丁氣羰甲基吲哚-2 -羧酸 上面製得之_ (0.065 Μ耳;23.8克)溶於400奄升乙酵 (請先閲背而之注意事項#填寫本頁) -41- 本紙汰尺度边用中國Η家標準(CNS)1?^垛格(210x297公使) 81. 6. 10,000¾ (H) 202448 Λ 6 Η 6 五、發明説明(4〇) 及100毫升二甲替甲鼸胺之混合液中。添加1克Pd-c,混 合物於室溫,大氣壓力下籯化。攫拌30分鐘後,吸附理論 體積的氫。在滑石上將催化嫌遘濾並且使溶鋼蒸發至乾。 獲得结晶化殘餘物,其用二異丙醚洗之。獲得15.3克白色 结晶。 熔黏=177¾。 B&gt;1-乙釀吲哚-2-羧酸。 含蚓哚-2-菝酸(0.06莫耳;10克)·三乙胺(0.15莫耳 ;21.25克&gt; Μ酸酐(0.07 5莫耳;7.5克)及4-二甲胺基 吡啶(0.0 06莫耳;0.8克及二氱甲烷之混合物,於室溫 攪拌18小時。然後將反應混合物倒入出=2埋衢水溶液。形 成之沈*物β濾後•在烘箱内·於真空乾嫌之。將二氯甲 烷相傾析,置碗酸納乾嫌並且蒸至3/4體稹。第二種收成 物為卜乙釀吲哚-2-羧酸沈《物。將二種收成物混合•得 9.4克灰裼色结晶。 熔點=168¾ C) 1-苄氧獷胺基翊哚-2-羧酸 將8克吲哚-2-羧酸溶於120毫升二氛甲烷•然後添加 10克三乙胺及1克4-二甲胺基吡啶。 此反應混合物《«拌後冷卻至。於少於5 t之 溫度下,滴加8.5克苄氧羰基氯。讓此混合物播拌《夜· 然後於興空下濃鏑。殘餘物溶於500 «升乙酸乙酯,然後 過濾。母液於輿宜下濃縮並且溶於5 0奄升二斌甲烷。母液 ««後•於輿空下濃埔。 (請先閱-!·**?背而·A注意事項再填寫本頁) 裝· 訂- 線. • 4 2 - 本紙張尺度边用中®®家堞毕(CNS)T4規格(2)0x297公;Sb) 81. 6. 1〇,〇〇〇張(Η) 202448 Λ 6 _Π_6_ 五、發明説明(Μ) 重量=2.4克油狀物 HHR(DHSO): 5.38(2H, s. ClU-CeHs) ; 7.0-8.0(10H, . Har) 0 du-第三丁氧蒙基吲哚-έ-羧酸 將30毫升含6克二磺酸二第三丁醮之溶液滴加至30奄升 含4克吲哚-2-羧酸,4毫歼三乙胺及0.4克二甲胺基吡 啶之乙腾溶液中。於室溫攪拌2小時並且去除形成之沈澱 物*乙騎藏蒸饑去除之*殘餘物溶於二氣甲烷。有機相用 水洗後,乾嫌並且濃縮至乾。 熔黏=117 t:; 產率=66¾ «施例1 2- [ (2-吲哚基)羰联基]-4- (2,4-二甲氧苯基)-5-苄基噻唑 (請先W讀背而之注意事項洱墦寫本頁)Ministry of Economic Affairs lr: 芈 :: 工 消 f, '· Cooperative Du Yin ¾. "4 Melt Sticky 7 3C 2-C1 72 2-OCH3 159-160 4-CH3 112-114 Preparation Preparation of H Indole Carboxylic Acid : This paper standard is used in the S «Household iMCNS) T4 regulation (210x297 public release) 81. 6. 10,000 sheets (H) 2,03 ^ 48 Λ 6 Η 6 Ministry of Economic Affairs 屮 央 桴;! Tr- ^; M Gongxiao 1V · Cooperative Duin 3i V. Description of the invention (39) A) Bu third butoxycarbonylmethyl indole-2-carboxylic acid. A) Indole-2-carboxylic acid benzyl sulfide. 5 g of N , N'-carbonyldiimidazole was introduced into a solution containing 5 g of indole-2-carboxylic acid and 50 ml of anhydrous tetrahydrofuran; after stirring at room temperature for 12 hours, 3.7 g of benzyl yeast was added. * This reaction was heated at its reflux temperature ; The latter is steamed under reduced pressure to remove the cocoon. _ Maintain reflux for 8 hours. The residue is dissolved in ethyl acetate. The organic phase is washed with a 1N aqueous solution of sodium oxide and dried before the cocoon evaporates. Yellow residue Μ isopropanol recrystallization. Melting point = 136t: Yield = 85% b) l- the third butoxymethyl «I indole-2-salicylic acid benzyl chloride 80% hydrogenated sodium oil suspension (0.075 mole; 2.25g) Under cyanide, between (^ -51), add to the Indole-2-carboxylic acid benzyl ester (0.072 mol; 18.18 g) in 200 liters of dimethylmethanilamide solution. Allow the mixture to equilibrate to room temperature again, and stir the mixture for 1 hour. Then at lOt: dropwise Bromo-acid tertiary butyl amine (0.072 mol; 14 g). The reaction mixture was left at room temperature for 3 hours. The dimethylformamide was distilled off and the residue was dissolved in water successively. After extraction, the organic phase was allowed to dry and evaporated. The residue was crystallized with diisopropyl ether. 23.8 g of white crystals were obtained. Melt viscosity = 95 * C c) Bu third butane carbonylmethyl indole -2 -The carboxylic acid prepared above (0.065 μM; 23.8 g) is dissolved in 400 liters of ethyl yeast (please read the backing notes beforehand #fill this page) -41- This paper is used for standard size. Standard (CNS) 1? ^ Duo grid (210x297 ambassador) 81. 6. 10,000¾ (H) 202448 Λ 6 Η 6 V. Description of the invention (4〇) and 100 ml of a mixed solution of dimethylmethanamine. Added 1 gram of Pd-c, the mixture was boiled at room temperature under atmospheric pressure. After stirring for 30 minutes, the theoretical volume of hydrogen was adsorbed. The catalyst was filtered on talc and the molten steel was evaporated to dryness. The residue was crystallized, which was washed with diisopropyl ether. 15.3 g of white crystals were obtained. Melt viscosity = 177¾. B &gt; 1-Ethylindole-2-carboxylic acid. Containing vermole-2-smilic acid (0.06 M Ear; 10 g) · triethylamine (0.15 mol; 21.25 g> M anhydride (0.07 5 mol; 7.5 g) and 4-dimethylaminopyridine (0.0 06 mol; 0.8 g and dimethane The mixture was stirred at room temperature for 18 hours. Then the reaction mixture was poured into an aqueous solution of 2 buried burial. After the formed sediment is filtered, it is dried in a vacuum oven. Decant the dichloromethane phase, place in a bowl and let dry and steam to 3/4 weight. The second product is the indole-2-carboxylic acid precipitate. Mix the two harvests • 9.4 grams of gray crystals are obtained. Melting point = 168¾ C) 1-benzyloxypyridinamine-2-carboxylic acid Dissolve 8 g of indole-2-carboxylic acid in 120 ml of dichloromethane • Then add 10 g of triethylamine and 1 g of 4-dichloromethane Methylaminopyridine. This reaction mixture was cooled to after stirring. At a temperature of less than 5 t, 8.5 g of benzyloxycarbonyl chloride was added dropwise. Let this mixture play "Ye ·" and then Xingkong under the thick dysprosium. The residue was dissolved in 500 «L of ethyl acetate and then filtered. The mother liquor was concentrated under public opinion and dissolved in 50 mL of dibin methane. Mother liquor «« After the Yu Yukong down to Nongpu. (Please read-! · **? And · Notes for A before filling out this page) Binding · Binding- Line. • 4 2-This paper is used in the standard side ®®Kasabi (CNS) T4 specifications (2) 0x297 male; Sb) 81. 6. 1〇, 〇〇〇 Zhang (Η) 202448 Λ 6 _Π_6_ V. Description of the invention (Μ) Weight = 2.4 grams of oil HHR (DHSO): 5.38 (2H, s. ClU- CeHs); 7.0-8.0 (10H,. Har) 0 du-Third-butoxymontyl indole-shaped-carboxylic acid 30 ml of a solution containing 6 g of disulfonic acid di-tributyric acid was added dropwise to 30 liters Contains 4 g of indole-2-carboxylic acid, 4 mM triethylamine and 0.4 g of dimethylaminopyridine in an ethyl acetate solution. Stir at room temperature for 2 hours and remove the precipitate formed * The residue removed by steaming in Yiqizang is dissolved in methane. After washing the organic phase with water, it is dried and concentrated to dryness. Melt adhesion = 117 t: Yield = 66¾ «Example 1 2- [(2-Indolyl) carbonylcarbonyl] -4- (2,4-dimethoxyphenyl) -5-benzylthiazole ( (Please read the notes beforehand to write this page)

經濟部屮央榀準杓卩工消奸合作杜印^The Ministry of Economic Affairs of the People's Republic of China, the Ministry of Economic Affairs, the Ministry of Economic Affairs

Ry = -CH2-C6H5 t ; 將根據製供A於上面製備之1.96克2-胺基-4-(2.4-二甲 氧苯基)-5-苄基噻唑* 1.22克1-乙釀基吲哚-2-羧酸· 0.85克三乙胺及2.95克BOP ,溶於20奄升二甲替甲釀胺。 反應混合物於室通搢拌2 4小時,然後倒入出=2之級®溶 液°黄色沈《物««濾分開,用水洗後溶於乙酸乙酯。此 -43- 各紙5民凡度逍用中HB家樣準(CNS)T4規岱(210X297公釐) 81. 6. 10,000¾ (H) £02448 五、發明説明(&amp;2) 溶液陸纜用出=2之緩衢溶液*用水•用5 %磧酸氩納溶液 及用水洗之,然後置HgSO*乾埽並且於真空下濃縮之。殘 餘物藉由在矽膠上色蘑分析纯化之•溶離劑:二氱甲烷/ 乙酸乙酯98/2(M積比)。 纯粹產物部份濃縮,得一殘餘物,其用含3克以2(:〇3之 8 0毫升甲酵溶液攪拌24小時處理之。甲酵於真空壤煽,殘 餘物溶於水/乙醚混合液。白色沈灘物鞴β分两並且用鍵 洗之9 重悬=0. 97克 熔點=201 -202 υ (請先閲讀背而之注意事項#填寫本頁) 根據本發明之化合物,其被描述在下表6 法製得。 係Μ相同方 裝. 訂· 線. 經濟部屮央柃準x;:cx工消作合作社印3i 44- 81. 6. 10,000張(H) 本认5良尺度逍用中國Η家榀毕(CNS)&gt;fM規怙(210x297公让) ^02448 Λ 6 Π 6 五、發明説明(^3) 宪 6Ry = -CH2-C6H5 t; 1.96 g of 2-amino-4- (2.4-dimethoxyphenyl) -5-benzylthiazole * 1.22 g of 1-vinyl indole prepared above according to Preparation A Indole-2-carboxylic acid · 0.85 g of triethylamine and 2.95 g of BOP, dissolved in 20 liters of dimethyltinamide. The reaction mixture was stirred in the room for 24 hours, and then poured into a solution of grade 2 = solution. The yellow precipitate was separated by filtration, washed with water, and dissolved in ethyl acetate. This -43- Each paper 5 Min Fan Du Xiao used in the HB home sample standard (CNS) T4 standard Dai (210X297 mm) 81. 6. 10,000¾ (H) £ 02448 V. Description of invention (&amp; 2) Solution land cable Use a retarding solution = 2 * water • wash with 5% sodium argonate solution and water, then dry with HgSO * and concentrate under vacuum. The residue was analyzed and purified by coloring mushrooms on silica gel. Dissolving agent: dimethane / ethyl acetate 98/2 (M product ratio). The pure product was partially concentrated to obtain a residue, which was treated with a solution containing 3 g of 2 (: 〇3 to 80 ml of formazan for 24 hours. The formazan was stirred in a vacuum soil, and the residue was dissolved in water / ether mixture Liquid. The white sinker β is divided into two and washed with a bond of 9 resuspended = 0.97 g melting point = 201 -202 υ (please read back to the precautions # fill in this page) according to the compound of the present invention, its It is described in the following table 6 and produced by the following method. It is the same as the M. Square. Thread. Thread. Ministry of Economic Affairs: 揮 央 惃 准 x;: cx 工 消 作 作 社 社 Printed 3i 44-81. 6. 10,000 sheets (H) Originally recognized as 5 good standards Happy Use of Chinese Η Family Completion (CNS) &gt; fM Regulations (210x297 Concession) ^ 02448 Λ 6 Π 6 V. Description of Invention (^ 3) Constitution 6

N ΗN Η

H,CO OCH 經濟部屮央標準而=?工消奸合作杜印31 ^ 實施例號碼 RV 熔黏7 3C 2 ,ch:O 225 3 &lt;〇&gt;-1 /〇CH3 272 4 262 5 ^^Sdch3 225 6 V och3 283 -45- 本紙又度逍用中S Η家標毕(CNS) ΤΊ規格(210x29/公度) 81. 6. 10,〇〇〇張'(H) (請先閲讀背而之注意事項再填寫本頁) 裝· 訂- 線· £02448 Λ 6 Β6 經濟邶屮央橾準沁Μ工消赀合作杜印驭 五、發明説明(¥f) 實施例7 2-[(卜第三丁氧羰氧甲基- 2-0¾哚基)羰胺基]-4-笨基-5-羥乙基噻唑。 (I ) : Rv = -(CH2) 2-0H ; Rlv = -CeHs; Ri=H; - 2 ! CH2C〇2C\CH3)3 將2克上面製備之胺基醇(根據製備B ,表2)· 2.75克 卜第三丁氣羰基吲哚-2-嫌酸,1.4克三乙胺及4.9克 Β0Ρ溶於15毫升二甲替甲釀胺。於室溫放董*夜,將此反 應混合物倒入磷酸鼸埋®液,出=2。藉邊濾將沈教物分開 ,用水洗後,溶於乙酸乙醮。此溶液陸績用5 %»13 1^〇3溶 液及用水洗之*箱傾析分離,有檐相置MsSOe乾爍並且於 興空濃缩》 殘餘物藉由在矽膠上色履分析純化之*溶雕劑:二氯甲 烷/甲酵100 + 0.5(體積比)。 被溶離出來之第一僩產物相當於去醢化化合物(0及N 醯化•熔點=70TC )。 預期產物是第二俚被溶離出來的。 重置=1 . 2克 熔點=180-1811 賁施例8 2-[(1-第三丁氧羰甲基-2-吲哚基)欺胺基]-4-苯基-5-68 酸乙基噻唑 (請先閲讀背而之注意事項再填·寫本頁) 裝· 訂' 線- -46- 本紙張尺度通用中國S家楳毕(CNS)T4垛tM2]0x2i)V公龙) 81. 6. 10,〇〇〇張(H) S02448 Λ 6 I? 6 五、發明説明(45)H, CO OCH Ministry of Economic Affairs Standards and Standards =? Work elimination cooperation Du Yin 31 ^ Example number RV Melt adhesion 7 3C 2, ch: O 225 3 &lt; 〇 &gt; -1 / 〇CH3 272 4 262 5 ^ ^ Sdch3 225 6 V och3 283 -45- This paper is used again and again. S Η Family Standard (CNS) ΤΊ specification (210x29 / degrees) 81. 6. 10, 〇〇〇 Zhang '(H) (Please read first Contrary to the precautions, please fill out this page) Packing · Ordering-Line · £ 02448 Λ 6 Β6 Economical Beiyang, Yangqin, Qin, Mong, Consumers, Cooperation and Cooperation Du Yinyu 5. Description of Invention (¥ f) Example 7 2- [ (Bu third butoxycarbonyloxymethyl-2-0¾ indolyl) carbonylamino] -4-benzyl-5-hydroxyethylthiazole. (I): Rv =-(CH2) 2-0H; Rlv = -CeHs; Ri = H;-2! CH2C〇2C \ CH3) 3 2 g of the amino alcohol prepared above (according to Preparation B, Table 2) · 2.75 g of the third butane carbonyl indole-2-hydrophobic acid, 1.4 g of triethylamine and 4.9 g of BOP were dissolved in 15 ml of dimethyltinamide. Let Dong * at room temperature overnight, pour this reaction mixture into the emulsified phosphate phosphate solution, the output = 2. Separate the Shenjiao by side filter, wash with water, and dissolve in ethyl acetate. This solution was separated by decantation with a 5% »13 1 ^ 〇3 solution and a water-washed * box. The eaves phase was placed on MsSOe and dried and concentrated in Xingkong. The residue was purified by color analysis on silica gel. * Dissolving agent: dichloromethane / formaldehyde 100 + 0.5 (volume ratio). The first poloxane product dissolved out is equivalent to the de-enylated compound (0 and N yin • melting point = 70TC). The expected product was dissolved by the second slang. Reset = 1. 2 g Melting point = 180-1811 Ben Example 8 2-[(1-Third-butoxycarbonylmethyl-2-indolyl) pyridyl] -4-phenyl-5-68 acid Ethylthiazole (please read the precautions before filling and writing this page) Binding and Ordering Line--46- This paper size is common to China S Jiayu Bi (CNS) T4 stack tM2] 0x2i) V male dragon) 81. 6. 10, 〇〇〇 Zhang (H) S02448 Λ 6 I? 6 V. Description of the invention (45)

(I) : R, = Η ; Z(I): R, = Η; Z

R IV -= -CsH5; Rv * CH3-COO-(CH2)2- CH2C〇2C-(CH3)3 經濟部屮央從準^卩工消费合作杜印级 將0.30克上面製得之產物懸浮在5毫升吡啶中。添加 1.2毫升_酸酐,反應混合物於室溫攪拌遇夜。然後将混 合物倒入由=2之硫酸鹽緩衢液•沈毈物薄遢濾分開,用水 洗後•再溶於二氯甲烷。此溶液陸續用5 96HaHC03溶液洗 之,鞴傾析分開,有機相置MgS0«乾嫌,經邊濾後,於真 空濃縮之。殘餘物在矽謬上色層分析鈍化之,溶離劑:二 氯甲烷/乙酸乙_98/2(觸稹比)。重鼉=0 . 16克 NHR(DMSO): 1.48 (9H , s , t-Bu〇2C) ; 2 . 00 (3H , s , CH3CO2); 3,24(2H, t, J=71U, CH2噻 唑;4 · 3 0 ( 2 H , t . J = 7 fU , C H 2 0 A c ); 5,40(2H, s, CHzCOzt-Bu); 7.2-7.9(10H, b. Har); 12.8(1H, s, NHCO) 〇«施例9 2-[(l-羧甲基-2-吲哚基)嫌胺基]-4-苯基-5-»酸乙基噻 啤〇 47- 本紙5lt尺度边用中《«家樣準([吣)1»4規格(2丨0&gt;&lt;297公:«:) 9 先 閲 背 而 之 事 項 再 寫 本 页 81. 6. 10,000張(H) £02448 Λ 6 Π 6 五、發明説明(46) (I): Ri = Η ; Ζ = ;RjV = ; Rv= CHyCOO-CCH〗),-R IV-= -CsH5; Rv * CH3-COO- (CH2) 2- CH2C〇2C- (CH3) 3 The Ministry of Economic Affairs levies 0.30 g of the product prepared above from the quasi- ^ industrial and consumer cooperation Duin grade 5ml of pyridine. 1.2 ml of _anhydride was added, and the reaction mixture was stirred at room temperature overnight. Then pour the mixture into a sulfate retardant solution of = 2, thinly filter the sediment, wash it with water, and dissolve in methylene chloride. This solution was washed successively with 5 96HaHC03 solution, and the decanter was decanted and separated. The organic phase was dried with MgS0 «, after side filtration, it was concentrated in vacuum. The residue was passivated by silica gel color layer analysis. Dissolving agent: dichloromethane / ethyl acetate_98 / 2 (touching ratio). Heavy weight = 0.16 g NHR (DMSO): 1.48 (9H, s, t-Bu〇2C); 2.00 (3H, s, CH3CO2); 3,24 (2H, t, J = 71U, CH2thiazole ; 4 · 3 0 (2 H, t. J = 7 fU, CH 2 0 A c); 5,40 (2H, s, CHzCOzt-Bu); 7.2-7.9 (10H, b. Har); 12.8 (1H , s, NHCO) 〇 «Example 9 2-[(l-carboxymethyl-2-indolyl) quasi-amino] -4-phenyl-5-» acid ethylthiopyrene 〇47- Original paper 5lt scale In the use of the "« home sample standard ([吣) 1 »4 specifications (2 丨 0> &lt; 297 public:« :) 9 Read the details before writing this page 81. 6. 10,000 sheets (H) £ 02448 Λ 6 Π 6 V. Description of the invention (46) (I): Ri = Η; Z =; RjV =; Rv = CHyCOO-CCH〗),-

CH2C〇2H 將上面製得之化合物0.〗5克溶解在2毫升笨甲81及10奪 升三氟_酸中。 混合物於室潘放置45分鐘’然後於輿空潇箱之。獲得之 殘餘物用正己烷及乙_ (50/ 50&gt;之混合液洗後乾嫌。 重置=0. 14克 熔點=217-218t: 實胞例10 2-[(1-乙釀基-2-蚓跺基)嫌胺基]-4-(2,4-二甲氧苯基 )-5-乙氧期甲基噻唑° (I) : R, = H: Z:CH2C〇2H 5 g of the compound prepared above was dissolved in 2 ml of Benjia 81 and 10 trifluoro-acid. The mixture is placed in the room pan for 45 minutes ’and then placed in the Yukongxiao box. The obtained residue was washed with a mixture of n-hexane and ethyl 50 (50/50>) and dried. Reset = 0.14g melting point = 217-218t: real cell example 10 2-[(1-ethyl alcohol- 2-Echlamido) quasi-amino] -4- (2,4-dimethoxyphenyl) -5-ethoxy stage methylthiazole ° (I): R, = H: Z:

RIV h : R、. = (ΓΗ;(ΓΗ,-ΟΟΟ·0Η,- (請先閲邠背而^注意事項洱填寫本頁) 裝· 訂_ 線-RIV h: R 、. = (ΓΗ; (ΓΗ , -ΟΟΟ · 0Η ,-(please read 邠 背 and ^ Notes and fill in this page first) 装 · 定 _ 线-

N 經濟部屮央標準AM工消&quot;合作社印製 將1.5克2-胺基-4-(2,4~二甲氣苯基)-5-乙氣羧甲基_ 畦,1克1-乙釀基蚓哚-2 -羰酸· 0.7奄升三乙胺及2.39克 Β0Ρ溶於15毫升二氯甲烷。此反應混合物室澴攪拌《夜, 然後於興空灞縮之。殘餘物溶於乙酸乙酷,此溶液陸鑛用 出=2之級®溶液,用5 %NaHC03溶液及用水洗之,然後有 機相置MgS0&lt;t乾燥並且於興空瀠缩之。殘餘物在矽膠上色 48 本紙尺度逍用中01 81家楳準(CNS)TM規仂(210X297公及) 81. 6. 10,000張(H) 9 % 03448 Λ 6 Π 6 五、發明説明(47) 靥分析纯化之,溶離黼:二氯甲烷/乙酸乙醮100/2.5(钃 稹比)。 重量=1.2克 熔黏=130-135 t: 寅施例11 2-[(2-吲哚基)羰胺基]-5-乙氧羰基-4-苯基噻唑N The Ministry of Economic Affairs Standards for the AM Industry & Cooperatives will print 1.5 g of 2-amino-4- (2,4 ~ dimethyl gas phenyl) -5-ethyl gas carboxymethyl, 1 g 1- Ethyl lumbendo-2-carbonyl acid 0.7 L triethylamine and 2.39 g BOP were dissolved in 15 ml dichloromethane. The reaction mixture was stirred in the room "Night, then Yu Xingkong shrank." The residue was dissolved in ethyl acetate, and this solution was used as a grade 2 solution, washed with 5% NaHC03 solution and water, and then organically dried with MgS0 &lt; t and condensed in Xingkong. The residue is colored on silicone 48. The paper is used on a scale of 01. 81 81 Standard (CNS) TM (210X297) 81. 6. 10,000 sheets (H) 9% 03448 Λ 6 Π 6 V. Description of the invention (47 ) Analysis and purification of tantalum, dissolved ion: dichloromethane / acetate acetate 100 / 2.5 (granium ratio). Weight = 1.2g Melt viscosity = 130-135 t: Example 11 2-[(2-Indolyl) carbonylamino] -5-ethoxycarbonyl-4-phenylthiazole

(I) : R, = Η ; Z(I): R, = Η; Z

R IV = - C6H5 ; Ry = CH3CH2-〇CO- 閲ir 背 而 之· 注 意 事 項 再 m 寫 本 頁 經济部屮央榀平々=::工消奸合作社印51 根據上面描述之實施例l〇的方法進行製備,製得化合物 2-[(1-乙釀基-2-吲哚基)羰胺基]-4-苯基-5-乙氧嫌基噻 唑(1.5克)並且在0.6克Na2C03存在下溶於100奄升乙酵 。此混合物於室溫攪拌48小時•然後於真空濃縮之。殘餘 物在水中碾製,然後加最小置的二氯甲烷,纆遇濾後乾爍 〇 重最=1.1克 熔點=248¾ ff施例12 2-[(2-吲哚基)嫌胺基]-4-(2,4 -二甲氧苯基)-5-羧甲基噻 睡。R IV =-C6H5; Ry = CH3CH2-〇CO- read ir to the contrary · Notes and then write this page Ministry of Economic Affairs 屮 央 榀 平 々 = :: 工 消 盗 合作社 印 51 According to the embodiment 10 described above The method was prepared to obtain the compound 2-[(1-ethynyl-2-indolyl) carbonylamino] -4-phenyl-5-ethoxycarbonylthiazole (1.5 g) and was present in 0.6 g Na2C03 Dissolve in 100 liters of ethyl yeast. The mixture was stirred at room temperature for 48 hours. It was then concentrated in vacuo. The residue was milled in water, and then the smallest dichloromethane was added, and it was dried after filtration. Weight = 1.1 g, melting point = 248¾ ff Example 12 2-[(2-Indolyl) amido]- 4- (2,4-Dimethoxyphenyl) -5-carboxymethylthiophene.

(Γ) : R. = H : Z N ! Η =ί| η 丨· 人力.(Γ): R. = H: Z N! Η = ί | η 丨 Human power.

OCH, ; Rv = -CHt-COOH OCH· 49- 本紙張尺度遑用中《«家標準(CNS)T4規格(210x297公;«:&gt; 81. 6, 10,000張(H) £02448 Λ 6 Π 6 五、發明説明 根據上面實施例10製備之0.5克2-[(l-乙醣基-2-吲哚 基)羰胺基]-4-(2,4-二甲氧苯基)-5-羧甲基噻唑,將其溶 於10毫升95°乙酵*然後添加1.5奄升2N NaOH。 此反應 混合物於室溫搢拌過夜,然後於真空濃縮之。殘餘物溶於 由=2乏媛街溶液,沈澱物藉《濾分開,用水洗後,過濾, 然後用水軽洗之。 重量=0.28克 熔點=284t: 根據上面實施例7-12之方法進行製備*製得下表7所描 述之化合物。 ih 閱tr 背 而 之- 注 意 事 項 再 塡 寫 本 π 裝 玎 線 經濟部屮央標準而W工消设合作社印¾ 本紙尺度边用中《8)家樣準(〇肊)肀4規怙(2丨0&gt;&lt;297公放) 50- 81. 6.〗0,000張(H) ^02448 Λ 6 U 6 五、發明説明(49) mOCH,; Rv = -CHt-COOH OCH · 49- This paper is used in the "« Home Standard (CNS) T4 specification (210x297); «:> 81. 6, 10,000 sheets (H) £ 02448 Λ 6 Π 6 5. Description of the invention 0.5 g of 2-[(l-ethosyl-2-indolyl) carbonylamino] -4- (2,4-dimethoxyphenyl) -5 prepared according to Example 10 above -Carboxymethylthiazole, dissolve it in 10 ml of 95 ° ethyl acetate * and then add 1.5 mL of 2N NaOH. The reaction mixture was stirred overnight at room temperature and then concentrated in vacuo. The residue was dissolved in U = 2 Street solution, the precipitate is separated by filtration, washed with water, filtered, and then washed with water. Weight = 0.28g Melting point = 284t: Prepared according to the method of Examples 7-12 above * Prepared as described in Table 7 below Compounds. Ih read tr the other way round-note the notes and write a copy of the book π to the standard of the Ministry of Economic Affairs and to be printed by the Cooperative Society ¾ This paper is used in the standard "8) Family Sample Standard (〇 肊) 肀 4 regulations (2 丨 0 &lt; 297 public announcement) 50-81. 6.〗 0,000 sheets (H) ^ 02448 Λ 6 U 6 V. Description of the invention (49) m

c NH-C,、W A i .1 Uc NH-C, W A i .1 U

NN

Rc ϋ 經濟部屮央標準--? Μ工消费合作社印3i 實施例號磚1 T m r9 熔點;eC 13 -CO2CH3 1 H 254 14 -co2ch3 -&gt; H 181 15 -OH 2 -ch2co2h 131 16 -OH 2 H 242 17 -OH 3 H 213 18 .-OCOCH3 2 H ·—— 168 19 -OCOCH3 3 H 192 20 -o-co-c6h5 2 -ch2co2h 216 21 -O-CO-ierr-Bu 2 H 229 22 -CO2H 1 H 260 23 -CO2H 2 H &gt; 300 24 -CO2H 2 -ch2-co2h 239-240 25 -CO2H 1 -CH2-C〇2H 199-200 -51- (請先閲說背而^注意事項再塥寫本頁) 本紙5fc尺度边用中H國家详毕規格(210X297公使) 81. 6. 10,000張(Η) 202448 Λ 6 Π 6 五、發明説明(5〇) 表 7 (纽清) I 實施例號碼 丁 m Rg 熔點,·- eC , 26 -co2ch3· -) -ch:-co2h 202-203 27 -co2ch3 1 -CH,-CO,H 183-185 28 -C-N-(CH3)2 丨1 1 -CH2-C〇2H 252 0 Η 29 -C-N-CH. . .1 l -CH2-C〇2H 233-234 〇 30 1-0 l -ch2-co2h 241-242 0 實施例31 2-[(2-吲哚基)羰胺基]-4-苯基- 5-[2-(1-吡咯啶羰基 )-1-乙基]噻唑。 :請先閲讀背而之注意事項再填寫本頁) 裝· 線· 經濟部屮央伐準·Α Η工消费合作社印5i (I) : R, = Η ; Ζ 人 I Η ;Rjy = -CgH^ ; Ry = -((ΓΗ:):-。。·' | 52 本fcUfc尺度边用中SH家榣毕(CNS)T4規怙(2】0X297公;《:) 81. 6. 10,000張(Η) Λ 6 II 6 ^02448 五、發明説明(51 ) 將0.5克實施例14所描述之酯添加至5毫升吡咯啶中· 此混合物於室溫攪拌邊夜•然後倒入pH =2之嫌衡溶液中。 沈澱物濾分開,然後溶於乙酸乙酯中。此溶液用出 =2之緩衡溶液洗後,用水洗之,有櫬相藉傾析分開,置 MgS〇4乾埭後,於真空濃縮。Rc ϋ Standard of the Ministry of Economic Affairs-? 3G printed by the Mongong Consumer Cooperative Society No. 1 Brick 1 T m r9 Melting point; eC 13 -CO2CH3 1 H 254 14 -co2ch3-&gt; H 181 15 -OH 2 -ch2co2h 131 16- OH 2 H 242 17 -OH 3 H 213 18 .-OCOCH3 2 H ---- 168 19 -OCOCH3 3 H 192 20 -o-co-c6h5 2 -ch2co2h 216 21 -O-CO-ierr-Bu 2 H 229 22 -CO2H 1 H 260 23 -CO2H 2 H &gt; 300 24 -CO2H 2 -ch2-co2h 239-240 25 -CO2H 1 -CH2-C〇2H 199-200 -51- (please read the notes and ^ Notes first (Further writing this page) 5fc scale of this paper is used in the detailed specifications of the H countries (210X297 ministers) 81. 6. 10,000 sheets (Η) 202448 Λ 6 Π 6 V. Description of the invention (5〇) Table 7 (New York) I Example number D m Rg Melting point,-eC, 26 -co2ch3----ch: -co2h 202-203 27 -co2ch3 1 -CH, -CO, H 183-185 28 -CN- (CH3) 2 丨 1 1 -CH2-C〇2H 252 0 Η 29 -CN-CH ... 1 l -CH2-C〇2H 233-234 〇30 1-0 l -ch2-co2h 241-242 0 Example 31 2-(( 2-Indolyl) carbonylamino] -4-phenyl-5- [2- (1-pyrrolidinylcarbonyl) -1-ethyl] thiazole. : Please read the precautions before filling in this page) Installation · Thread · Ministry of Economic Affairs, Central Standards · Α Η Industry and Consumer Cooperatives printed 5i (I): R, = Η; ZO people I Η; Rjy = -CgH ^; Ry =-((ΓΗ:):-.. '| 52 This fcUfc scale is used in the SH family's home (CNS) T4 regulation (2) 0X297; ":) 81. 6. 10,000 sheets ( Η) Λ 6 II 6 ^ 02448 5. Description of the invention (51) Add 0.5 g of the ester described in Example 14 to 5 ml of pyrrolidine. The mixture was stirred at room temperature overnight. Then it was poured into pH = 2 The precipitate is separated by filtration and then dissolved in ethyl acetate. This solution is washed with a slow-balanced solution of = 2, and then washed with water. Separated by decantation. After drying with MgS〇4, Concentrate in vacuo.

重量=0.48克 熔黏=179TC 根據上面實豳例10之方法進行製供,製得在下表8描述 之化合物32-51。 9 7^. 閲 請, 背 而 之. 注 意 事 項 再 寫 本 裝 訂 線 經濟部屮央標準^:^工消仿合作社印51 -5 3 - 本紙張尺度边用中Η Η家楳準(CNS) ΤΜ規格(210x297公坺) 81. 6. 10,000¾ (Η) 202448 五、發明説明(52) Λ 6 Η 6Weight = 0.48g Melt viscosity = 179TC According to the method of Example 10 above, the compound 32-51 is prepared as described in Table 8 below. 9 7 ^. Please read it, back to the back. Notes to re-write the gutter standard of the Ministry of Economics ^: ^ Gongxiao imitation cooperatives printed 51 -5 3-This paper is used for the standard side Η Η 家 楳 准 (CNS) ΤΜ Specifications (210x297 public) 81. 6. 10,000¾ (Η) 202448 V. Description of the invention (52) Λ 6 Η 6

實施例號碼 τ m Γ4 溶點;% (請先閲請背而之注意事項再墦寫本頁) -cooch3 -cooc2h5 ,c2h:Example number τ m Γ4 Melting point;% (please read the notes to the back before writing this page) -cooch3 -cooc2h5, c2h:

-N c2h5 -C-NII ' o / -C-NIIo 經濟部屮央找準而工消赀合作社印¾ -C-NII vo -NFh NH-C-CH-II . o 2 2-N c2h5 -C-NII 'o / -C-NIIo The Ministry of Economic Affairs is looking for the right and the work is printed by the cooperative ¾ -C-NII vo -NFh NH-C-CH-II. O 2 2

4-F 2-CI H H 4-F 2-CI H H 224-225 178 180 239 243-244 187-188 202-203 261-262 裝 訂 線 -5 4 本紙張尺度边用中8困家樣準(CNS)^M規格(210x297公龙) 8L 6, ]〇,〇〇〇張⑻ ^02448 Λ 6 Π 6 五、發明説明(53) 表 8 (mm) 經濟部屮央伐準灼W工消价合作杜印51 實施例號瑪| T m \ ! ; ^ • i 1 i 1 I溶點.;ec t - 40 -o-c-ch3 • i ) 4-F 188-kS^ 41 〇 -O-C-OCH, 丨丨 2 H 208-209 42 II 〇 -NH-C-O-^rr -Bu II 2 H 223-224 43 II 〇 -NH-C-0-CH-; ,1 J II 2 H 264 44 II 〇 H I -NH-C-N'-C7H^ 丨丨 Z 3 2 H 248-249 45 II 〇 -NH-C-(CH9)9-C09H 11 “ - 2 H 275-276 46 II 0 H 1 -NH-C-N-C2H5 2 H 209-210 47 2 H 196-197 48 -O-C * 0 och3 OCH^ 2 H 218-219 -5 5 _ 81. 6. 10,000張(Η) (請先WW背而之注意事項再堝¾本頁) 裝· 訂 線· 20344Β η 6 五、發明説明(54) 表 3 (mm) -一丨 實施例號碣 Τ m Γ4 ί i熔點;eC t 1 49 CH} 丨·。卞-备 τ Η 1 UO-142 50 〇 / ch3 •〇-C-&lt;g)-CH3 〇 τ Η 270-271 51 2 Η 212-213 (請先閲讀背而之注意事項#蜞寫本頁) 實施例52 2-[(2-吲哚基)羰胺基]-4-苯基-5-苯胺基-羰氧乙基噻唑4-F 2-CI HH 4-F 2-CI HH 224-225 178 180 239 243-244 187-188 202-203 261-262 Gutter-5 4 This paper size is used in the middle of the 8-sleeved home standard (CNS ) ^ M specifications (210x297 male dragon) 8L 6,] 〇, 〇〇〇 Zhang ⑻ ^ 02448 Λ 6 Π 6 V. Description of invention (53) Table 8 (mm) Ministry of Economic Affairs Du Yin 51 Example No. Ma | T m \!; ^ • i 1 i 1 I melting point .; ec t-40 -oc-ch3 • i) 4-F 188-kS ^ 41 〇-OC-OCH, 丨丨 2 H 208-209 42 II 〇-NH-CO- ^ rr -Bu II 2 H 223-224 43 II 〇-NH-C-0-CH- ;, 1 J II 2 H 264 44 II 〇HI -NH -C-N'-C7H ^ 丨 丨 Z 3 2 H 248-249 45 II 〇-NH-C- (CH9) 9-C09H 11 "-2 H 275-276 46 II 0 H 1 -NH-CN-C2H5 2 H 209-210 47 2 H 196-197 48 -OC * 0 och3 OCH ^ 2 H 218-219 -5 5 _ 81. 6. 10,000 sheets (Η) (please pay attention to the precautions before WW and then copy this book Page) Binding · Thread · 20344B η 6 V. Description of the invention (54) Table 3 (mm)-a 丨 Example number Τ m Γ4 ί i Melting point; eC t 1 49 CH} 丨 .. Bian-prepared τ Η 1 UO-142 50 〇 / ch3 • 〇-C- &lt; g) -CH3 〇τ Η 270-271 51 2 Η 212-213 (please read back to the precautions # 蜞 write this page) Example 52 2-[(2-Indolyl) carbonylamino] -4-phenyl-5-anilino-carbonyloxyethyl Thiazole

(I) : R, = H : Z 1(I): R, = H: Z 1

Ν·丨 Η β, &lt;Ν · 丨 Η β, &lt;

經 濟 屮 央 準 工 消 fi' 合 作 社 印 A)2-[U-乙钃基-2-吲B朵基)]捩胺基-4-苯基-5-苯胺羰 氧乙基噻唑。 0.75克根據寅施例16製«之醉及0.2奄升興氰酸笨酯· 於室溫在5 «升二氮甲烷中播伴«夜。形成之沈澱物藉過 濾分開,然後在矽膝上色層分析純化之,溶離劑:二氮甲 - 5 6 - 81. 6. 10,000¾ (Η: S02448 82.12.22 五、發明説明(55) 烷/乙酸乙豳95/5(«積比 重曼=0.52克 熔點=1561C B)化合物52 將±面製備之化合物0.5克*溶於30«升乙酵及5奄升 水•然後添加0.21克Ha2C〇s » ' 此琴_混合物於室溫攪拌通夜•然後於冥空濃縮之。殘 餘物溶於乙酸乙醣並且睡縝用ITa2C〇3溶液及用水洗之。奄 拥相薄傾析分開並且於真空濃缩之。殘餘物溶於乙鍵。 重* = 0. 4克 熔點=2491C 苴施例53 2-[(2-18丨D采基)祭肢基]-4,5 -二S-[5,4-d]-lH -睡哩并苯Economically, the central quasi-industrial fi's co-printed A) 2- [U-ethinyl-2-indodoyl)]] amino-4-phenyl-5-anilinecarbonyloxyethylthiazole. 0.75 g «Drunken and 0.2 liter l-dibenzyl cyanate» prepared according to Example 16 at the room temperature in 5 «L diazomethane </ b> night. The precipitate formed was separated by filtration, and then purified by chromatography on a silica gel. The dissolving agent: diazomethane-5 6-81. 6. 10,000¾ (Η: S02448 82.12.22 V. Description of the invention (55) / Acetyl acetate 95/5 («Specific gravity man = 0.52g melting point = 1561C B) Compound 52 0.5 g of compound prepared in ± surface * dissolved in 30« L ethyl acetate and 5 L water • Then add 0.21 g Ha2C〇s »'This violin_mixture was stirred overnight at room temperature • Then concentrated in the empty space. The residue was dissolved in ethyl acetate and washed with ITa2C〇3 solution and washed with water. The phase was separated by decantation and concentrated in vacuum Shrink. The residue is dissolved in the B bond. Weight * = 0.4 g Melting point = 2491C Example of sack 53 2-[(2-18 丨 D mining base) sacrificial limb base] -4,5-diS- [5 , 4-d] -lH -Sleep Acene

并雜革。 (I) : R, = Η ; Z Ν I Η (請先閲丸背而之·&gt;i.意事項νφ填•寫本頁) ;Rv and RjV = 0-(CH2)-&gt;-And mixed leather. (I): R, = Η; Z Ν I Η (please read the back of the pill first · &gt; i.Importance νφfill • write this page); Rv and RjV = 0- (CH2)-&gt;-

Μ浒部屮央標準杓β工消1V·合作社印31 將1克上面製得(製備卩)之噻唑*2.6克&amp;0卩,0.93克 卜乙醢基《I哚-2-數酸及0.46克三乙胺,在30奄升二甲替 醯胺中混合。此反應混合物於室溫播拌30小時。二甲替甲 醢胺蒸發後,殘餘物溶於乙酸乙酯並且用水洗。有拥相置 碕酸納乾烯後蒸發。殘餘物在矽膠上色層分析,溶離劑: 二氯甲烷/甲醉100+0.5(照積比)。獲得0·9克黄色泡沫 •將此泡沫物溶於其中巳添加乙酵(100奄升)之二氢甲烷 57 本紙張ΛΛϋ用中困困家«UMCNS) 1Μ規«(210x297公*) 81. 6. 10,000ft (Η) Λ 6 Η 6 五、發明説明(56) 中。添加10毫升2H NaOH ,此灌合物室瀣攪拌1小時。有 機溶繭蒸發後,殘餘物溶於乙黢乙_並且用出=2之縵銜溶 液洙之。有檐相置MgS0«乾嫌後《濾並且蒸乾》得黄色 结矗•然後用二《[甲烷洙後•再用乙酵洗之》 重量=0.45克 熔》&gt;260t: 賁腌例54 2-[(2-吲哚基 &gt;羧胺基]-4-苯基-5-(1-六氫吡啶基)噻唑 (請先閲?5?背而之注意事項典堪寫本頁)Μ 浒 部 屮 楮 汓 β 揓 工 消 1V · Cooperative cooperative printing 31 1 gram of thiazole prepared above (preparation) * 2.6 g &amp; 0,0.93 g of ethylpyridinyl "I-dole-2-number acid and 0.46 g of triethylamine, mixed in 30 liters of dimethyltamide. The reaction mixture was broadcast at room temperature for 30 hours. After dimethylformamide was evaporated, the residue was dissolved in ethyl acetate and washed with water. There is a coherent phase of sodium naphthenic acid after evaporation. Chromatographic analysis of the residue on silica gel, dissolving agent: dichloromethane / methanone 100 + 0.5 (accumulation ratio). Obtain 0.9 g of yellow foam. Dissolve the foam in it and add ethyl yeast (100 liters) of dihydromethane 57. This paper ΛΛϋ is used in the sleepy home «UMCNS) 1Μ regulation« (210x297 public *) 81. 6. 10,000ft (Η) Λ 6 Η 6 V. Description of the invention (56). 10 ml of 2H NaOH was added, and the filling chamber was stirred for 1 hour. After the organic solvent cocoon evaporates, the residue is dissolved in ethyl sulfonate and used to dissolve the solution of tang = 2. Set with the eaves MgS0 "Dry and then" filter and steam to dry "to get a yellow knot • Then use two" [methane soo • re-washed with ethyl yeast "Weight = 0.45 grams of melting" &gt; 260t: Ben pickling example 54 2-[(2-Indolyl> Carboxamido] -4-phenyl-5- (1-hexahydropyridyl) thiazole (please read first? 5? Contrary to this, the code can be written on this page)

經浒部屮央標準::Γβ工消赀合作社印製 A)2-胺基-4-苯基-5-(1-六氲吡啶基)噻唑 將含1克2-胺基-4-苯基-5-溴噻唑,1.7克六氫吡啶及 25毫升絕對乙酵之混合液回流48小時。乙酵於真空下濃縮 。殘餘物溶於50毫升水及10«升30%Ha0H。用乙酸乙酯萃 取後•有機相置Na2S0«乾烯並且《濾。溶液於真空濃鏑之 ,殘餘物以興丙醚再结晶。 霣量=0.41克 熔點=135-1 37t: B )化合物5 4 將0.4克下面獲得之產物溶於5 0«升二氮甲烷。陸績添 加0.33克1-乙釀基吲哚-2 -羧酸· 0.82克Β0Ρ及0.19克三 -58- 本紙ft尺度边用中Η «家樣苹(CNS)IM規怙(2】0:&lt;297公;¢) 81. 6. 10,000張⑻ ^03448 Λ 6 Η 6 五、發明説明(5?) 乙胺。此反應混合物於室灞攪拌4天。添加2 5毫升水並且 薄傾析將有機相分開•置Na2S〇4乾爍後,於真空壤箱之。 殘餘物溶於50毫升絕辑乙酵,並且添加10«升2.5N NaOH ,此混合物於室溫攪拌3小時》混合物於興空濃縮後*殘 餘物溶於50«升水,用乙酸乙釀萃取*有櫬栢藉傾析@ · 置Na2S0«乾爍後•於真空壤箱之。殘餘物K乙酸乙醱再结 晶。 重量=0.26克 熔黏&gt;260*C 根據*施例54之方法進行製供^製得下表9描述之化合 物55及56。According to the standard of the Ministry of Economic Affairs: Γβ printed by the Cooperative Society A) 2-amino-4-phenyl-5- (1-hexapyridyl) thiazole will contain 1 gram of 2-amino-4-benzene The mixture of 5-bromothiazole, 1.7 g of hexahydropyridine and 25 ml of absolute ethyl acetate was refluxed for 48 hours. The yeast is concentrated under vacuum. The residue was dissolved in 50 ml of water and 10 μl of 30% Ha0H. After extraction with ethyl acetate • The organic phase was placed with Na2S0 «dryene and filtered. The solution was concentrated in vacuum with dysprosium, and the residue was recrystallized with propyl ether. Amount = 0.41 g Melting point = 135-1 37t: B) Compound 5 4 0.4 g of the product obtained below was dissolved in 50 mg of diazomethane. Lu Ji added 0.33 g of 1-ethynyl indole-2 -carboxylic acid. 0.82 g of B0P and 0.19 g of San-58- ft scale of this paper was used in the middle «Home Sample Apple (CNS) IM regulations (2) 0: &lt; 297 public; ¢) 81. 6. 10,000 sheets ⑻ ^ 03448 Λ 6 Η 6 V. Description of the invention (5?) Ethylamine. The reaction mixture was stirred at room temperature for 4 days. Add 25 ml of water and separate the organic phase by thin decantation. After drying with Na 2 SO 4, place in a vacuum soil box. The residue was dissolved in 50 ml of absolute yeast, and 10 «L of 2.5N NaOH was added, and the mixture was stirred at room temperature for 3 hours. After the mixture was concentrated in Xingkong * The residue was dissolved in 50« L of water and extracted with ethyl acetate * There is 抇 柏 擊 擊 擊 @ · After placing Na2S0 «after dry flashing, put it in a vacuum soil box. The residue K was recrystallized from ethyl acetate. Weight = 0.26g Melt adhesion> 260 * C According to the method of * Example 54, the compounds 55 and 56 described in Table 9 below were prepared.

RV\^S NH-C- (請先閲讀背而之注意事項#«寫本頁) 裝- 訂_RV \ ^ S NH-C- (please read the notes on the back # «write this page)

N i Η 9施例號琢 1 Rv 熔點J °c 55 -N V〇H &gt; 300 56 /~\ 247-249 -N N-C-0-CoHc \_/ 1! ~ 〇 -5 9 _ 遑 度 尺 5) CN /V 家 (21 公 Η (V 張 I 10· 6 81 ^02448 Λ 6 It 6 五、發明説明(58) 實施例57 2-[(2-吲哚基)欲胺基]-5-澳-4-苯基噻唑。N i Η 9 Example No. 1 Rv Melting point J ° c 55 -NV〇H &gt; 300 56 / ~ \ 247-249 -N NC-0-CoHc \ _ / 1! ~ 〇-5 9 _ 遑 度 尺5) CN / V home (21 gH (V Zhang I 10 · 6 81 ^ 02448 Λ 6 It 6 V. Description of the invention (58) Example 57 2-[(2-indolyl) amine group] -5 -O-4-phenylthiazole.

(I) : R, = Η ; Z I Η ;R【V = ;Ry = Br 經濟部屮央標準·/ί·;Α工消费合作杜印5i 將3.9克(0.015莫耳) 氯甲烷。 添加3.26克1-乙釀基蚓 三乙胺,此反應混合物於 升埋衢至出=2之水溶液, Na:*S04乾嫌並且於輿空下 酵•然後添加5克Na2C〇3 真空下,在低溫瀠縮後· 液,用乙酸乙酯萃取後, «濾後,於輿空下濃鏞。 麵:CH2CU。去除頂纗不 •其於溶_蒸發後,以二 0 里量=2.8克 熔貼=224-226 C «施例58 2-[(2-吲哚基)羧胺基]-5 -甲氧基-4 -笨基噻唑 2-肢基-5-溴噻唑溶於60奄升二 哚-2-羧酸· 8 . 1克 室灌攪拌 此混合物 蘭煽之。 。此混合 溶於100 有機相置 殘餘物在 純物之後 氯甲烷/ 8天,然 經傾析後 殘餘物溶 物於室搢 «升緩衡 Na2S〇4^ 矽膠上色 •預期產 二異丙8* Β0Ρ · 1.85克 後添加100毫 ,有機相置 於100毫升甲 拌3小時,於 至pH =2之水溶 堍。混合物烴 層分析,溶雛 物被溶鐮出來 琨合液再结晶 (請先M-ir背而之注意事項再墦寫本頁) 裝- 訂· 線· -60 本紙5民尺度边《1中《«家楳毕(CNS)IM規格(210x297公;«:) 81. 6. 10,000¾ (Η) 五、發明説明(59)(I): R, = Η; Z I Η; R [V =; Ry = Br, the Ministry of Economic Affairs, the central standard · / ί ;; A industrial consumer cooperation Duin 5i will 3.9 grams (0.015 mol) of methyl chloride. Add 3.26 g of 1-ethylenium triethylamine. The reaction mixture is buried in a quarry to an aqueous solution of = 2. Na: * S04 is dry and leaven in the air. Then add 5 g of Na2C〇3 under vacuum. After shrinking at a low temperature, the liquid was extracted with ethyl acetate, and after «filtration, it was concentrated under the air. Face: CH2CU. After removing the top layer, dissolve it and evaporate it to 20 li = 2.8 g of melt paste = 224-226 C «Example 58 2-[(2-indolyl) carboxamido] -5 -methoxy Benzyl-4-benzylthiazole 2-limb-5-bromothiazole dissolved in 60 liters of diole-2-carboxylic acid. 8.1 g of this mixture was stirred in a room irrigator. . This mixture was dissolved in 100 organic phase residues. After pure matter, methyl chloride / 8 days, and then after decantation, the residue was dissolved in the room «rise slow balance Na2S〇4 ^ coloring of silicone rubber • expected to produce diisopropyl 8 * Β0Ρ · 1.85g after adding 100 milliliter, the organic phase was placed in 100ml of for 3 hours, and dissolved in water until pH = 2. Analysis of the hydrocarbon layer of the mixture, the lysate is dissolved by the sickle, and the recrystallized solution (please pay attention to M-ir first and then write this page) Binding-Order · Line · -60 This paper 5 people standard side "1 in "« Homewood (CNS) IM specifications (210x297 g; «:) 81. 6. 10,000¾ (Η) V. Description of the invention (59)

(I) : R1 = Η : Z(I): R1 = Η: Z

Λ 6 Π 6 :=-匸6闩5 : Rv = -〇CH: 將3. 15克2-胺基-5-甲氧基-4-苯基噻唑溶於60毫升 CH2CU。添加3.26克卜乙鼸基《I哚-2-羧酸,8. I2.克Β0Ρ 及1.86克三乙胺•此反應混合物於室湛攢拌一星期。添加 50毫升水後,有檐相被傾析,置Na2S〇4乾蜾後,遢濾並且 於真空下灞縮。殘餘物溶於100毫升.甲酵•添加10克 K2C〇3 ,滙合物於室邋攪拌遢夜。此混合物於真空下濃縮 ,殘餘物溶於水,形成之沈澱物藉遘濾分拥並且用 CIUCU洗之。 重量=1.7克 熔點=&gt;260t: 根據上面實施例之方法進行製備*製得下表10描述之化 合物59-61 。 先 閲 in 背 而 之 注 意 事 項 % 本 頁 裝 η 線 經濟部屮央榀準/'Jn工消1V·合作杜印3i -61 - 本紙張尺度逍用中明Η家榣平(CNS)T4規怙(2)0x29/公放) 81. 6. 10,000張⑻ 32. 五、發明説明(g〇)Λ 6 Π 6: =-匸 6 latch 5: Rv = -〇CH: 3.15 g of 2-amino-5-methoxy-4-phenylthiazole was dissolved in 60 mL of CH2CU. Add 3.26 grams of ethyl ethene "I-dol-2-carboxylic acid, 8. I2. Grams of BOP and 1.86 grams of triethylamine. This reaction mixture was kept in the chamber for one week. After adding 50 ml of water, the eaves phase was decanted. After drying with Na2SO4, it was filtered and shrunk under vacuum. The residue was dissolved in 100 ml. Formazan • 10 g of K2C〇3 was added, and the conjugate was stirred sloppyly in the room. The mixture was concentrated under vacuum, the residue was dissolved in water, and the formed precipitate was separated by filtration and washed with CIUCU. Weight = 1.7 g. Melting point = &gt; 260t: Preparation according to the method of the above example * Compounds 59-61 described in Table 10 below were prepared. First read in Contrary Notes% Installed on this page η Line Ministry of Economics 搮 央 榀 准 / 'Jn 工 消 1V · Cooperate Duyin 3i -61-This paper standard is easy to use in the Ming Dynasty Η 家 榣 平 (CNS) T4 regulations怙 (2) 0x29 / Public) 81. 6. 10,000 sheets ⑻ 32. V. Description of the invention (g〇)

IQIQ

X Η - c — ;l 0 Λ 6 η 6 ΗX Η-c —; l 0 Λ 6 η 6 Η

Example No. m.p.; °C 59 2-C1 260-262 60 4-CH3 252-254 61 2-OCH3 j 248-250 實施例62 2-[(2_吲哚基)羰胺基]-5-羥*-4-苯基噻唑Example No. mp; ° C 59 2-C1 260-262 60 4-CH3 252-254 61 2-OCH3 j 248-250 Example 62 2-[(2-indolyl) carbonylamino] -5-hydroxyl * -4-phenylthiazole

V (I) R, Η ; ΖV (I) R, Η; ZO

RR

IVIV

•CgΗ^ ; Rγ = -OH• CgΗ ^; Rγ = -OH

N I H 經濟部屮央榣準X/M工消价合作社印¾N I H The Ministry of Economic Affairs, the Central People's Republic of China, X / M Industrial Consumer Price Cooperative Printing ¾

將0.58克根據賁施例58製得之噻唑溶於100 «升 (:112(:12。於室溫添加4.98奄升2&gt;&lt;三溴化硼之(^2(:12溶’.讓 此反應混合物攫拌24小時。再添加4.98奪升BB「3,此混合 物於室溫放置5天,最後再添加4.9 8克BBr3,此反麽混合 物室溫放置48小時。然後賴添加4N HaOH溶液調至pH _ 6 2 - 本紙5fc尺度边用中a Β家槔準(CNS) ΤΜ規格(210X297公徒) 81. 6. 10,000張(Η) 辦448 Λ 6 Π 6 五、發明説明(61) = 5-6,有拥相用50奄升4Ν NaOH萃取2次。水相鞴添加 2N HC1溶液中和之。混合物用CH2CU萃取,有機相置 Na2S〇4乾煉後,遇濾並且真空濃纗,產生一结晶化殘餘物 Ο 重量=0.5克 熔點=237-239X: (請先閲請背而之注意苹項再塡寫本頁) 裝- 訂' 線· 經濟部屮央榀準x,(:cr工消价合作杜印51 63 本紙5fc尺度逍用中SS家標iMCNS)TM規ίΜ210χ29/公及) 81. 6. 10,000張(Η)0.58 g of the thiazole prepared according to Ben Example 58 was dissolved in 100 liters (: 112 (: 12. Add 4.98 liters of 2 &gt; &lt; boron tribromide (^ 2 (: 12 dissolved in the room temperature. Let The reaction mixture was stirred for 24 hours. 4.98 liters of BB "3 were added again. The mixture was left at room temperature for 5 days. Finally, 4.98 grams of BBr3 was added. The mixture was left at room temperature for 48 hours. Then 4N HaOH solution was added. Adjusted to pH _ 6 2-This paper is used in the 5fc scale of the edge of a home standard (CNS) TM specifications (210X297) 81. 6. 10,000 sheets (Η) 448 Λ 6 Π 6 V. Invention description (61) = 5-6, and the supported phase was extracted twice with 50 liters of 4N NaOH. The aqueous phase was added with 2N HC1 solution to neutralize it. The mixture was extracted with CH2CU, the organic phase was dried with Na2S〇4, filtered and concentrated in vacuo , A crystallization residue is produced Ο Weight = 0.5 g Melting point = 237-239X: (please read first, please pay attention to Apple and then write this page) Binding-Order 'Line · Ministry of Economic Affairs 汮 央 満 准 x, ( : cr industry price cooperation Du Yin 51 63 original paper 5fc standard for the use of SS home standard iMCNS) TM regulation ί210 × 29 / public and) 81. 6. 10,000 sheets (Η)

Claims (1)

A? 藥 … 梂雾利申册藿 ΒΤ夂申請專钊範蜀修氐夂(年月〉 C7—---------- - - D7 六'申請專利範圊 公 式(I )之2 -醯胺基噻唑 修正泣1. 2 9 本年冷ή丨1獄 RvA? Drugs ... The application of "Zhenwuli" is a special application for Fan Zhaoxiu (year and month) C7 —------------D7 Six's formula for patent application (I) 2-Amidyl thiazole correction cries 1. 2 9 This year's cold 丨 1 prison Rv όπο 1 - R.— ΝΥ—Ν S 經濟部中央標準扃印製 式中 - 1U代表氫原子;(Ci-CJ烷基或具(Ci-Ca)烷基之笨亞 烴基;式-Za-NRds之胺亞烴基,其中Zi代表(c2-c4) 亞烴基且及R5個自分別代表Η或(U-Ca)烷基或與其 連接之氮原子形成一飽和雜環,涤選自嗎啉基,吡咯唆 基,六氫吡啶基,六氫吡畊基及(Ci-C3) 4 -烷基六氫啦 畊基;式-Z2COORe之視情況酯化羧亞烴基,其中叾2代表 (h-U)亞烴基代表Η或(Ci-Ce)烷基;(C2-Cs) 氰亞烴基;式- Z3CONR7Re之胺基甲醯亞烴基,其中Z3代 表(Ca-“)亞烴基且卩7及R8分別代表Η或(“-“)烷 基,或具Ν之雜環N R 4 R s ; (C 2 - C β )羥亞烴基,或 (Ci-Ci。)烷氧亞烴基; - RIV代表未被取代或被一或多個(Ci-Cd烷基取代之 (C3-C7)環烷基;芳基係選自苯基,其為未被取代或攜 帶一或多個取代基者,此取代基選自鹵素原子,尤其氣 或氟,(Ci-Ce)烷基,及(Ci-Cs)烷氧基及硫代烷氧基 ,硝基及三氟甲基,及..雜環,其包含至少一個選自〇, S及Η之雜原子者,尤其呋喃基I噻吩基,吡咯基,吡 (請先聞讀背面之注意事項再溪窝本頁) f 4 (210X297 公濩) % 0^4¾8 A7 B7 C7 D7 六、申請專利範面 唑基,咪唑基I吡啶基,吡畊基,噁唑基及噻唑基,其 視情況被(Ci-Cs)烷基或鹵素原子或(Ci-Cs)烷氧基取 代或Rv及RIV —起代表下基:όπο 1-R.— ΝΥ—Ν S In the Central Ministry of Economic Standards-printed formula-1U represents a hydrogen atom; (Ci-CJ alkyl group or a stupid alkylene group with (Ci-Ca) alkyl group; formula -Za-NRds Amine alkylene group, where Zi represents (c2-c4) alkylene group and R5 form a saturated heterocyclic ring from a nitrogen atom connected to Η or (U-Ca) alkyl or respectively, selected from morpholinyl, Pyrrolidinyl, hexahydropyridinyl, hexahydropyridinyl and (Ci-C3) 4 -alkyl hexahydroalkenyl; formula -Z2COORe optionally esterifies carboxyalkylene groups, of which 2 represents (hU) The hydrocarbyl group represents Η or (Ci-Ce) alkyl; (C2-Cs) cyanoalkylene; the amino-methylene hydrocarbylene group of the formula-Z3CONR7Re, where Z3 represents (Ca- ") alkylene and 7 and R8 represent Η, respectively Or ("-") alkyl, or heterocyclic ring NR 4 R s with Ν; (C 2-C β) hydroxyalkylene, or (Ci-Ci.) Alkoxyalkylene;-RIV represents unsubstituted or (C3-C7) cycloalkyl substituted with one or more (Ci-Cd alkyl; aryl is selected from phenyl, which is unsubstituted or carries one or more substituents, this substituent is selected from Halogen atom, especially gas or fluorine, (Ci-Ce) alkyl, (Ci-Cs) alkoxy and thioalkoxy, nitro and trifluoromethyl, and .. heterocycles, which contain at least one heteroatom selected from 〇, S and Η, especially furyl Ithiophene Base, pyrrolyl, pyridine (please read the precautions on the back and then this page of Xiwo) f 4 (210X297 Kang)% 0 ^ 4¾8 A7 B7 C7 D7 VI. Applying for a patented oxazolyl, imidazolyl I pyridyl , Pyridinyl, oxazolyl and thiazolyl, which are optionally substituted with (Ci-Cs) alkyl or halogen atoms or (Ci-Cs) alkoxy or Rv and RIV together represent the following groups: P/nP 經噻唑環4位上的苯基碳連接並且其中u等於1-3,視 情況攜帶一或多個(np)取代基XP,此取代基為相同或相 異,選自鹵素原子,((^-(:3)烷基及烷氧基,硝基及三 氟甲基,ηρ等於0-3 ; —— Rv代表- (CHzh-X基,其中m是0-5且X代表 • 鹵素原子,較佳溴原子,羥基,(C3-C7)環烷基, 苯基其可被選自鹵素原子,(Ca-Cs)烷基或烷氧基 ,或硝基|胺基•羥基或三氟甲基其中一基取代者 , _ 選自-C00H ; -COOXi ;其中-0-COX:;或 -S C 0 X i ; ( 0 ) q - S - X !其中 Q = 0 , 1 或 2 ; -O-COOXi; N-CO-Xi其中 X3 = H或(Ci-Cs )烷基; HN-C-0-X -NH-C-NHXi其中 W=0 或 li II o w (請先閱讀背而之注意事項再填寫本頁) 經濟部中央標準局印裝 s ; -NH-C-(CH2)3-C00H其中 s=2,3,4 II o 2- f 4(210X297 公尨) 844 η ο 7 7 7-A B c D 經濟部中央標準局印裝 六、申請專利範面 其中Xi代表(Ci-Cs)烷基;笨基其可被一或多個選自齒 素原子,(Ci-C3)烷基或烷氧基或硝基,胺基*羥基或 三氟甲基取代者;金剛烷基;選自-CONXiXs; -NXiXz之 —基;其中XiR表氫,(Ci-Cs)烷基或笨基其未被取代 或被一或多個基取代者,此取代基選自鹵素原子, (Ca-Cs)烷基或烷氧基,或硝基,胺基,羥基或三氟甲 基取代者且χ2代表氬原子,(Ci-Cs)烷基,或變更為 乂1及χ2與其連接之氮原子構成一雜環,此雜環選自吡咯 啶或六氫吡啶,其未被取代或被一氧基或被羥基取代者 ,後者為未被取代或被醢基或被-(:0(^1或-(:0”1\2基取 代者; 或爱更為lUaa-Cs)烷氧基;羥基;具5或6元之環 狀胺;其未被取代或被氧基或羥基取代者;六氫吡畊 基,其未被取代或被- COOAlk基N-取代,其中Aik代 表(Ci-Cd烷基;羧酸基,-NX2X4基,其中5U = H或 X4=-(CH2)t-X5 , t 等於2, 3或4 且 X5代表-0H , -O-CO-Rz &gt; -NHC0R2 - -HH-C-NHR2 其中R2代表(Ct-Ce)烷基;或- NR2R3基,其中1?2或1?3分 別代表Η ,(Ca-Ce)烷基,笨基其未被取代或被一或多 個取代基取代•此取代基選自鹵素原子或(Κ3)烷基 或(Ci-Cs)烷氧基,或R2RR3與其連接之氮原子構成具 5或6 —元之雜環: 甲4(210X297 公发) .................................* .................3t..............................ir•…:&gt;.....................sf (請先閲讀背面之注意事項再填弈本页) 8442 ο 0Λ A B c D 經濟部中央橾準局印製 六、申請專利範® Z代表含一或多個雜原子之雜瓖,此雜原子選自0, s及 N ,此雜環耦合至一芳族環,此芳族環也可包含一選自 0, S及N之雜原子並且可被一或多個基取代者,此取代 基選自鹵素原子,(Ca-Ca)烷基及烷氧基,或苄氧基· 硝基,胺基及三氟甲基,可能該雜原子N為芳香性或圼 -NH形式•其為未被取代或被(U-C4)烷基,羧亞烴基 -Z4-C00Rlo取代,其中z4代表亞烴基且1^。是 Η ,苄基或(Cx-Ce)烷基;胺基甲醮亞烴基 -Ζ5-(:0Νυ12 ,其中r5代表((:!-“)亞烴基且Rn及 R12分別代表Η ,(Ci-Ce)烷基,或與N形成飽和雜環 諸如嗎啉基或六氫吡啶基;醢基C0R13 ,R13代表 (C : - C Ο烷基或苯基;烷氧羰基-C 0 0 R : 4 ,其中R : 4為 第三丁基或苄基; Μ及式(I )之化合物與無機或有機酸及鹼之附加鹽。 2 . 根據申請專利範圍第1項之式(I )之化合物,其中Ζ 代表笨并噻吩基,笨并呋喃基,笨并噁唑基,笨并眯唑 基,苯并噻唑基,喹啉基,異DS啉基,Ug喏啉基,哮啉 基及[2 , 3 - c ]-噻吩并或[3 , 2 - c ]吡啶基,異吲哚基或吲 U朵基’其視情況被取代者,且吲哚基為視情況在氮上被 (Ci-Cd烷基,羧烷基-Z4-C00R1o取代者,其中代表 (Ci-C^)亞烴基且R10代表η ,苄基或(Ct-Ce)烷基; 胺基甲醸基-Zs-CONRuR^ •其中R5代表(Ci-“)亞烴 基且Rn及R12分別代表Η ,(Ci-Ce)烷基或與N形成 飽和雜環諸如嗎啉基或六氫吡啶基;醯基,-COR13,其 -4 - f 4 (210X 297公尨) (請先閑讀背面之注意事項再填寫本頁) .装· .打· 〇^44β Βτ C7 _;_ D7 六、申請專利範面 中R13代表(Ci-Cd烷基笨基;垸氧羰基- COOR14 ,其 中Ri 4代表第三丁基或苄基;及其鹽類。 3 . 根據申請專利範圍第1項之化合物,其中R ζ代表Η , (Ci-Ca)烷基或-Zi-NIUIU ,其中具有與申 請專利範圍第1項相同意義者,Z代表吲哚基,其未被 取代或在氮上被取代者且RIV代表笨基。 4. 一種根據申請專利範圍第1項之經取代2 -醯胺基-5-噻 唑之製法,其中下式之經取代2 胺基-5 -噻唑: (請先閲讀背面之注竞事巧再填寫本頁} R〇iP / nP is connected via a phenyl carbon at the 4-position of the thiazole ring and where u is equal to 1-3, optionally carrying one or more (np) substituent XP, which is the same or different, selected from halogen atoms, ((^-(: 3) alkyl and alkoxy, nitro and trifluoromethyl, ηρ is equal to 0-3; —— Rv represents-(CHzh-X group, where m is 0-5 and X represents • Halogen atom, preferably bromine atom, hydroxyl group, (C3-C7) cycloalkyl group, phenyl group which can be selected from halogen atom, (Ca-Cs) alkyl group or alkoxy group, or nitro | amino group • hydroxy group or Where one of the trifluoromethyl groups is substituted, _ is selected from -C00H; -COOXi; where -0-COX :; or -SC 0 X i; (0) q-S-X! Where Q = 0, 1 or 2 ; -O-COOXi; N-CO-Xi where X3 = H or (Ci-Cs) alkyl; HN-C-0-X -NH-C-NHXi where W = 0 or li II ow (please read the back Please pay attention to this page and then fill out this page) Printed s by the Central Bureau of Standards of the Ministry of Economic Affairs; -NH-C- (CH2) 3-C00H where s = 2,3,4 II o 2- f 4 (210X297 Koji) 844 η ο 7 7 7-AB c D Printed by the Central Bureau of Standards of the Ministry of Economic Affairs 6. Patent application profile where Xi represents (Ci-Cs) alkyl; stupid can be selected by one or more Atomic atom, (Ci-C3) alkyl or alkoxy or nitro group, amino group * hydroxy or trifluoromethyl substituted; adamantyl group; selected from -CONXiXs; -NXiXz-group; wherein XiR represents hydrogen , (Ci-Cs) alkyl or stupyl which is unsubstituted or substituted by one or more groups, this substituent is selected from a halogen atom, (Ca-Cs) alkyl or alkoxy, or nitro, amine Group, hydroxy or trifluoromethyl substituted and χ2 represents an argon atom, (Ci-Cs) alkyl, or changed to 1 and χ2 and the nitrogen atom to which they are connected to form a heterocyclic ring, the heterocyclic ring is selected from pyrrolidine or Hydropyridine, which is unsubstituted or substituted with a monooxy group or a hydroxy group, the latter being unsubstituted or substituted with an acyl group or substituted with-(: 0 (^ 1 or-(: 0 "1 \ 2 group; or Love is more lUaa-Cs) alkoxy; hydroxyl; a cyclic amine with 5 or 6 members; it is unsubstituted or substituted by oxy or hydroxy; hexahydropyridyl, which is unsubstituted or substituted-COOAlk N-substituted, where Aik represents (Ci-Cd alkyl; carboxylic acid group, -NX2X4 group, where 5U = H or X4 =-(CH2) t-X5, t is equal to 2, 3 or 4 and X5 represents -0H , -O-CO-Rz &gt; -NHC0R2--HH-C-NHR2 where R2 represents (Ct- Ce) alkyl; or-NR2R3 group, where 1? 2 or 1? 3 respectively represent Η, (Ca-Ce) alkyl, stupid group which is unsubstituted or substituted by one or more substituents • This substituent is selected From a halogen atom or (Κ3) alkyl or (Ci-Cs) alkoxy, or R2RR3 and the nitrogen atom to which it is connected to form a 5 or 6-membered heterocycle: A 4 (210X297 public) ...... ................................................... 3t .... ......................... ir •…: &gt; .................. ... sf (please read the precautions on the back before filling in this page) 8442 ο 0Λ AB c D Printed by the Central Bureau of Economic Affairs of the Ministry of Economy VI. Applying for a patent Fan® Z stands for heteroatom containing one or more heteroatoms , The heteroatom is selected from 0, s and N, the heterocycle is coupled to an aromatic ring, the aromatic ring may also contain a heteroatom selected from 0, S and N and may be substituted by one or more groups , This substituent is selected from halogen atoms, (Ca-Ca) alkyl and alkoxy groups, or benzyloxy · nitro, amine groups and trifluoromethyl groups, the hetero atom N may be aromatic or N-NH form • It is unsubstituted or substituted by (U-C4) alkyl, carboxyalkylene-Z4-C00Rlo, where z4 Table 1 and ^ alkylene. Is Η, benzyl or (Cx-Ce) alkyl; aminomethan alkylidene-Z5-(: 0Νυ12, where r5 represents ((:!-") Alkylene and Rn and R12 represent Η, (Ci- Ce) alkyl, or form a saturated heterocyclic ring with N such as morpholinyl or hexahydropyridyl; acetoxy C0R13, R13 represents (C: -C Ο alkyl or phenyl; alkoxycarbonyl -C 0 0 R: 4 , Where R: 4 is a third butyl or benzyl group; Μ and the compound of formula (I) and additional salts of inorganic or organic acids and bases. 2. The compound of formula (I) according to item 1 of the patent application scope, Wherein Z stands for benzothienyl, benzofuranyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, quinolinyl, iso-DS-linyl, Ug-kelinolyl, oxazolinyl and [2 , 3-c] -thieno or [3, 2-c] pyridyl, isoindolyl or indolyl ', which is optionally substituted, and indolyl is optionally substituted on the nitrogen (Ci- Cd alkyl, carboxyalkyl-Z4-C00R1o substituted, which represents (Ci-C ^) hydrocarbylene and R10 represents η, benzyl or (Ct-Ce) alkyl; aminomethylammonium-Zs-CONRuR ^ • where R5 represents (Ci- ") alkylene group and Rn and R12 represent Η, (Ci-Ce) alkyl or form a saturated heterocyclic ring with N such as morpholinyl or hexahydropyridyl; acetyl, -COR13, its -4-f 4 (210X 297 guo) (please read the notes on the back first Please fill in this page again.) · · · · · 〇 ^ 44β Βτ C7 _; _ D7 VI. In the patent application, R13 stands for (Ci-Cd alkyl stupid; oxocarbonyl-COOR14, where Ri 4 stands for Tributyl or benzyl; and their salts. 3. The compound according to item 1 of the patent application scope, where R ζ represents Η, (Ci-Ca) alkyl or -Zi-NIUIU, which has the 1 item with the same meaning, Z stands for indolyl, which is unsubstituted or substituted on nitrogen and RIV stands for stupid group. 4. A substituted 2-amido-5- The preparation method of thiazole, in which the substituted 2-amino-5-thiazole of the following formula: (please read the note on the back and fill in this page) R〇i 其中R° α代表與I取代基相同意義者,其中存在之胺基 是經N -保護,RIVa及RVe代表RIV及1相同意義者*其 中羥基或胺基是經0 -及N-保護者,此化合物用式乙° -C00H之官能衍生物處理,其中Z° 代表與Z取代基相 \ 同者,其中NH2或NH基為經保護者,然後· 經濟部中央標準局印^ - 當R° i,含N-保護或0 -保護基時 &gt; 將此 基去保護,由此獲得之產物視情況進行醯化或烷基 化,以產生根據申請專利範圍第1項之化合物,其 中取代基R i | R ϊ v及R v如申請専利範圍第1項所定 義者,或其鹽類其中之一者。 5 . 一種根據申請專利範圍第1項至第3項中任一項之式( 甲4(210X297 公发) 六、申請專利範® 6 . AT B7 C7 D7 I )之化合物的製法,其中Z代表吲哚環其在氮上未被 取代且在笨基上視情況被取代者,其特激在於式(I )其 中Z代表吲哚環之對應化合物,係由胺基噻唑用下式之 酸的活化形式醯化製備之: (Xi)ni COOH N I Q 其中Q代表保護基且Xi分別代表鹵素* (C:t-C3)烷基, (Ca-Cs)烷氧基,N02 mCF3, 且ni等於ο - 3者醯化, Κ產生氮去保護後之對應取代吲哚基。 式(X I ')之化合物 X. R Υ -Ν ΝΗ- (請先閱讀背面之注意事項再填宵本頁) •装. .打· IV (XI 其中RIV如申請專利範圍第1項所定義者且X代表 (Ci-Cs)烷氧基I六氫吡啶基其未被取代或被4 -羥基取 代者或4 -烷氧羰基六氫吡畊,其中烷氧基圼匕-^形式 者。 式(I X )之化合物 *線· 經濟部中央搮準局印焚 X1 X2-N-(CH2)rnt 1 v-sWhere R ° α represents the same meaning as the I substituent, and the existing amine group is N-protected, RIVa and RVe represent RIV and 1 have the same meaning * wherein the hydroxyl or amine group is protected by 0- and N-, This compound is treated with a functional derivative of the formula B ° -C00H, where Z ° represents the same as the Z substituent, where the NH2 or NH group is protected, and then printed by the Central Bureau of Standards of the Ministry of Economic Affairs ^-when R ° i, when containing an N-protected or 0-protected group> deprotect this group, and the resulting product may be acylated or alkylated as appropriate to produce a compound according to item 1 of the patent application, in which the substituent R i | R ϊ v and R v are as defined in item 1 of the scope of application, or one of their salts. 5. A method for preparing a compound according to any of the formulas 1 to 3 of the patent application scope (A 4 (210X297 public issue) 6. Patent application model 6. AT B7 C7 D7 I), where Z represents The indole ring is unsubstituted on the nitrogen and optionally substituted on the stupid group, the particularity of which is the formula (I) where Z represents the corresponding compound of the indole ring, which is composed of an aminothiazole with an acid of the following formula The activated form is prepared by acylation: (Xi) ni COOH NIQ where Q represents a protecting group and Xi represents halogen * (C: t-C3) alkyl, (Ca-Cs) alkoxy, N02 mCF3, and ni is equal to ο -The three are acetylated, and the corresponding substituted indolyl group after nitrogen deprotection is produced by K. The compound of formula (XI ') X. R Υ -Ν ΝΗ- (please read the precautions on the back and then fill in the page) • Installed ... Hit · IV (XI where RIV is as defined in item 1 of the patent application scope And X represents (Ci-Cs) alkoxy I hexahydropyridyl which is unsubstituted or substituted with 4-hydroxyl or 4-alkoxycarbonyl hexahydropyridinium, wherein the alkoxy-dagger- ^ form. (IX) Compound * Line · Central Bureau of Economic Affairs of the Ministry of Economic Affairs, India X1 X2-N- (CH2) rnt 1 vs Η 2 N R IV (IX) f 4(210X297 公尨) AT2〇3448 C7 D7 六、申請專利範® 中 X 其且 CNJ者 或一 1之 為中 E 其 ,類 者鹽 義其 定或 所基 項h2 N 1X I 第或 圍基 範胺 利亞 專醯 請酞 申表 如代 8 其 3 ,第 物至 合項 姐1 。 藥第合 發圍混 之範劑 劑利形 抗專賦 拮請種 素申一 泌據少 戽根至 及種與 素 一, 縮少物 收至合 s含化 膽包之 作其項 用為一 種戤任 一 特項 (請先閑讀背面之注意事邛再滇荈本頁) .装· •打· •線. 經濟部中央揉準局印製 甲4(210X297 公廣) 第號專利肀讶黨Η 2 NR IV (IX) f 4 (210X297 public) AT2〇3448 C7 D7 VI. In the patent application range ® X and CNJ or one of the 1 is Chinese E, the category of salt is defined or based on h2 N 1X I The first or the second base of the phenanthrene specialty should be applied as the table of the 8th 3, the first to the first sister of the item 1. The medicine of the first round of the mixed medicine is a kind of anti-specialty agent, and it can be used as a kind of medicine. Any of the special items (please read the notes on the back of Qiong first, and then go to this page). Installed • • Hit • • Line. Printed Armor 4 (210X297 Public Broadcasting), No. 4 Patent No. of the Party 2 ^ '^{ ti-^r jx Μ) 表I :對受髖CCKA (大鼠'胰臟),CCKB(天竺鼠 -走質)及胃泌素(天竺鼠之胃腺)之生化結果 賁钿號碼 CI5〇 CCK A (Μ) • CI50 CCK B (M) CI50胃泌素(M) 1 4.10-9 7.10·7 2.1〇-6 2 LIO'8 LIO-5 &gt; ΙΟ'5 3 3.ΙΟ'8 1.10-6 6.10-6 4 1.10·8 4.10-7 5.10-7 5 LIO·8 &gt; 10-5 NT 6 9.10-9 &gt; 10-5 ' NT 7 (1) (1) (1) 8 (1) (1) (l) 9 4.1〇-!〇 3.10-7 , NT 10 3.10-9 ‘ 1.10:7 4.10-7 _ 11 LIO'9 6.10-7, &gt; 10-5- 12 8.10-9 3.10-6 2.10-6 - 13 7.1〇-10 2.10-7 1.10-6 14 2.1〇-10 8.10-7 1.10-5 15 1.10-9 6_10·7 2.10-6 16 3.10-9 9.10-7 1.10-6 17 LIO·9 ' 2.10-6 5.10-6 18 1.10-10 4.10-7 1.10-6 19 1.10*9 7.10-7 &gt; 10-5 20 4.1〇-10 9_10-7 1.10-6 21 2.1〇-9 1.10-6 1.10-5 22 3.10-9 3.10-6 6.10-6 J23- 3.10-9 1.10·5 NT.- 24 2.10-9 2,6.1〇-6 3.10-6 25 ^ 5·1〇-9 1.10_5 NT _ 26 4.1〇-10 1,7.10-6 1.10-6 27 3.10-10 1,8.10-7 7.10-7 28 1.10-9 4.10-7 • 3.IO-7 29 8.10·10 2_10-7 3.IO-7 30 2.10-10 2.1〇-7 3.IO-7 31 2.10·10 4.1〇-7 1.10-5 32 3.10-10 6.10-7 5.IO-7 33 3.10-^ 2.10-7 3.IO-7 34 1.10-9 6.10-7 NT 35 2.1〇-10 9.10-8 -•&gt;3.10-L· 36 4.10*10 2.10-7 2.10-7 2 辦443 表 I (續) 實例號碼 CI5〇 CCK A (Μ) CI5〇 CCK Β (Μ) α50胃泌素(μ)': 37 2.10'10 5.10-8 3.10-7 38 6.10-9 &gt; 10*5 NT 39 3.1〇-10 1.10-6 2. ΙΟ-6 40 5.1〇-10 3.10-6 2.10-6 41 3.10-10 4.10-6 3.10-6 42 2.10-9 5.10-6 7_10-6、 43 1·1〇-9 3.10-6 3.10·7 44 2.10'10 1.10-6 2.10-6 45 -.3.10·10 .5.10-7 3·10_7 46 一 5_10_10 9.10-7 · 4.10-7 47 3.10-7 :&gt; 10;5 NT 48 1.10-9 3,6.10-6 &gt; 1〇-5 49 LI。·8 &gt; ΙΟ*5 NT 50 3.10-9 &gt; ΙΟ'5 NT 51 6.10-9 1.10-5 NT 52 3.10-9 :-5.10-7 1.10-6 53 7.10-9 &gt; ΙΟ-5 NT 54 2.1〇-8 3.10-6 NT 55 3.10-9 &gt; ΙΟ*5 NT 56 1.10-9 &gt; ΙΟ'5 NT 57 NT NT NT 58 6.10-10 &gt; ι〇-5 . NT :-. 59 一 3.10-10 &gt; ΙΟ&quot;5 NT 60 1·10-9 &gt; ΙΟ-5 NT 61 7.10-10 4. ΙΟ'7 4.10-7 62 4·10_7 &gt; ι〇-5 NT (1)中間物;NT ;表示未測 &gt; -3 - _一 表I :腺泡澱粉酶分泌之抑制作用及小鼠空胃 之抑制作用 實例號碼 澱粉酶分泌 CI5〇 (M) (親外) 空 胃 de50 (體內) PO mg/kg IV mg/kg .9 1.10'8 &gt;0.5 0.045 13 &gt;2 0.120 14 0.66 ' 0.372 16 2.10-8 18 0.14 0.002 」、 20-- * &gt;2 0.045 26 - 3.10-8 ‘ ... - 31 0.31 ; 0.350 35 0.10 ' 0.015 - 39 3.10-8 40 6.10-8 41 2.1〇-8 44 3.10-8 46 7.10-8 • 59 4.10*82 ^ '^ {ti- ^ r jx Μ) Table I: Biochemical results of CCKA (rat's pancreas), CCKB (guinea pig-propagation) and gastrin (gastric gland of guinea pig) of the recipient hips 〇CCK A (Μ) • CI50 CCK B (M) CI50 gastrin (M) 1 4.10-9 7.10 · 7 2.1〇-6 2 LIO'8 LIO-5 &gt; ΙΟ'5 3 3.ΙΟ'8 1.10 -6 6.10-6 4 1.10 · 8 4.10-7 5.10-7 5 LIO · 8 &gt; 10-5 NT 6 9.10-9 &gt; 10-5 'NT 7 (1) (1) (1) 8 (1) (1) (l) 9 4.1〇-! 〇3.10-7, NT 10 3.10-9 '1.10: 7 4.10-7 _ 11 LIO'9 6.10-7, &gt; 10-5- 12 8.10-9 3.10-6 2.10-6-13 7.1〇-10 2.10-7 1.10-6 14 2.1〇-10 8.10-7 1.10-5 15 1.10-9 6_10 · 7 2.10-6 16 3.10-9 9.10-7 1.10-6 17 LIO · 9 '2.10-6 5.10-6 18 1.10-10 4.10-7 1.10-6 19 1.10 * 9 7.10-7 &gt; 10-5 20 4.1〇-10 9_10-7 1.10-6 21 2.1〇-9 1.10-6 1.10- 5 22 3.10-9 3.10-6 6.10-6 J23- 3.10-9 1.10 · 5 NT.- 24 2.10-9 2,6.1〇-6 3.10-6 25 ^ 5.10-10-9.10_5 NT _ 26 4.1〇 -10 1,7.10-6 1.10-6 27 3.10-10 1,8.10-7 7.10-7 28 1.10-9 4.10-7 • 3.IO-7 29 8.10 · 10 2_10-7 3.IO-7 30 2.10- 10 2.1〇-7 3. IO-7 31 2.10 · 10 4.1〇-7 1.10-5 32 3.10-10 6.10-7 5.IO-7 33 3.10- ^ 2.10-7 3.IO-7 34 1.10-9 6.10-7 NT 35 2.1〇- 10 9.10-8->> 3.10-L · 36 4.10 * 10 2.10-7 2.10-7 2 Office 443 Table I (continued) Instance number CI5〇CCK A (Μ) CI5〇CCK Β (Μ) α50 gastrin (Μ) ': 37 2.10'10 5.10-8 3.10-7 38 6.10-9 &gt; 10 * 5 NT 39 3.1〇-10 1.10-6 2. ΙΟ-6 40 5.1〇-10 3.10-6 2.10-6 41 3.10-10 4.10-6 3.10-6 42 2.10-9 5.10-6 7_10-6, 43 1 · 10-9 3.10-6 3.10 · 7 44 2.10'10 1.10-6 2.10-6 45 -.3.10 · 10. 5.10-7 3 · 10_7 46-5_10_10 9.10-7 · 4.10-7 47 3.10-7: &gt;10; 5 NT 48 1.10-9 3,6.10-6 &gt; 1〇-5 49 LI. · 8 &gt; ΙΟ * 5 NT 50 3.10-9 &gt; ΙΟ'5 NT 51 6.10-9 1.10-5 NT 52 3.10-9: -5.10-7 1.10-6 53 7.10-9 &gt; ΙΟ-5 NT 54 2.1 〇-8 3.10-6 NT 55 3.10-9 &gt; ΙΟ * 5 NT 56 1.10-9 &gt; ΙΟ'5 NT 57 NT NT NT 58 6.10-10 &gt; ι〇-5. NT:-. 59 a 3.10- 10 &gt; ΙΟ &quot; 5 NT 60 1 · 10-9 &gt; ΙΟ-5 NT 61 7.10-10 4. ΙΟ'7 4.10-7 62 4 · 10_7 &gt; ι〇-5 NT (1) intermediate; NT; Not tested &gt; -3-_One Table I: Inhibition of secretion of acinar amylase and inhibition of empty stomach in mice Example number Amylase secretion CI5〇 (M) (foreign) empty stomach de50 (in vivo) PO mg / kg IV mg / kg .9 1.10'8 &gt; 0.5 0.045 13 &gt; 2 0.120 14 0.66 '0.372 16 2.10-8 18 0.14 0.002' ', 20-- * &gt; 2 0.045 26-3.10-8' .. .-31 0.31; 0.350 35 0.10 '0.015-39 3.10-8 40 6.10-8 41 2.1〇-8 44 3.10-8 46 7.10-8 • 59 4.10 * 8
TW081104270A 1991-06-05 1992-06-01 TW202448B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9106814A FR2677356B1 (en) 1991-06-05 1991-06-05 HETEROCYCLIC DERIVATIVES OF SUBSTITUTED ACYLAMINO-2 THIAZOLES-5, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.

Publications (1)

Publication Number Publication Date
TW202448B true TW202448B (en) 1993-03-21

Family

ID=9413505

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081104270A TW202448B (en) 1991-06-05 1992-06-01

Country Status (24)

Country Link
US (2) US5314889A (en)
EP (1) EP0518731B1 (en)
JP (1) JP3199451B2 (en)
KR (1) KR100222309B1 (en)
AT (1) ATE170186T1 (en)
AU (1) AU650754B2 (en)
BR (2) BR9202156A (en)
CA (1) CA2070526A1 (en)
CZ (1) CZ289003B6 (en)
DE (1) DE69226729T2 (en)
ES (1) ES2121575T3 (en)
FI (1) FI922589A (en)
FR (1) FR2677356B1 (en)
HK (1) HK1012397A1 (en)
HU (1) HU221312B1 (en)
IE (1) IE921814A1 (en)
IL (1) IL102004A (en)
MX (1) MX9202662A (en)
NO (1) NO300135B1 (en)
NZ (1) NZ243009A (en)
RU (1) RU2059637C1 (en)
TW (1) TW202448B (en)
UA (1) UA26899C2 (en)
ZA (1) ZA923981B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4303676A1 (en) * 1993-02-09 1994-08-11 Bayer Ag 1-aryltriazolin (thi) one
FR2701708B1 (en) * 1993-02-19 1995-05-19 Sanofi Elf Polysubstituted 2-amido-4-phenylthiazole derivatives, process for their preparation, pharmaceutical composition and use of these derivatives for the preparation of a medicament.
FR2703995B1 (en) * 1993-04-16 1995-07-21 Sanofi Elf 5-ACYLAMINO 1,2,4-THIADIAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1995032963A1 (en) * 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
MX9604483A (en) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Benzamide derivative, compositions containing said derivative and use thereof.
WO1998035707A1 (en) 1997-02-18 1998-08-20 Thomas Jefferson University Compositions that bind to pancreatic cancer cells and methods of using the same
CO4970713A1 (en) * 1997-09-19 2000-11-07 Sanofi Synthelabo DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
FR2768737B1 (en) * 1997-09-19 2000-05-19 Sanofi Sa CARBOXAMIDOTHIAZOLA DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
JP4145654B2 (en) * 2001-01-26 2008-09-03 塩野義製薬株式会社 Cyclic compound having thrombopoietin receptor agonist activity
WO2002062775A1 (en) * 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
ES2610611T3 (en) * 2002-01-18 2017-04-28 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
US20030225054A1 (en) * 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
FR2854158B1 (en) * 2003-04-25 2006-11-17 Sanofi Synthelabo 2-ACYLAMINO-4-PHENYLETHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US7361658B2 (en) * 2003-07-17 2008-04-22 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
LT3002283T (en) * 2003-12-26 2017-09-11 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
JP2008514547A (en) 2004-05-23 2008-05-08 ハウシー・ファーマシューティカルズ・インコーポレーテッド Theramutein modulator
FR2872813B1 (en) * 2004-07-09 2007-01-19 Sanofi Synthelabo 2-CARBAMID-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP1781287A4 (en) * 2004-08-13 2008-02-27 Genentech Inc Thiazole based inhibitors of atp-utilizing enyzmes
FR2876692B1 (en) * 2004-10-19 2007-02-23 Sanofi Aventis Sa 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
JP4774995B2 (en) * 2005-01-12 2011-09-21 アステラス製薬株式会社 Pharmaceutical composition comprising an acylaminothiazole derivative as an active ingredient
BRPI0611187A2 (en) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc amino thiazide derivatives as inhibitors of human stearoyl coa desaturase
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd Thiazole derivative
TWI457125B (en) 2005-08-02 2014-10-21 A prophylactic agent for for sleep disorders
KR20080074166A (en) * 2005-11-08 2008-08-12 아스테라스 세이야쿠 가부시키가이샤 Compositions and methods for treating thrombocytopenia
FR2895989B1 (en) * 2006-01-06 2010-04-30 Sanofi Aventis 2-CARBAMID-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
AU2007208225B2 (en) * 2006-01-25 2013-05-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
CN101096363B (en) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-three-substituted thiazole compound, preparation method, medicament composition and pharmacy use thereof
EP2452674B1 (en) * 2006-08-08 2014-03-26 Akarx, Inc. Compositions and methods for increasing blood platelet levels in humans
EP2240029A4 (en) * 2008-01-07 2012-08-22 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
MX2010010659A (en) 2008-03-31 2010-10-26 Genentech Inc Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use.
WO2011019990A1 (en) * 2009-08-14 2011-02-17 Eisai, Inc. Use of e5501 for stimulating platelet production
NZ599090A (en) 2009-09-28 2014-02-28 Hoffmann La Roche Benzoxepin pi3k inhibitor compounds and methods of use
ES2444779T3 (en) 2009-09-28 2014-02-26 F. Hoffmann-La Roche Ag Benzoxazepine compounds PI3K inhibitors and their use in cancer treatment
EP2547676B1 (en) * 2010-03-17 2015-07-29 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
RU2013143747A (en) 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг BENZOXAZEPINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF APPLICATION
KR20140131359A (en) 2012-02-17 2014-11-12 에프. 호프만-라 로슈 아게 Tricyclic compounds and methods of use therefor
JP2022500499A (en) 2018-09-07 2022-01-04 ピク セラピューティクス, インコーポレイテッド EIF4E Inhibitors and Their Use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3210368A (en) * 1964-09-29 1965-10-05 Ciba Geigy Corp Certain 2-amino-4-aryl-5-n, n-disubstituted amino-lower alkyl-thiazole compounds
ATE67185T1 (en) * 1985-07-09 1991-09-15 Pfizer SUBSTITUTED OXINDOL-3-CARBOXAMINE AS AN ANTI-INFLAMMATORY AND PAIN RELIEF.
DE3705934A1 (en) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl derivatives, processes for their preparation, and their use as medicaments
US4971978A (en) * 1987-09-21 1990-11-20 Nadzan Alex M Derivatives of D-glutamic acid and D-aspartic acid
WO1989005812A1 (en) * 1987-12-22 1989-06-29 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their medicinal use
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IE921814A1 (en) 1992-12-16
BR1100786A (en) 2000-03-14
FI922589A (en) 1992-12-06
BR9202156A (en) 1993-02-02
EP0518731A1 (en) 1992-12-16
FR2677356B1 (en) 1995-03-17
ZA923981B (en) 1993-12-01
HU221312B1 (en) 2002-09-28
US5380736A (en) 1995-01-10
UA26899C2 (en) 1999-12-29
RU2059637C1 (en) 1996-05-10
DE69226729D1 (en) 1998-10-01
AU1727992A (en) 1992-12-10
IL102004A (en) 1997-04-15
HK1012397A1 (en) 1999-07-30
KR930000492A (en) 1993-01-15
AU650754B2 (en) 1994-06-30
IL102004A0 (en) 1992-12-30
ES2121575T3 (en) 1998-12-01
CA2070526A1 (en) 1992-12-06
DE69226729T2 (en) 1999-05-06
NO922215L (en) 1992-12-07
HU9201870D0 (en) 1992-08-28
CS169392A3 (en) 1992-12-16
KR100222309B1 (en) 1999-10-01
EP0518731B1 (en) 1998-08-26
FR2677356A1 (en) 1992-12-11
JP3199451B2 (en) 2001-08-20
HUT75870A (en) 1997-05-28
NO300135B1 (en) 1997-04-14
JPH05155871A (en) 1993-06-22
US5314889A (en) 1994-05-24
FI922589A0 (en) 1992-06-04
MX9202662A (en) 1992-12-31
CZ289003B6 (en) 2001-10-17
ATE170186T1 (en) 1998-09-15
NZ243009A (en) 1995-05-26
NO922215D0 (en) 1992-06-04

Similar Documents

Publication Publication Date Title
TW202448B (en)
US7863279B2 (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
JP4843040B2 (en) Novel heterobicyclic derivatives useful as inhibitors of hepatic carnitine palmitoyltransferase
US20070049558A1 (en) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
TW294665B (en)
US20070021405A1 (en) Aryl- and heteroarylpiperidinecarboxylate-derivatives methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors
TW461889B (en) 1H-pyrido[3,4-b]indole-4-carboxamide derivatives, their preparation and their application in therapeutics
KR20090080567A (en) Sulfonamide derivatives as liver carnitine palmitoyl transferase(l-cptl)
BRPI0614578A2 (en) compound, pharmaceutical composition as protein kinase inhibitors, as well as their method and use
Ferraris et al. Design and synthesis of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries
TW201105664A (en) Cyclopenta[c]pyrrole-2-carboxylate derivatives, preparation and therapeutic use thereof
AU2010247212B2 (en) 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
CN110461847A (en) (S) -7- (1- (butyl- 2- alkynes acyl group) piperidin-4-yl) -2- (4- Phenoxyphenyl) -4,5,6,7- tetrahydro-pyrazole simultaneously the crystal form of [1,5-a] pyrimidine -3- formamide, its preparation and purposes
CN102216300A (en) Compounds and compositions as protein kinase inhibitors
US4210648A (en) II-Aminoacyl-5,11-dihydro-6H-pyrido(2,3-B) (1,4)benzodiazepin-6-ones and salts thereof
WO2011001931A1 (en) Novel oxadiazole derivative
TW295584B (en)
JPS63264481A (en) Novel piperidines, drug composition and manufacture
CA2175498C (en) Phenylindole compounds
CA1321996C (en) Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
Kim et al. P1′ oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1
TW502005B (en) 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives, their preparation and their therapeutic application in the treatment and prevention of disorders related to 5-HT4 and/or H3 receptors
JPH0788357B2 (en) Piperazine compound
CA2266510A1 (en) N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics
US5367078A (en) 3-oxadiazolyl-1,6-naphthyridine derivatives